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General Introduction
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1) The haemostatic process
The vascular system is of vital importance for functioning of the human body. Blood
components are involved in the transport of oxygen, nutrients, hormones, and other
signalling molecules to all organs and tissues, and also in the removal of waste
products. Also, blood plays a vital role in the maintenance of body temperature. When
the integrity of the vascular tree is disturbed, a complex process referred to as
haemostasis is initiated to stop the bleeding and to heal the damaged blood vessel(s).
The haemostatic process is tightly regulated; the haemostatic plug formed closes the
rupture in the vessel, but not the vessel itself. A disbalanced haemostatic system can be
a consequence of congenital deficiencies or dysfunctionalities of the system, or may be
due to acquired defects induced by unrelated diseases or by drugs affecting
haemostasis. Disturbance of the haemostatic balance results in either a bleeding or a
thrombotic tendency (or a combination of both in rare situations).
Haemostasis can be divided into 5 distinct processes.
1) On rupture of a vessel, vasoconstriction is initiated as a first measure to limit blood
loss.
2) Blood platelets adhere to subendothelial components and aggregate to form a platelet
plug, which closes the damaged vessel.
3) The formation of a fibrin clot stabilizes the primary haemostatic plug.
4) The generation of plasmin through the fibrinolytic system results in breakdown of the
clot.
5) Repair and regeneration of the damaged vessel.
Although the haemostatic process is presented here as a sequence of distinct events, the
actual process involves a complex interplay between these haemostatic sub-processes.
Vasoconstriction
The role of vessel wall contraction in haemostasis is poorly understood. Also, the agents
involved in vasoconstriction are poorly defined. Molecules derived from endothelium
(endothelins)1, platelets (serotonin and thromboxane A2)
2,3, or the coagulation system
(fibrinopeptide B, bradykinin)4 may be involved in vasoconstriction mediated by the
contraction of smooth muscle. Vasoconstriction might be more significant in arteries
than in veins, due to the presence of bigger muscular coats in arteries. Although it is
conceivable that vasoconstriction contributes to haemostasis, as the reduction of flow
might facilitate other haemostatic processes, the significance of this process remains to
be elucidated.
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Platelet adhesion and aggregation
Blood platelets circulate in a quiescent state, which is maintained by both active and
passive inhibitory elements provided by intact endothelium. Endothelial cells excrete
the platelet inhibitors prostaglandin I2
5, and nitric oxide6. In addition, endothelial cells
express the transmembrane ecto-ADPase CD397, which inhibits platelet function by
hydrolyzing ADP from activated platelets, thereby preventing ADP-induced platelet
activation (see below). Moreover, platelet adhesion to intact endothelium is prevented
by its negative charge, which is provided by heparan sulphate moieties present on the
luminal side of the cells.
Rupture of a vessel exposes subendothelial components to the blood. A number of
proteins, which are adhesive to platelets, reside in the subendothelium. These include
collagen8, von Willebrand factor (vWF)9, fibronectin10, vitronectin11, laminin12, and
thrombospondin13. Platelets adhere to the subendothelium, become activated, and
subsequently platelet-platelet interactions are formed, resulting in a platelet aggregate,
which serves as a first measure to close the damaged vessel.
Figure 1. Schematic representation of platelet adhesion and aggregation under flow conditions. A)
Rolling of platelets over collagen-bound vWF mediated by GPIb. B) Firm attachment mediated by
a2b1 and glycoprotein VI (GP VI) binding to collagen, and by aIIbb3 binding to collagen-bound
vWF. C) Platelet activation, secretion, and spreading. D) Aggregate formation.
11
Chapter 1
Adhesion of platelets to the vessel wall presumably proceeds in a two-step mechanism
(Figure 1). First, platelets are slowed down by transient binding of platelet glycoprotein
Ib to von Willebrand factor bound to subendothelial collagen14. Subsequently, a
stationary contact between platelet and subendothelium is accomplished by binding of
one or more platelet integrins and other receptors to their ligands in the
subendothelium. Specifically, integrin a2b1 and glycoprotein VI can bind to collagen,
aIIbb3 can bind to vWF, fibrinogen, vitronectin, and thrombospondin, a5b1 can bind to
fibronectin, a6b1 can bind laminin, and avb3 can bind vitronectin
11.
After adhesion, platelets become activated by a number of agonists including collagen
and thrombin. Platelet activation is propagated by excretion of thromboxane A2,
which is synthesized in the platelet on stimulation, and by factors excreted from
intracellular granules, such as ADP and serotonin. Platelet activation involves binding
of the herefore mentioned agonists to their specific receptors. These receptors are either
seven transmembrane G-protein-coupled receptors (GPCR), or receptors coupled to
tyrosine kinases. A well-characterised GPCR is the classical thrombin receptor, also
referred to as protease activated receptor-1 (PAR-1)15. An interesting feature of PAR-
1 is that it carries its own ligand. Thrombin cleaves an N-terminal peptide from the
receptor, thereby exposing a new N-terminus which binds to another region of the
receptor thereby activating it16. PAR-1 cleavage by thrombin is strongly enhanced
when thrombin is bound to glycoprotein Ib17.
Platelet activation results in signal transduction pathways, which eventually lead to
shape change, aggregation, release of granule contents, and synthesis of propagators of
platelet activation.
Platelet activation is accompanied by expression of procoagulant surface, i.e., negatively
charged phospholipids. In unactivated platelets, anionic phospholipids such as
phosphatidylserine (PS) and phosphatidylethanolamine (PE) are restricted to the inner
leaflet of the platelet membrane through the cooperative action of an ATP-dependent
aminophospholipid translocase and an ATP-dependent floppase. On platelet
activation, PS and PE are translocated to the outer leaflet by activation of a calcium-
dependent phospholipid scramblase (for a review see18). Exposure of procoagulant
surface facilitates thrombin generation required for enhancement of platelet activation
and the generation of fibrin (see below).
A second mechanism by which platelet activation supports fibrin generation is the
excretion of proteins involved in coagulation as well as inhibitors of clot breakdown
from alpha granules.
Platelet activation results in activation and clustering of aIIbb3, which subsequently can
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bind fibrinogen and vWF. Bridging of fibrinogen and vWF between two platelets results
in aggregation, which leads to the formation of a stable platelet plug.
Fibrin formation
Blood coagulation, or the process of fibrin formation, consists of a complicated sequence
of enzymatic reactions, eventually leading to the generation of thrombin. Thrombin is
not only responsible for platelet activation, but also for the cleavage of fibrinogen into
fibrin. Fibrin spontaneously polymerizes and forms an insoluble mesh, which stabilizes
the platelet plug.
In 1964, two groups independently proposed the cascade model of coagulation19,20. In
this model, the generation of thrombin involved a sequential series of steps in which
activation of one clotting factor led to the activation of another. Through sequential
activation of clotting factors an enormous amplification of the initial signal could be
accomplished. The first signal was thought to be initiated by either intrinsic activation
via coagulation factor XII, or extrinsic activation via the tissue factor-VIIa complex.
Although these two activation pathways are nowadays still highly significant in the
diagnostic laboratory (i.e., intrinsic and extrinsic activation are used in the APTT and
Figure 2. Schematic representation of tissue factor-induced coagulation. Activation steps leading to
the generation of thrombin are represented by the uninterrupted lines. The interrupted lines
represent inhibitory systems. TF: tissue factor, TFPI: tissue factor pathway inhibitor, PZ:
protein Z, ZPI: protein Z-dependent protease inhibitor, APC: activated protein C, PS: protein S,
TM: thrombomodulin, AT: antithrombin, HC-II: heparin cofactor II, a2-M: a2-macroglobulin.
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PT assay, respectively), it is currently believed that the extrinsic pathway is the
physiological initiator of haemostasis21. The intrinsic pathway seems not to play a role
in normal haemostasis, but might become important in pathological situations such as
sepsis22. A schematic representation of the TF-induced coagulation pathway is presented
in figure 2.
Coagulation is initiated when cells expressing the transmembrane receptor tissue factor
(TF) are exposed to the blood. Traditionally, it is believed that under normal conditions
tissue factor expressing cells are located exclusively extravascular21, although TF
synthesis can be induced in endothelial cells and monocytes by bacterial components
or inflammatory cytokines23,24. However, recent data suggested that tissue factor
expressing cells may circulate in the bloodstream under normal conditions25. In an
intact vasculature, the tissue factor in blood cells is thought to be ‘encrypted’ (i.e.,
inactive), presumably due to a lipid environment not supporting initiation of
coagulation26. It has also been suggested that encryption of TF is a consequence of
dimerisation. Upon activation of TF-bearing cells, TF has been shown to monomerise,
and it has been suggested that this is the event that triggers TF decryption27.
When active (decrypted) tissue factor is in contact with blood, its complex with factor
VIIa initiates coagulation. Factor VII circulates in the blood in both zymogen and
activated form. Activated factor VIIa does not have any relevant enzymatic activity on
its own. Only on binding to tissue factor and in the presence of anionic phospholipids,
factor VIIa is able to activate its substrates, factors IX and X, by limited proteolysis.
The activation of factor VII proceeds when it is bound to tissue factor. A number of
mechanisms by which factor VII is activated have been proposed, including activation
by TF-VIIa28, factor Xa29, factor IXa29, thrombin30, hepsin31 and a poorly
characterised ‘factor VII activating protease’32. Factor Xa, however is nowadays
believed to be the physiological activator of factor VII during injury33. Factor IXa is
thought to be responsible for the maintenance of low levels of factor VIIa in circulation34.
The TF-VIIa complex activates factors IX and X. The efficiency of activation depends on
the concentration of TF. At low concentrations of TF factor IX is predominantly
activated, whereas at high TF factor X is the preferred substrate35. Factors IXa and
Xa then assemble into the tenase and prothrombinase complex, respectively. The
tenase complex, consisting of the enzyme factor IXa, cofactor VIIIa, and zymogen
factor X bound to a lipid surface containing anionic phospholipids, results in the
activation of factor X by factor IXa. Similarly, the prothrombinase complex (enzyme
factor Xa, cofactor Va, and zymogen factor II assembled on a procoagulant surface)
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results in the generation of thrombin. Figure 3 shows a schematic representation of
initiation of coagulation and assembly of tenase and prothrombinase complexes.
The procoagulant surface is required for all steps in thrombin generation so far
described. The function of the procoagulant surface is not only to localize thrombin
generation at the site of injury, but also to accelerate reaction velocity by producing a
profound drop in the Km of the reaction36,37. Binding of (pro)enzymes to an anionic
lipid surface is facilitated by the presence of c-carboxylated glutamic acid residues (Gla
residues) in the N-terminal part of these proteins. Besides factors VII, IX, X, and II, also
the anticoagulant proteins C, S, and Z (see below), and the amplifier of platelet activation
GAS6 contain Gla residues. The posttranslational modification of glutamic acid residues
to Gla residues is regulated by a vitamin K-dependent carboxylase38. Gla residues bind
calcium ions, and binding of Gla proteins to a lipid surface is a consequence of calcium
bridge formation between protein and lipid surface.
The role of the cofactors Va and VIIIa in the prothrombinase and tenase complex,
respectively, is to accelerate velocity of substrate conversion (Vmax), presumably by
inducing a conformational change in their respective enzymes36,37.
The thrombin generated by TF-induced coagulation amplifies its own generation by
Figure 3. Tissue factor-induced coagulation, and the assembly of tenase and prothrombinase
complexes. The TF-VIIa complex can activate factors IX and X. Activated factor IX enters the
tenase complex consisting of enzyme factor IXa, activated cofactor VIIIa, substrate factor X,
and the catalytic phospholipid surface containing anionic phospholipids. Activated factor X,
resulting from tenase activity or from TF-VIIa activity enters the prothrombinase complex
consisting of enzyme factor Xa, activated cofactor Va, substrate factor II, and the catalytic
phospholipid surface, leading to the generation of thrombin.
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activating the procofactors V and VIII, and by activation of factor XI. Factor XIa can
activate factor IX, which can subsequently participate in a tenase complex. A relatively
small amount of thrombin is required for the cleavage of fibrinogen into fibrin, platelet
activation, factor V activation, and factor XIII activation39. Activated factor XIII is a
transglutaminase which stabilizes polymerized fibrin by crosslinking gamma or alpha
chains in adjacent fibrin molecules by introducing e(c-glutamyl)lysyl isopeptide bonds40.
In vitro experiments indicate that thrombin generation continues after clot formation,
and that in fact the bulk of thrombin is formed after clot formation39,41. These higher
concentrations of thrombin are required for the activation of TAFI (see below).
The generation of thrombin is controlled and terminated by a number of inhibitory
mechanisms including the presence of blood flow, which removes (activated) clotting
factors from the site of injury, and a number of inhibitory protein systems, acting on
different steps in the coagulation cascade.
The activity of the TF-VIIa complex is regulated by the tissue factor pathway inhibitor
(TFPI)42. TFPI is a kunitz type inhibitor and inhibits coagulation in a two step
mechanism. First, TFPI binds to activated factor Xa, thereby inhibiting its proteolytic
activity. Next, the TFPI:Xa complex binds with high affinity to factor VIIa in the TF-
VIIa complex, resulting in a fully inhibited quaternary TF:VIIa:TFPI:Xa complex.
Propagation of coagulation is inhibited by the protein C system, which inactivates
cofactors Va and VIIIa43. Activation of the protein C system is initiated when
thrombin binds to the endothelial cell surface receptor thrombomodulin. Once bound
to thrombomodulin, thrombin loses its procoagulant properties, and becomes able to
activate protein C and TAFI (see below). Activated protein C, together with its
cofactor protein S, inactivates factors Va and VIIIa by limited proteolysis.
Localisation of protein C to the endothelial surface is facilitated by the transmembrane
receptor EPCR (endothelial protein C receptor). Protein S also displays anticoagulant
activity independently of protein C, presumably involving displacement of coagulation
factors from the procoagulant surface44.
Antithrombin regulates thrombin generation by inactivating thrombin, factor Xa, factor
IXa, factor XIa, and factor VIIa by forming a stable 1:1 complex, thereby inactivating
the enzyme45. The inhibitory potential of antithrombin is greatly accelerated by heparin
or the heparin-like glycosaminoglycans present on endothelial cells.
Two other plasma proteins, heparin cofactor II and a2-macroglobulin are also
stoichiometric inhibitors of thrombin46,47.
Finally, a recently characterized inhibitory system of coagulation is the protein Z/protein
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Z dependent protease inhibitor (ZPI) system. ZPI inhibits factor Xa, and protein Z
serves as a cofactor for this inhibitory reaction48.
Recently, the above-described model of coagulation has been refined to a cell-based
model49. In this model, emphasis is placed on the surfaces on which the different
coagulation reactions occur. Coagulation initiates on tissue factor-bearing cells, such as
fibroblasts or smooth muscle cells. A small amount of thrombin is generated on the
(procoagulant) surface of these cells, and the thrombin generated results in platelet
activation, and activation of factors Va and VIIIa. For full thrombin generation, the
procoagulant surface of the activated platelet is required. Factor IXa formed on the TF-
bearing cell diffuses to the platelet surface. Factor IXa, but not factor Xa is assumed to be
able to transport from the TF bearing cell to the platelet50, as factor Xa in solution is
rapidly inactivated by antithrombin or TFPI, but factor IXa in solution has a relatively
long half life. Factor IXa combines on the platelet surface with factor VIIIa, and starts
activating factor X, which in its turn combines with factor Va to generate thrombin.
Fibrinolysis
A formed fibrin clot needs to be removed when the integrity of the vessel is restored.
Fibrin degradation proceeds by a process referred to as fibrinolysis (see figure 4 for a
schematic overview). Fibrinolysis is initiated by the conversion of the plasma protein
plasminogen into plasmin. Plasmin is a rather unspecific serine protease, able to cleave
multiple peptide bonds in the fibrin molecule, but it also can proteolyse a number of
other proteins, including coagulation factors V51 and VIII52, TFPI53, and others.
The physiological activator of fibrinolysis is thought to be tissue type plasminogen
activator (tPA)54. tPA is synthesized by endothelial cells, which both constitutively
excrete and store this molecule55. tPA is found in plasma in small quantities in
complex with its physiological inhibitor plasminogen activator inhibitor 1 (PAI-1)56.
Presumably, the tPA excreted by endothelial cells near the site of the injury is
responsible for fibrinolysis in vivo. Alternatively, plasminogen can be activated by
urokinase plasminogen activator (uPA). uPA circulates as a single chain proenzyme
(scuPA), and is activated by plasmin or by kallikrein generated via the contact
activation system of coagulation57. uPA can bind to a specific receptor (uPAR), which
is present on many cell types58. Binding of uPA to uPAR localizes plasminogen
activation, but also leads to intracellular signalling which has been shown to play an
important role in tissue development59. It has been suggested that uPA is primarily
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responsible for plasminogen activation in tissue, whereas tPA is responsible for clot lysis
in the circulation. PAI-1 is most probably also the physiological relevant inhibitor of
uPA60.
tPA and plasminogen can bind to lysine and arginine residues on partially degraded
fibrin61,62. Binding of tPA and plasminogen to the fibrin clot markedly enhances the
plasminogen activating activity of tPA. Moreover, these interactions serve to localize
plasmin to the fibrin clot. In solution, plasmin is rapidly inhibited by the plasma
protein a2-antiplasmin. Bound to fibrin, plasmin is relatively resistant to inhibition by
a2-antiplasmin. uPA does not bind specifically to fibrin.
Fibrin clots are made more resistant to fibrinolysis by two mechanisms involving
thrombin. Firstly, thrombin activates factor XIII, which stabilizes the fibrin clot by
crosslinking gamma or alpha chains in adjacent fibrin molecules by introducing e(c-
glutamyl)lysyl isopeptide bonds40. Activated factor XIII also crosslinks a2-antiplasmin
to the fibrin clot, thereby contributing to the inhibition of fibrinolysis. Secondly,
thrombin (or thrombomodulin-bound thrombin) can activate thrombin activatable
fibrinolysis inhibitor (TAFI)63. Activated TAFI cleaves C-terminal lysine and arginine
Figure 4. Schematic representation of the fibrinolytic system, and its link with the coagulation
system. Activation pathways leading to the generation of plasmin, and subsequent breakdown of
the clot are represented by uninterrupted lines. Inhibitory pathways are represented by interrupted
lines. PAI-1: plasminogen activator inhibitor-1, tPA: tissue-type plasminogen activator, uPA:
urokinase, TAFI: thrombin activatable fibrinolysis inhibitor, HRG: histidine-rich glycoprotein,
a2-AP: a2-antiplasmine.
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residues from partially degraded fibrin, thereby preventing tPA and plasminogen
binding64. Relatively high concentrations of thrombin are required for TAFI activation.
It is believed that these high amounts of thrombin are generated after clot formation via
thrombin-mediated factor XI activation (see figure 5)65. TAFI can also be activated by
thrombomodulin-bound thrombin. TAFI activation by thrombomodulin-bound
thrombin is approximately 1200 more efficient than TAFI activation by thrombin66. It
is possible that both activation pathways contribute to TAFI activation in vivo,
depending on the amount of thrombomodulin expressed near the site of injury. It has
to be noted that thrombomodulin-bound thrombin can also express profibrinolytic
properties mediated by protein C activation. Activated protein C stimulates
fibrinolysis by inhibiting thrombin generation, and thus TAFI activation. It has been
shown that the concentration of thrombomodulin determines its preference for TAFI
or protein C activation67.
Platelet activation also contributes to down-regulation of fibrinolysis by excretion of
PAI-168 and a2-antiplasmin from its a-granules
69. Moreover, platelets contain the a-
subunit of factor XIII70, and platelets are able to bind (and thereby localize) factor
Figure 5. The role of factor XI in the thrombomodulin-independent activation of TAFI. Tissue
factor-initiated coagulation results in the generation of a small amount of thrombin required for
clot formation (dark arrows). After formation of the clot, thrombin generation continues via a
factor XI-dependent pathway (grey arrows). The generation of this secondary thrombin burst
results in the activation of TAFI. (Redrawn from Bouma et al.194)
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XIII through aIIbb3, thereby contributing to the stability of the haemostatic plug and its
resistance to fibrinolysis71.
Repair
Ultimately, the haemostatic plug needs to be replaced by a novel layer of endothelial cells
and underlying extracellular matrix. The fibrin clot not only serves to close a damaged
vessel wall, but also acts as a scaffold for invading inflammatory, endothelial, and other
tissue cells during tissue repair72. The formation of a new endothelium proceeds through
a process referred to as angiogenesis. A highly similar process referred to as
vasculogenesis, is essential during fetal development. Furthermore, angiogenesis plays
an important role in pathological conditions such as cancer (the formation of new
bloodvessels is essential to supply a tumor with oxygen and nutrients)73.
Angiogenesis is facilitated by the (cross linked) fibrin clot, which in conjunction with
fibronectin forms a provisional matrix for the influx of endothelial and other tissue
cells, and inflammatory cells, which are also involved in angiogenesis. These cells use
integrin receptors to interact with this matrix. Endothelial cells detach from their
established matrix, devide, and subsequently migrate over the fibrin-fibronectin matrix
towards the site of injury74. The signal for angiogenesis comes from angiogenic growth
factors (such as VEGF-A, bFGF, aFGF, or HGF), often in conjunction with cytokines
(such as TNF-a). The migration of cells is also facilitated by enzymes of the matrix
metalloprotease (MMP) family, and by uPA-mediated plasmin generation, which are
able to proteolyse different matrix components, thus making a path for the migrating
cells75,76. Once the new cells have found their way, the provisional matrix needs to be
removed by the fibrinolytic system. A proper balance between the formation of the
provisional matrix and its removal is essential for the wound healing process. When
the formation of the matrix is disturbed, wound healing is delayed, and defective
matrix breakdown may lead to fibrosis.
2) Congenital bleeding disorders
This section will describe congenital defects in the haemostatic system in humans leading
to a bleeding diathesis. The classic modalities available to treat these patients during
bleeding episodes, or prophylactically during surgery will be discussed.
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Platelets
Numerous congenital defects in platelet function, which result in a bleeding diathesis,
have been described. Platelet abnormalities found include deficiencies in adhesive
receptors, deficiencies in signal transduction pathways or signalling receptors,
deficiencies in intracellular granules, and deficiencies in the development of platelet
procoagulant potential. Furthermore, a defect in vWF, resulting in defective platelet-
vessel wall interaction also results in a bleeding tendency.
A congenital deficiency of the glycoprotein Ib/V/IX complex leads to a severe bleeding
disorder referred to as Bernard-Soulier syndrome (BSS)77. Its prevalence is extremely
rare; a prevalence of less than 1 in 1.000.000 has been estimated from literature. BSS is
usually inherited as an autosomal recessive trait. Next to the defective primary platelet-
vessel wall interaction, patients with BSS suffer from thrombocytopenia, and their
platelets show morphological abnormalities. Specifically, extremely large platelets with
enhanced expression of PS on the outer leaflet are found in BSS patients.
A congentital qualitative or quantitative deficiency of the integrin aIIbb3 is known as
Glanzmann’s thrombasthenia (GT)78. GT is inherited in a recessive manner. Patients
with GT have a severe bleeding tendency as a consequence of defective platelet-vessel
wall interaction, and more importantly, the complete absence of platelet-platelet
interaction.
Bleeding problems in both BSS and GT consist of epistaxis, petechiae, ecchymoses,
menorrhagia, gingival bleeding, gastrointestinal bleeding, and bleeding associated with
trauma or surgery.
A deficiency in the collagen receptor a2b1 has been described in only two (female)
patients79,80. This deficiency is associated with a mild bleeding tendency and partial
resolution of the bleeding disorder was seen in both patients. Also, a deficiency in the
other known collagen receptor, glycoprotein VI, is associated with a mild bleeding
tendency81.
Defects in platelet membrane receptors involved in signalling pathways have been
described. These deficiencies, however, are extremely rare, and usually lead to a mild
haemorrhagic disorder. Two groups have reported patients with a hereditary defect in
one of the platelet ADP receptors P2Y12, resulting in a moderate bleeding tendency
82.
Two Japanese families with a defective thromboxane A2 receptor have been described83.
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Likewise, defects in platelet signal transduction mechanisms are known, but they are also
extremely rare. These deficiencies include defects in arachidonic acid metabolism and
thromboxane A2 production, defects in Gaq, defects in calcium response, and reduced
protein phosphorylation84.
Patients with various abnormalities in platelet granules have been described85. A
deficiency of dense granules is referred to as d-storage pool deficiency (SPD). d-SPD is
a heterogenous, mostly mild bleeding disorder, which can occur both as a primary,
autosomal dominant inherited disorder, or as a component of a multisystem disorder
such as the Hermansky-Pudlak syndrome, the Chediak Higashi syndrome, and the
Wiskott-Aldrich syndrome. As dense granules contain ATP and ADP, a defect in these
granules leads to defective propagation of platelet activation.
A deficiency in platelet a-granules (which contain proteins involved in coagulation and
fibrinolysis) is referred to as gray platelet syndrome. This mild bleeding disorder is
usually accompanied by moderate thrombocytopenia, and enlarged platelets. It is
usually inherited in an autosomal recessive manner. A variant a-granule disorder is
called Quebec platelet disorder. This bleeding disorder is characterized by excessive
proteolysis of a-granule proteins, presumably due to the presence of large amounts of
uPA in the a-granules86.
A combined a,d-SPD is a rare disorder characterized by moderate to severe defects in
both d and a-granules.
An extremely rare defect in the platelet’s potential to develop procoagulant activity is
referred to as Scott syndrome87. Scott syndrome is a relatively severe bleeding
tendency, which is inherited in an autosomal recessive manner. Platelets from patients
with Scott syndrome lack the ability to translocate phosphatidylserine from the inner
to the outer leaflet, presumably due to a defect in the activation of the phospholipid
scamblase. Defective PS expression on activation is also observed in erythrocytes and
lymphocytes from these patients. The defective PS expression is accompanied by a
reduced ability to shed microvesicles on activation.
The most common inherited platelet-related bleeding disorder is von Willebrand’s
disease (vWD)88. Patients with a qualitative or quantitative defect in vWF have a
bleeding diathesis due to defective platelet-vessel wall interaction, and to defective
platelet-platelet interaction. The prevalence of vWD is estimated at 1% of the general
population. The prevalence of clinically relevant vWD is presumably around 10-fold
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lower (i.e., 1:1000). Seventy percent of the clinically relevant vWD is caused by a type 1
vWD, in which decreased levels of vWF (20-50% of normal) are present in plasma. Type
1 vWD is inherited in an autosomal dominant manner, and is associated with a mild
bleeding tendency. In type 3 vWD, a complete deficiency of vWF (<1% of normal) is
present, accompanied by severely reduced levels of coagulation factor VIII (3-10% of
normal). Type 3 vWD is characterized by severe bleeding and appears to be inherited
as an autosomal recessive trait. Several subtypes of type 2 vWD are distinguished, all
of them are characterized by an abnormal structure or function (i.e., a discordance
between antigen and activity). Type 2A is the most common type 2 vWD. It is
characterized by an absence of larger (more reactive) multimers. In type 2B vWD, a
mutation causes vWF to bind spontaneously to GPIb. The platelet-vWF complexes
are rapidly cleared from the circulation. As a consequence, a loss of larger multimers
and thrombocytopenia occurs. In type 2N vWD, factor VIII binding to vWF is
defective, with a haemophilia A-like phenotype (see below) as a result. Finally, type
2M vWD refers to a defective interaction with GPIb, with normal or nearly normal
multimeric pattern.
Standard treatment for all platelet-related bleeding disorders (except for vWD) in case of
uncontrolled haemostasis or prophylactically during surgery consists of platelet
transfusion. However, platelet transfusion in these patients may lead to
alloimmunisation. Antibodies to both HLA determinants and to the deficient protein
(e.g., GP Ib in case of BSS) may be formed. The development of these antibodies
makes further platelet transfusion ineffective.
1-desamino-8-d-arginine vasopressin (DDAVP) is frequently administered to patients
with SPD, BSS, and GT, although efficacy in BSS and GT has not been thoroughly
established yet. Antifibrinolytic agents may be useful in oral cavity bleedings. In
women with menorrhagia, the use of oral contraceptives may be beneficial.
Treatment of bleeding complications in vWD depends on the type of the disease.
Patients with type 1 vWD may be given DDAVP, which increases vWF levels in
plasma by inducing vWF release from endothelial cells. Many type 2 and nearly all
type 3 vWD patients do not respond to DDAVP. In these patients infusion of vWF-
concentrates is indicated. As DDAVP also releases tPA from endothelial cells,
adjunctive therapy with antifibrinolytics may be beneficial. Menorrhagia may be
treated with oral contraceptives or estrogens, as these compounds tend to increase
plasma vWF levels.
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Coagulation
Inherited deficiencies in all procoagulant proteins associated with a bleeding diathesis
have been described in humans, with the exception of tissue factor. Experiments with
TF knockout mice suggest that TF is not only involved in initiating coagulation, but
also in the formation of the vascular system89. Therefore, it has been suggested that TF
deficiency in humans is not compatible with life.
The most common deficiencies in procoagulant proteins are factor VIII and factor IX
deficiency (haemophilia A and B, respectively)90. Haemophilia A is an X-linked
disorder with an estimated prevalence of 1:10.000 males. Its severity depends on the
residual FVIII activity. Severe haemophilia (FVIII levels <1%) is a serious bleeding
disorder, characterized by spontaneous bleeding primarily in joints and muscles from
early infancy. In moderate haemophilia (FVIII levels 1-5% of normal) spontaneous
bleeding is uncommon, but patients do bleed after surgery or following trauma. In
mild haemophilia (FVIII levels 6-30% of normal) spontaneous bleeding is rare, but
bleeding after trauma or surgery does occur.
Haemophilia B is clinically indistinguishable from haemophilia A. This X-linked
disorder occurs in 1 out of every 25.000-30.000 male births.
Factor XI deficiency (haemophilia C) has a much milder phenotype than haemophilia A
or B91. It is inherited in an autosomal recessive manner. Factor XI deficiency is relatively
rare, except in Ashkenazi Jews, in which the prevalence of homozygous factor XI
deficient individuals is estimated at 0.1-0.3%. Factor XI deficient patients particularly
bleed after surgery that involves tissues with high fibrinolytic activity such as the oral
cavity, the urinary tract, tonsils and nose. This phenotype might be explained by the
role of factor XI in the activation of TAFI65. In contrast to haemophilia A and B, the
severity of the bleeding diathesis in factor XI deficient patients does not correlate with
the residual factor XI activity levels.
The therapy of choice for patients with haemophilia A and B consists of factor
replacement therapy. Both prophylactic administration of factor concentrates, as well
as an on-demand approach are currently used. With the introduction of recombinant
factor VIII and IX, viral safety is warranted. In mild haemophilia, factor VIII levels
can be temporarily increased by administration of DDAVP. Antifibrinolytic agents
are frequently used as adjunctive therapy, particularly in case of mucous membrane
bleeding and dental procedures. Factor replacement therapy may be complicated by
the development of inhibitory antibodies against the infused protein. Inhibitory
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antibodies develop in 25-30% of patients with haemophilia A92 and in 1-3% of patients
with haemophilia B93 at some point during their life. Approaches for eradication of
inhibitors include immunoabsorption94, and immune tolerance therapy (infusion of
high doses of factor VIII concentrates)95. Treatment of bleedings in a patient with
inhibitors consists of the infusion of porcine factor VIII96 (which also carries a risk
for inhibitor development), and (activated) prothrombin concentrates97.
In patients with factor XI deficiency, plasma transfusion is given when major surgical
procedures are performed. Factor XI concentrates are available, but administration of
these products is associated with development of laboratory signs of DIC98.
Antifibrinolytic agents may be administered as well.
Relatively rare are deficiencies in coagulation factors VII, X, II, and V99. Factor VII
deficiency is an autosomal recessive disorder with unknown prevalence. Factor VII
deficient patients with low levels of factor VII frequently present with a severe
haemorrhagic disorder. Patients with a factor VII level of 5% or more, usually have a
mild bleeding tendency. Factor X deficiency, also inherited in an autosomal recessive
trait, results in a moderate to severe bleeding tendency, primarily from soft tissues and
mucous membranes. Menorrhagia may occur in women with factor X deficiency. Factor
II deficiency is a rare disorder, with about 50 patients described worldwide. Factor II
deficiency is characterized by mild to moderate mucocutaneous and soft-tissue
bleeding. Factor V deficiency (initially called parahaemophilia) is also a rare
autosomal recessive disorder, with a prevalence of 1:10.000.000. Factor V deficiency
manifests itself as a moderate bleeding tendency, the bleeding complications
particularly include ecchymoses, epistaxis, and gingival bleeding.
Bleedings in factor VII, X, II and V deficiency can be controlled by plasma infusion. In
factor VII, X, and II deficiency prothrombin concentrates may also be given.
A hereditary deficiency of fibrinogen occurs as an autosomal recessive disorder100.
Afibrinogenemia is a rare disorder, with a prevalence of 0.5 in a million. Bleeding
problems in afibrinogenemia include umbilical cord bleeding, gum bleeding, epistaxis,
gastrointestinal bleeding, menorrhagia, and intracranial bleeding. The bleeding
diathesis varies from minimal to severe, and especially intracranial haemorrhage may
be fatal. Paradoxically, thrombotic complications have also been reported in young
patients with afibrinogenemia101.
Replacement therapy with fibrinogen concentrates or plasma may be required, but has
been reported to be associated with thromboembolic complications.
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A deficiency of factor XIII occurs with a prevalence of 0.5 in a million102. This disease,
which is inherited in an autosomal recessive manner, results in a moderate to severe
bleeding disorder. Manifestations of factor XIII deficiency include umbilical cord
bleeding, ecchymosis, hematomas, prolongued bleeding following trauma (which may
occur 12 to 36 hours after the event), and intracranial bleeding. Also, a higher rate of
spontaneous abortion, and problems with wound healing may occur.
Replacement therapy with factor XIII concentrates is convenient, because of the long
half-life of factor XIII, and the small quantities of factor XIII required for effective
haemostasis.
Fibrinolysis
Hereditary deficiencies of the fibrinolytic inhibitors a2-antiplasmin and PAI-1 have been
described in only a small number of patients103,104. Both deficiencies result in a life long
bleeding disorder, with manifests itself as delayed bleeding after surgery or trauma, or
spontaneous bleeding such as ecchymosis and epistaxis. Bleedings in these patients are
mainly controlled by antifibrinolytic agents. A hereditary deficiency of the recently
discovered fibrinolytic inhibitor TAFI has not yet been reported. A complete lack of
phenotype in the TAFI knockout mouse may suggest that an isolated TAFI deficiency
in humans is not associated with a serious bleeding tendency105.
Isolated reports as well as a family with a bleeding tendency due to excessive plasma tPA
activity have been reported106,107. In these cases, treatment with antifibrinolytic drugs
proved effective.
3) Acquired or drug-induced bleeding disorders
Defects in platelet number or function, coagulation, fibrinolysis, or a combination may
be a consequence of disease states of which the underlying cause is not primarily related
to haemostasis. This chapter will discuss some common disease states, which are
frequently associated with a bleeding tendency.
A common complication of treatment with drugs used in treatment or prevention of
thromboembolic events is the occurrence of bleeding complications. The bleeding
complications associated with antiplatelet, anticoagulant, and profibrinolytic drugs
will be briefly described.
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Liver disease
Both chronic and acute hepatic failure induce severe changes in the haemostatic system.
Platelets, coagulation, and fibrinolysis all become affected. In chapter 3 of this thesis, an
extensive overview of the haemostatic abnormalities found in liver disease will be given.
Renal failure
Renal disease is associatedwith ableeding tendency,which is ascribed to a combinationof
abnormalities in platelet function, abnormal platelet-vessel wall interaction, anemia, and
abnormalities in the endothelium108-111.After the introduction of dialysis to treat patients
with renal failure, the extent and severity of bleeding complications in these patients
decreased tremendously. However, excessive bleeding after trauma, during surgery, or
following smaller invasive procedures such as renal biopsy is still frequently seen. Also
gastrointestinal bleeding is common in these patients. Next to bleeding complications,
patients with chronic renal failure also experience thrombotic complications, such as
vascular access thrombosis, cardiovascular disease, and renal vein thrombosis111. The
thrombotic tendency in uremic patients presumably is caused by a combination of
general risk factors such as hyperlipidemia, hypertension, and glucose intolerance, and
the presence of a hypercoaguable state caused by decreased levels of AT, protein C, and
protein S, and the presence of hypofibrinolysis.
Platelet abnormalities found in patients with uremia include reduced in vitro aggregation
and secretion in response to a variety of agonists, decreased development of platelet
procoagulant activity on stimulation, and impaired clot retraction. Toxins that
accumulate in plasma from patients with renal failure are implicated in the
development of these platelet defects. Guanidinosuccinic acid, a product of an
alternative pathway of ammonia detoxification has been suggested to play a role in the
in vitro platelet defects. Moreover, it has been demonstrated in animal and in human
studies that this compound may be involved in elevated production of nitric oxide by
endothelial cells, thereby contributing to an in vivo platelet defect.
Abnormal platelet-vessel wall interaction in uremia has been observed using in vitro
perfusion systems, possibly also related to the presence of uremic toxins in plasma.
Part of this defect is caused by the low haematocrit in uremic blood. Also, part of the
adhesion defect is compensated for by the presence of elevated concentrations of vWF
in uremic plasma112.
Endothelial abnormalities that might contribute to the bleeding tendency in uremia
27
Chapter 1
include enhanced production of prostacyclin (presumably also triggered by uremic
toxins), and nitric oxide.
Management of bleeding in uremia consists of the correction of the anemia, either by the
administration of erythropoietin, or by red cell transfusion. Furthermore, DDAVP and
vWF concentrate appear to be effective in improving haemostasis even though vWF
levels are normal in uremia.
Acquired thrombocytopenia
Thrombocytopenia is defined as a peripheral platelet count of less than 150.000/ll. Three
distinct mechanisms can cause acquired thrombocytopenia: decreased platelet
production, decreased platelet survival, and increased pooling of platelets in the
spleen. Furthermore, hereditary forms of thrombocytopenia have been described
(either as isolated disorder, or associated with other defects), but these forms will not
be discussed here.
Thrombocytopenia as a consequence of decreased platelet production is usually caused
by damage to megakaryocytes in the bone marrow by e.g., malignancies, chemicals,
drugs, or viral infections.
Thrombocytopenia caused by decreased platelet survival is due to either increased
platelet destruction, or increased platelet consumption. Increased platelet destruction
can be drug induced, and usually immune mechanisms are involved. A classical
example is heparin-induced thrombocytopenia113. In this syndrome, antibodies against
the heparin-platelet factor 4 complex mediate platelet activation and subsequent
aggregation via binding to platelet Fc receptors. Increased platelet consumption may
be a consequence of disseminated intravasular coagulation (see below) or by
thrombotic thrombocytopenic purpura (TTP) or the hemolytic uremic syndome
(HUS). TTP and HUS are poorly characterized systemic disorders of the
microcirculation, in which an unusally high amount of high molecular weight
multimers of vWF is responsible for spontaneous platelet aggregation in the arterial
microvasulature. Autoantibodies against or mutations in the vWF-cleaving protease
(ADAMTS-13) are presumably responsible for accumulation of high molecular weight
multimers114,115.
Thrombocytopenia as a consequence of increased platelet pooling in the spleen is the
consequence of enlargement of the spleen most often occuring as a complication of
liver disease (see chapter 3).
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As acquired thrombocytopenia usually is associated with an underlying disease,
treatment of the primary condition is the treatment of choice. Platelet transfusions
may be required in case of bleeding complications, but may be ineffective if antibodies
against platelets are present. For TTP and HUS, plasma exchange results in
normalisation of vWF protease levels, and consequently in normalisation of vWF
multimeric pattern.
Disseminated intravascular coagulation
Severe infection, sepsis, trauma, malignancies, and various other disease states may be
accompanied by disseminated intravascular coagulation (DIC)116. In DIC, the
underlying condition results in systemic activation of coagulation, with important
roles for tissue factor and inflammatory cytokines117,118. Clotting activation results in
micothrombosis in a diversity of organs, leading to multiple organ failure. As a
consequence of systemic activation of coagulation, consumption of platelets and
clotting factors leads to a hypocoagulant state, with bleeding complications as a
consequence.
Treatment of coagulation abnormalities in DIC is difficult, as both a procoagulant and
hypocoagulant state are present. Inhibition of the procoagulant state in DIC may be
accomplished by anticoagulants such as heparin, antithrombin concentrates, protein C
concentrates, TFPI concentrates, and active site inactivated factor VIIa119. Bleeding
episodes may be controlled by infusion of platelet concentrates and plasma.
Antiplatelet drugs
Treatment of thrombotic manifestations, particularly in atherosclerothic cardiovascular
disease, may be assisted by use of drugs inhibiting platelet function. The oldest anti
platelet drug is aspirin (acetylsalicylic acid), which inhibits platelet function by
blocking the enzyme cyclooxygenase involved in the conversion of arachidonic acid to
thromboxane A2. Novel platelet inhibitors include inhibitors of aIIbb3, such as
abciximab (Fab fragments of a humanized antibody), Eptifibatide (a cyclic peptide
containing a KGD sequence), and tirofiban (a peptidomimetic molecule mimicking an
RGD sequence). Finally, inhibitors of P2Y12, such as ticlopidine and clopidogrel, are
currently in use in different clinical settings120.
Aspirin and P2Y12 inhibitors are used in secondary prevention of thrombosis in patients
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with established vascular disease. Aspirin also has been shown to be effective in primary
prevention of myocardial infarction. Inhibitors of aIIbb3 are only used in acute situations
(e.g., myocardial infarction) or during interventional procedures (e.g., stenting,
percutaneous coronary revascularisation).
An important complication of the use of antiplatelet drugs is an increased bleeding risk,
especially after surgery or trauma121.
Aspirin use is associated with spontaneous gastrointestinal bleeding, presumably as a
consequence of both inhibition of platelet function and ulceration and mucosal
damage by the drug. The effect of aspirin in the surgical setting is less clear. The
bleeding risk may be reversed simply by withdrawing the drug, but as aspirin
irreversably inhibits platelet function, it takes several days for the aspirin effect to be
completely reversed.
Spontaneous bleeding associated with the use of aIIbb3-inhibitors is uncommon, unless
the patient is also receiving heparin (see below)122,123. Also, surgical bleeding has been
reported to be elevated with the use of aIIbb3 drugs. An important complication
associated with the prolonged use of aIIbb3-inhibitors (especially abciximab) is the
development of thrombocytopenia, presumably initiated by immune mechanisms.
Bleeding complications in patients receiving anti-aIIbb3 drugs may be controlled simply
by withdrawing infusion of the drug. Due to the relatively short half-life of these
compounds, the induced platelet defect is rapidly reversed. When urgent bleeding
problems occur, platelet transfusion has been shown to reverse abciximab’s inhibitory
effect. However, in case of eptifibatide and tirofiban, which are dosed so that the peak
concentration is very high relative to the amount of aIIbb3 molecules present in
circulation, transfused platelets are most likely inhibited rapidly after infusion by free
circulating drug124.
Spontanous bleeding associated with the use of ADP receptor blockers has been reported
to be less frequent compared to patients treated with aspirin. Surgical bleeding has been
shown to be increased. Specific therapy to reverse bleeding has not been established in
humans, but animal experiments suggest that the use of aprotinin might be beneficial.
Drugs targeting the coagulation system
Inhibition of thrombin generation is considered an important aspect of antithrombotic
treatment. Traditionally, heparin or low molecular weight heparins have been used to
downregulate the coagulation system. These agents function by enhancing the activity
of antithrombin towards both factor Xa and thrombin. If prolongued anticoagulation
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is required, treatment with heparin is replaced by administration of oral anticoagulants
(OAC’s) such as warfarin125. OAC’s interfere with c-carboxylation of vitamin K
dependent coagulation factors (FVII, IX, X, II, protein C, S, and Z), thereby reducing
plasma levels of functional vitamin K-dependent proteins.
Recently, a synthetic pentasaccharide (Org31540/SR90107A, fondaparinux sodium,
Arixtra, PENTA), which selectively inhibits factor Xa in an antithrombin dependent
manner, has been introduced as an alternative to traditional low molecular weight
heparins (LMWH’s)126. Alternative strategies aiming at down-regulation of
coagulation include direct inhibition of thrombin, by low molecular weight inhibitors
such as D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone (PPACK)127 or
hirudin128, direct inhibition of factor X129, or inhibition of the tissue factor pathway by
active site inactivated factor VIIa (ASIS, FFRck-VIIa)130 or recombinant full length
tissue factor pathway inhibitor (rFL-TFPI)131.
The major complication of anticoagulant therapy using any of the mentioned
anticoagulant drugs is bleeding. In case of heparin use, bleeding may be treated with
protamine, which instantly neutralizes the anticoagulant function of heparin. LMWH
is not effectively neutralized by protamine. Reversal of oral anticoagulants may be
accomplished by administration of vitamin K. However, it takes time for the body to
synthesize new, functional coagulation factors. Administration of prothrombin
complex concentrates can be used if immediate reversal of OAC’s is required132.
However, the use of PCC’s is associated with a thrombotic risk133. For the new
generation anticoagulant drugs no consensus over reversal strategies exist. Most
probably, the use of PCC’s is also in these settings the treatment of choice.
Thrombolytic drugs
Treatment of arterial thrombosis, particularly myocardial infarction, but also of venous
thrombosis may be facilitated by the use of thrombolytic therapy134. Thrombolytic drugs
activate plasminogen into plasmin, thereby facilitating breakdown of a thrombus.
Recombinant tPA and uPA, and variants such as reteplase are human-derived
thrombolytic agents. Also, bacterial products such as streptokinase and staphylokinase
are currently in clinical use. A major complication of the use of thrombolytic agents is the
development of systemic haemorrhagic effects. Intracranial haemorrhage is an
important side effect of thrombolytic therapy, affecting 5 to 10 of 1000 patients
treated135. Bleeding episodes induced by thrombolytic drugs may be treated with
plasma infusion. Withdrawal of the infusion of the thrombolytic agent may be
31
Chapter 1
sufficient to neutralize the fibrinolytic state due to the short half-life of these drugs, and
immediate reversal of the effect of the fibrinolytic agent may be accomplished by
antifibrinolytic drugs such as tranexamic acid or e-aminocaproic acid.
4) Recombinant factor VIIa (rFVIIa) – a universal haemostatic agent?
The development of recombinant factor VIIa to treat inhibitor-complicated haemophilia
In the 1970’s, factor VIII and IX concentrates became available to provide replacement
therapy for patients with haemophilia. This was a major step forward in the treatment of
these patients, reducing morbidity and mortality. An important complication of
replacement therapy, however, is the development of inhibitory antibodies against
factor VIII or IX, as a result of which continuation of replacement therapy will be
ineffective92,93.
Initially, PCC’s and activated PCC’s were used to bypass the lack of intrinsic tenase
activity in inhibitor patients. However, these agents have a rather low efficacy rate (50-
60%)136,137 and are associated with thromboembolic complications133.
It was hypothesized that factor VIIa might be a useful alternative to treat inhibitor-
complicated haemophilia, as factor VIIa is virtually proteolytic inactive by itself, and
would thus not induce systemic coagulation, whereas coagulation would be enhanced
at sites of vascular injury where tissue factor is expressed. In 1983, the first publication
appeared in which factor VIIa purified from human plasma was succesfully used to treat
two patients with haemophilia A and high titre inhibitors138. The use of plasma-derived
factor VIIa for treating a large population of haemophilia patients would, however, not
be a realistic option, due to the low plasma concentration of factor VII and the low yield
of purification.
In 1986, factor VII was cloned139, and cDNAwas transfected into baby hamster kidney
cells140. The factor VII produced by this expression system is currently purified using
four chromatograpic steps (Q-sepharose, Immunoaffinity, and two anion-exchange
steps)140. Also a virus inactivation step using triton X-100 is included. During
purification, activation of factor VII, i.e., hydrolysis of a single peptide bond (Arg152-
Ile153) in the single chain protein to yield two-chain VIIa, is accomplished by an
incompletely understood mechanism141. Most probably, trace amounts of VIIa are
generated by cellular proteases during fermentation. These trace amounts of VIIa
could initiate VII autoactivation142. The obtained product is a highly purified protein
preparation with an extremely high degree of virus safety143.
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The amino acid sequence of rFVIIa was found to be identical to that of plasma derived
VIIa140. The posttranslational modifications of rFVIIa and plasma derived VIIa (such as
glycosylation and c-carboxylation) were highly comparable, and the enzymatic
properties of the two products were indistinguishable144.
In 1988, the first publication of the successful use of rFVIIa in a patient with inhibitor-
complicated haemophilia A undergoing surgery appeared145. In 1989, a compassionate
use program was initiated (patients with life or limb threatening bleedings in whom all
conventional therapy had failed and patients undergoing elective surgery were included)
and at the same time regular clinical studies were initiated. All studies showed that
rFVIIa was a safe and highly effective treatment both during bleeding episodes, and
prophylactically during surgery146-150. rFVIIa (NovoSeven) was approved in Europe
in 1996, in the United States in 1999, and in Japan in 2000.
The advised dosing schedule currently consists of bolus injections of 90-120 lg/kg
bodyweight every two hours. However, recent reports suggest higher dosages (up to
300 lg/kg) to be more effective151. Alternatively, continuous infusion may be
administered after a single bolus dose, but the efficacy of that approach seems less
effective, at least in some cases152. Adjunctive therapy with antifibrinolytic agents such
as tranexamic acid is frequently used. Recovery and clearance rate of rFVIIa may vary
substantially between patients. Especially in paediatric patients, clearance of rFVIIa
seems significantly higher than in controls153. Few options for laboratory monitoring
of rFVIIa treatment are currently available. A standard one-stage clotting assay, or an
assay employing a TF mutant incapable of supporting FVII autoactivation can be used
to determine rFVIIa activity in plasma154. Treatment should be aimed at achieving peak
levels of 60-90 U/ml (corresponding to 1.2-1.8 lg/ml or 24-36 nM)155.
Since approval, around 200.000 standard doses of rFVIIa have been administered, and
the number of reported serious side effects is extremely low. Only two haemophilia
patients with thromboembolic complications and three with acute myocardial
infarction have been reported in association with the use of rFVIIa. In all of them,
predisposing factors such as previous cardiovascular disease and advanced age were
present155.
Novel indications for rFVIIa
After the encouraging results of the use of rFVIIa in patients with haemophilia A and B,
case reports and small studies were published describing succesful use of rFVIIa in a
diversity of congenital and aqcuired bleeding disorders. Moreover, rFVIIa has been
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used in patients without any coagulopathy either to arrest bleeding, or to reduce blood
loss during surgery. It has been suggested that rFVIIa might become a universal
haemostatic agent. This section will discuss the current experience with rFVIIa in
clinical settings other than haemophilia.
Deficiencies of other coagulation factors
A number of patients with factor VII deficiency have been succesfully treated with
rFVIIa156. Only one patient, who was treated with an accidental overdose of 800 lg/kg
developed antibodies against VIIa157. Also, patients with factor XI deficiency158,159, and
a single patient with amyloid-induced factor X deficiency160 have been reported to
benefit from rFVIIa infusion.
Platelet-related bleeding disorders
Patients with various platelet-related bleeding disorders have been treated with rFVIIa.
Several patients with severe thrombocytopenia have been succesfully treated with
rFVIIa161. Moreover, dozens of patients with Glanzmann’s thrombasthenia have been
succesfully treated with rFVIIa during bleeding episodes and surgery162. It must be
noted, however, that these patients often receive adjunctive therapy such as
antifibrinolytic drugs and local measures such as topical thrombin and fibrin glue.
Treatment of a single patient with Bernard Soulier syndrome with rFVIIa for recurring
nosebleeds has been reported163. Finally, several case reports of patients with von
Willebrand’s disease treated with rFVIIa have been published164,165.
Hepatic failure and liver transplantation
The use of rFVIIa in patients with liver disease and during liver transplantation has
gained a lot of interest. Patients with liver failure may suffer from esophageal bleedings
and may be at increased risk of bleeding from small invasive procedures such as liver
biopsy. A blind randomised study dealing with safety and efficacy of the use of rFVIIa
during liver biopsy166, and several case reports describing efficacy of rFVIIa in patients
with liver failure during bleeding episodes have been published167,168.
Liver transplantation is despite major improvements in surgical techniques still
associated with substantial blood loss. A pilot study has shown that a single bolus dose
of rFVIIa significantly reduced transfusion requirements during liver transplantation169.
A drawback of this study, however, was the comparison with historic controls. More
extensive double blind, randomised clinical trials are currently ongoing.
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Renal failure
Two case reports describing the succesful use of rFVIIa to arrest bleeding in patients with
uremia have been published170,171.
Antiplatelet and anticoagulant drugs
rFVIIa has been implicated in treatment of bleedings induced by antithrombotic drugs.
Also, reversal of the anticoagulated state of these patients may be required for urgent
surgery. The actual experience with rFVIIa in these patients is, however, scarce. A
single case in which a patient who had received an antiplatelet drug (tirofiban) was
treated with rFVIIa has recently been reported18. rFVIIa has been administered to
healthy volunteers who were anticoagulated with acenocoumarol and reversal of
laboratory values such as the international normalized ratio (INR) was observed172. A
single case report of succesful use of a bleeding episode in a patient receiving oral
anticoagulation has been reported173. rFVIIa has been implicated in reversal of
anticoagulation by pentasaccharide, and reversal of laboratory values have been
shown in a phase I trial (Dr. M. Levi, personal communication).
Trauma, uncontrollable bleeding, and surgery in absence of preexisting coagulopathy
The possible use of rFVIIa in patients with uncontrollable bleeding due to severe trauma
has gained interest since the first report in 1999 on a patient with extensive bleeding due
to an intra-abdominal gun-shot wound who stopped bleeding on rFVIIa infusion after
all other possible treatment options were unsuccesful174. After this first case report seven
other critically ill, multitransfused trauma patients (gunshot wounds, stab wounds, and
trauma induced by car accidents) were succesfully treated with rFVIIa175.
A limited number of case reports described the use of rFVIIa in uncontrollable post-
surgical bleeding, such as gastrointestinal bleeding, in patients without preexisting
coagulopathy176-178. One centre reported the use of rFVIIa in 5 patients undergoing
heart valve replacement therapy179. rFVIIa was administered during or after surgery
while the patients experienced excessive and uncontrollable bleeding. In all cases
rFVIIa substantially reduced subsequent blood loss, and haemostasis was achieved in
all cases.
Finally, preliminary results from one randomised, double blind, placebo controlled, dose
escalating, single centre study has been reported in which rFVIIa was used during
prostatectomy180,181. This study showed a significant reduction in blood loss and
transfusion requirements.
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5) Mechanism of action of recombinant factor VIIa
The molecular mechanisms responsible for the haemostatic efficacy of rFVIIa in its
various clinical applications are poorly understood. It is also still unclear why
relatively high plasma concentrations of rFVIIa are required to induce effective
haemostasis in patients with haemophilia, and whether these concentrations are also
required to induce haemostasis in different patient populations. In this section the
current hypotheses on the mechanism of action of rFVIIa will be discussed.
Tissue factor-dependent enhancement of coagulation
Initial concepts on the mechanism of action of rFVIIa in haemophilia were based on
tissue factor-dependent enhancement of thrombin generation. The extremely low
incidence of thromboembolic complications on rFVIIa administration was explained
by the requirement for tissue factor for VIIa to be enzymatically active. It was
subsequently shown that rFVIIa infusion in non-bleeding chimpansees resulted in
significant increases in plasma levels of prothrombin fragment 1+2, and the activation
peptides of factor IX and X182. The effects for rFVIIa infusion could be abolished by
preinfusing an inhibitory antibody against tissue factor. These results pointed to a TF-
dependent mechanism, although it was still not clear why relatively high rFVIIa
concentrations are required for haemostatic efficacy. Moreover, experiments in
actively bleeding animals or in haemophilia A or B animals adressing the question of
TF-dependency have to our knowledge not been performed.
In vitro experiments provided an explanation for the requirement of relatively high
rFVIIa concentrations. Van ’t Veer et al. showed that endogenous zymogen factor VII
inhibits tissue factor-induced coagulation at low concentrations of TF183. In the
absence of factor VIII, the presence of zymogen factor VII significantly inhibited
thrombin generation, and addition of rFVIIa in pharmacologically relevant
concentrations restored thrombin generation to levels found in the presence of factor
VIII. A subsequent publication from the same group, however, showed that rFVIIa is
not able to restore thrombin generation in a haemophilia model but only restores
clotting time in a whole blood model184. In the same paper it was concluded that the
efficacy of rFVIIa in haemophilia blood is dependent of TF as in the absence of TF the
concentration of rFVIIa to reach similar thrombin generation than in its presence was
around 104 times higher.
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Tissue factor-independent enhancement of coagulation
In the early phase of development of rFVIIa it was observed that rFVIIa not only has an
effect on the prothrombin time, but that the activated partial thromboplastin time
(APTT) was also shortened by rFVIIa. This phenomenon could be explained by a
tissue factor-independent activation of factor X by rFVIIa185. Indeed, also in purified
systems it had already been shown that FVIIa was able to activate factor X in the
presence of calcium and phospholipids, albeit at a much slower rate than in the
presence of TF186. It was hypothesized that a TF-independent mechanism of action of
rFVIIa could be physiologically relevant, as a TF-dependent mechanism could not
explain relatively high plasma concentrations of rFVIIa required for haemostatic
efficacy. As the Kd for VIIa binding to TF is around 0.5 nM187, and the
concentrations of rFVIIa required for effective haemostasis are at least an order of
magnitude higher, it seemed unlikely that TF-rFVIIa interaction plays an important
role in inducing haemostasis.
The TF-independent mechanism of rFVIIa was further formulated using a cell-based in
vitro model. It was shown that rFVIIa could activate FX on the surface of freshly
isolated monocytes independently of tissue factor188. An endothelial cell line was not
able to support TF-independent FX activation and this finding provided an
explanation why rFVIIa treatment is not complicated by systemic induction of
coagulation. Thus, rFVIIa is able to activate FX independently of TF, provided that a
suitable cellular surface is provided. Whether the surface requirements only depend on
phospholipid composition, of if cellular receptors for rFVIIa are also involved remains
unclear.
When it was shown that rFVIIa is also able to bind directly to the surface of activated
platelets (with a Kd of around 90 nM) and activate FX independently of TF189, a refined
model for the TF-independent mechanism of action of rFVIIa was formulated. In the
cell-based model of coagulation as proposed by Hoffman, Monroe, and Roberts49,
coagulation is initiated on a tissue factor-bearing cell (e.g., a fibroblast or smooth
muscle cell). Binding of FVIIa to TF results in the generation of a small amount of
FXa and subsequently a small amount of thrombin is generated. This small amount of
thrombin activates platelets, and cofactors Va and VIIIa, but is not sufficient to generate
fibrin. The FXa generated on the TF bearing cell is rapidly inhibited by TFPI or
antithrombin if it leaves the surface. On the other hand, the factor IXa generated by
the TF bearing cell is relatively protected from inhibitors when it leaves the surface.
This factor IXa can bind to the activated platelets, and activate factor X, which
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subsequently combines with factor Va, leading to large-scale thrombin generation.
According to this model, haemophilia is a defect in platelet-mediated thrombin
generation. The efficacy of rFVIIa can according to the cell-based model be explained
by TF-independent activation of FX on the platelet surface facilitated by direct
binding of rFVIIa to activated platelets. The same concept is postulated for the
efficacy of rFVIIa in the various other indications190. Theoretically, for all indications,
TF-independent enhancement of thrombin generation on activated platelets by rFVIIa
could compensate for the haemostatic defect.
Enhancement of clot stability
Novel hypotheses on the mechanism of action of rFVIIa are not focussed on
enhancement of thrombin generation, but on the consequences of the enhancement of
thrombin generation. As obviously a damaged vessel wall is not closed by thrombin,
but by a haemostatic plug consisting of platelets and fibrin, it makes sense to
investigate the composition, structure, and stability of haemostatic plugs formed in
absence or presence of rFVIIa.
It has been demonstrated that the rate of thrombin generation determines fibrin structure
and stability191. In the presence of little thrombin the fibrin consists of thick fibres which
are easily dissolved by the fibrinolytic system, whereas thin, stable fibres are formed in the
presence of a higher concentration of thrombin192. Recently, He et al. demonstrated that
rFVIIa could normalize fibrin permeability in haemophilia plasma, directly indicating
that rFVIIa affects fibrin structure in this system193. The decrease in fibrin porosity on
rFVIIa addition might indicate enhancement of clot stability.
The enhancement of thrombin generation might enhance the stability of the haemostatic
plug by enhancing platelet activation and aggregation, factor XIII activation and TAFI
activation. Enhancement of platelet activation and aggregation might improve the
mechanical stability of the clot. Also, enhanced platelet activation might lead to an
increase in exposure of procoagulant surface, which might lead to a further
enhancement of thrombin generation. Enhanced fibrin crosslinking and enhanced
TAFI activity could result in a further protection of the haemostatic plug against
breakdown by the fibrinolytic system. Furthermore, enhanced platelet activation might
lead to enhanced secretion of PAI-1 and a2-antiplasmin from platelet a-granules, which
also contributes to down-regulation of fibrinolysis.
Whether the above mentioned processes are indeed involved in rFVIIa-mediated
enhancement of clot stability in vivo remains to be investigated.
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6. Aim of this thesis
In this thesis, novel hypotheses on the mechanism of action of rFVIIa in different
haemostatic disorders will be described. In the major part of this thesis, the focus will
be on the involvement of TAFI-mediated down-regulation of fibrinolysis in in vitro
systems representing various haemostatic disorders, and the effect of rFVIIa. In
chapter 2, the effect of rFVIIa on coagulation and fibrinolysis in plasma from patients
with severe haemophilia A has been investigated. In an appendix to chapter 2, similar
experiments were performed using mutants of rFVIIa with enhanced intrinsic (i.e., TF-
independent) activity. In chapters 3,4, and 5 the haemostatic disorders induced by liver
failure, the involvement of TAFI in the coagulopathy of liver failure, and the effects of
rFVIIa on TAFI-mediated down-regulation of fibrinolysis in patients with cirrhosis
and during liver transplantation are described. Chapter 6 deals with the effects of
antithrombotic drugs targeting different steps in the coagulation cascade on TAFI-
mediated down-regulation of fibrinolysis, and in chapter 7 the reversal of anticoagulant
and profibrinolytic effects of the novel heparin-derivative fondaparinux by rFVIIa is
described. In chapter 8, the focus is on the effects of rFVIIa on platelet adhesion under
flow conditions. More specifically, a model for the mechanism of action of rFVIIa in
patients with Glanzmann’s thrombasthenia, and patients treated with anti-aIIbb3 drugs
is proposed based on results of in vitro perfusion studies. In chapter 9, the results
presented in the previous chapters are discussed in a broader context. The advances in
the understanding of the mechanism of action of rFVIIa in its different applications are
discussed.
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Abstract
Recombinant factor VIIa (rFVIIa) is a novel prohaemostatic drug for patients with
haemophilia who have developed inhibitory antibodies. The postulation has been
made that haemophilia is not only a disorder of coagulation, but that hyperfibrinolysis
due to a defective activation of thrombin activatable fibrinolysis inhibitor (TAFI) might
also play a role. In this in vitro study, the potential of rFVIIa to downregulate fibrinolysis
via activation of TAFI was investigated. rFVIIa was able to prolong clot lysis time in
plasmas from 17 patients with severe haemophilia A. The prolongation of clot lysis
time by rFVIIa was completely abolished by addition of an inhibitor of activated
TAFI. The concentration of rFVIIa required for half maximal prolongation of clot
lysis time (Clys½-VIIa) varied widely between patients (median 73.0 U/ml; range 10.8-
250). The concentration of rFVIIa required for half maximal reduction of clotting time
(Cclot½-VIIa) was approximately 10-fold lower than the Clys½-VIIa value (median 8.4 U/
ml; range 1.7-22.5). Inhibition of TFPI with a polyclonal antibody significantly
decreased Clys½-VIIa values (median 2.6 U/ml; range 0-86.9), whereas Cclot½-VIIa
values did not change (median 7.2 U/ml; range 2.2-22.5). On addition of 100 ng/ml
recombinant full length TFPI, a nonsignificant increase of Clys½-VIIa values was
observed (median 119.2 U/ml; range 12.3-375.0), whereas Cclot½-VIIa values did not
change (median 8.8 U/ml; range 2.6-34.6). In conclusion, this study shows that rFVIIa
both accelerates clot formation and inhibits fibrinolysis by activation of TAFI in factor
VIII-deficient plasma. However, a large variability in antifibrinolytic potential of rFVIIa
exists between patients.
Introduction
Treatment of patients suffering from haemophilia is often complicated by the
development of inhibitory antibodies. In approximately 25-30% of patients with
haemophilia A92 and in approximately 1-3% of the patients with haemophilia B93,
inhibitors develop during their lifetime. A novel way to treat haemophilia patients with
inhibitors is the administration of recombinant factor VIIa (rFVIIa, NovoSeven)
195
.
rFVIIa has been shown to be a safe and effective prohaemostatic drug during bleeding
episodes or surgery148,196. Advantages over traditional treatment (i.e., factor
concentrates) are the lack of antigenicity and viral safety of rFVIIa143,197.
rFVIIa exerts its prohaemostatic effect via enhancement of the extrinsic coagulation
pathway in a tissue factor-dependent manner182. On binding of factor VIIa to tissue
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factor, factor VIIa is able to activate both factors IX and X, thereby leading to a primary
generation of thrombin. At high concentrations of tissue factor, factor X is the preferred
substrate for the tissue factor-VIIa complex, whereas at low tissue factor concentrations
factor IX is preferably activated. (for a review see 21). The ability of high-dose rFVIIa to
overcome the inhibitory effect of plasma factor VII on coagulation might play a role in
the enhancement of thrombin generation by rFVIIa183. After formation of the fibrin clot,
thrombin generation proceeds via the intrinsic pathway through activation of factor XI
by thrombin198. The secondary burst of thrombin, which is formed via this factor XI
feedback loop, results in the activation of TAFI (thrombin activatable fibrinolysis
inhibitor)65. Activated TAFI down-regulates fibrinolysis by cleaving C-terminal lysine
and arginine residues from partially degraded fibrin, thereby attenuating t-PA
mediated fibrinolysis199. Activation of TAFI is stimulated approximately 1200-fold on
thrombin binding to the cell surface receptor thrombomodulin66.
The discovery of TAFI as an important link between coagulation and fibrinolysis
stimulated the development of new concepts on the regulation of the haemostatic
system. A clotting factor deficiency such as haemophilia A might not only result in
defective clot formation, but also in accelerated clot degradation due to diminished
TAFI activation. Indeed, it has been shown that factor VIII-deficient plasma shows
premature lysis of tissue factor-induced clots due to a lack of TAFI activation, which
could be restored by addition of factor VIII200,201. Clinical evidence that supports the
hypothesis of haemophilia A being a defect in both coagulation and fibrinolysis has
been obtained from skin biopsy studies in patients with severe haemophilia A in which
abnormalities in a skin wound could not be observed until 2 hours after the wound was
made202. Although these abnormalities were initially explained by the decreased fibrin
forming capacity of these patients, an increased fibrinolytic potential could also
explain these observations. Another indication of disturbed down-regulation of
fibrinolysis in haemophilia is the efficacy of antifibrinolytic drugs like tranexamic acid
and e-aminocaproic acid in controlling bleedings in regions of the body with high
fibrinolytic activity, such as the oral cavity203,204.
Alternative mechanisms for the therapeutic effects of rFVIIa have been proposed. A
potential mechanism, hypothesized in the literature205, involves enhancement of
activation of TAFI. Another possible alternative mechanism involves thrombin
formation on activated platelets or monocytes independently of tissue factor188,189.
In this study, the antifibrinolytic potential of rFVIIa in plasma from different patients
with severe haemophilia A was explored. Also, the involvement of tissue factor
pathway inhibitor on rFVIIa mediated clot protection was investigated.
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Materials and Methods
Patients
Plasma samples from 17 patients with severe haemophilia Awere used. Of these 17, eight
patients had an inhibitor titre above 1 BU/ml. Patients had not received treatment with
factor VIII containing products for at least 72 hours before blood sampling. Pooled
normal plasma was obtained by combining plasma from 40 healthy volunteers. Blood
samples were obtained by venipuncture from the antecubital vein into 3.2% sodium
citrate (9:1, v/v). To obtain platelet poor plasma, the samples were centrifuged twice at
2000g for 15 minutes. Plasma samples were stored at –708C until use.
Materials
Recombinant human tissue factor (Innovin) was from Dade Behring GmbH (Marburg,
Germany). Carboxypeptidase inhibitor from potato (CPI) was purchased from
Calbiochem (La Jolla, CA). Tissue type plasminogen activator (t-PA) was from
Chromogenix (Mo¨lndal, Sweden). Recombinant factor VIIa, recombinant full length
tissue factor pathway inhibitor (rFL-TFPI), a polyclonal inhibitory antibody against
tissue factor, and a polyclonal inhibitory antibody against human factor VIII were
generous gifts from Drs U. Hedner and M. Kjalke (tissue factor/factor VII research,
Novo Nordisk, Denmark). A polyclonal inhibitory antibody against TFPI (13 mg/ml)
was a generous gift from Dr Walter Kisiel (University of New Mexico, Albuquerque,
NM, USA) and was used in a dilution of 1:100. Purified human factor VIII
(Monoclate-P) was from Armour Pharmaceuticals (Collegeville, PA, USA).
TAFI antigen levels were determined by a sandwich-type ELISA, using a monoclonal
capturing antibody and a polyclonal detection antibody as described206. TAFI levels
were expressed as percentage of pooled normal plasma. TFPI activity levels were
determined according to Sandset207. Factor II, VII, and X activity levels were
determined by a one stage clotting assay using factor II and factor X deficient plasma
from Boeringer Mannheim GmbH (Mannheim, Germany), and factor VII deficient
plasma from Helena Laboratories (Beaument, TX). Thromborel S from Dade Behring
(Mannheim, Germany) was used as thromboplastin reagent. Fibrinogen levels were
determined according to Clauss208, using thrombin obtained from Sigma (St. Louis,
MO). Levels of plasminogen were determined using the Coamatic plasminogen kit
from Chromogenix (Mo¨lndal, Sweden). Soluble thrombomodulin levels were
determined using the asserachrom Thrombomodulin ELISA kit from Diagnostica
Stago (Asnie`res, France).
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Phospholipid vesicles consisting of 40% L-a-dioleoylphosphatidylcholine, 20% L-a-
dioleoylphosphatidylserine and 40% L-a-dioleoylphosphatidylethanolamine (all from
Sigma, St. Louis, MO) were prepared according to Brunner209 with minor
modifications as described by van Wijnen210. Total phospholipid content of the vesicles
was determined by phosphate analysis according to Rouser211.
Clot lysis assay
Lysisofa tissue factor inducedclotbyexogenous t-PAwasstudiedbymonitoringchanges in
turbidity during clot formation and subsequent lysis essentially as described previously212.
A mixture of tissue factor (diluted Innovin, final dilution 105 times), CaCl2 (final
concentration 17 mM), t-PA (final concentration 30 U/ml; 56 ng/ml) and phospholipid
vesicles (final concentration 10 lM) was added to 75 ll of citrated plasma. The volume
was adjusted to 150 ll with Hepes buffer (25 mM Hepes, 137 mM NaCl, 3.5 mM KCl, 3
mM CaCl2, 0.1% BSA, pH 7.4), resulting in a final plasma concentration of 50%. After
mixing thoroughly, 100 ll of this mixture was transferred to a microtiter plate and
turbidity at 405 nm was measured in time at 37ºC in a Spectramax 340 kinetic microplate
reader (Molecular Devices Corporation, Menlo Park, CA, USA). Clot lysis time was
defined as the time from the midpoint of the clear-to-maximum-turbid transition, which is
defined as clotting time, to the midpoint of the maximum-turbid-to-clear transition. To
block possible residual factor VIII activity in haemophilic plasma which did not contain
an inhibitor, 10 BU/ml of a polyclonal antibody against human factor VIII was added
and preincubated at room temperature for 45 minutes. To assess the contribution of
TAFI activation to clot lysis time, experiments were performed in which CPI (25 lg/ml), a
specific inhibitor of activated TAFI199, was added to the plasma. The effect of rFVIIa on
fibrinolysis in haemophilic plasma was determined by performing clot lysis assays with
factor VIII deficient plasma to which different concentrations of rFVIIa was added.
Statistical analysis
Statistical analysis was performed using the GraphPad InStat (San Diego, USA)
software package. Statistical significance of the increase in mean clot lysis time on
addition of rFVIIa was determined by a repeated measures ANOVA followed by
Dunnett’s post test. Statistical differences between clotting times in the presence or
absence or an inhibitory antibody against tissue factor was determined by standard
t-test. Correlations were calculated using the Pearson correlation coefficient. Statistical
significance between differences in Clys½-VIIa or Cclot½-VIIa on manipulation of TFPI
was calculated by a repeated measures ANOVA followed by the Tukey post test. P values
<0.05 were considered statistically significant.
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Results
rFVIIa mediates down-regulation of fibrinolysis and acceleration of clot formation in factor
VIII-deficient plasma
To investigate whether rFVIIa restores down-regulation of fibrinolysis in factor VIII-
Figure 1. Effect of rFVIIa on clot formation and clot lysis time in plasma from a patient with severe
haemophilia A. Panel A shows the increase in clot lysis time upon addition of increasing
concentrations of rFVIIa (closed symbols). The increase in clot lysis time upon addition of 500
U/ml of rFVIIa could be completely abolised by addition of CPI (open symbol). Panel B shows
mean clot lysis times of 17 patients with severe haemophilia A upon addition of increasing
concentrations of rFVIIa. At concentrations of rFVIIa of 31.3 U/ml and higher, the increase in
clot lysis time was statistically significant. Error bars indicate standard error of mean. * p<0.01
vs clot lysis time in the absence of rFVIIa. Panel C shows the data from panel A fitted by an
exponential function. From this curve the concentration of rFVIIa required for half maximal
prolongation of clot lysis time (Clys½-VIIa) was calculated. Panel D shows the decrease in
clotting time upon addition of rFVIIa. These data were fitted by an exponential function and
from this curve the concentration of rFVIIa required for half maximal reduction of clotting time
(Cclot½-VIIa) was calculated.
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deficient plasma, clot lysis assays were performed using plasma from 17 patients with
severe haemophilia A in the presence of different concentrations of rFVIIa. A
polyclonal inhibitory antibody to human factor VIII was added to the plasma samples
in which no inhibitor was present, because a previous study showed that as little as
0.01% of factor VIII present in pooled normal plasma is sufficient to completely restore
down-regulation of fibrinolysis in factor VIII-deficient plasma201. A typical example of
the effect of rFVIIa on clot lysis time in haemophilic plasma is shown in figure 1A.
rFVIIa was able to prolong clot lysis time in all patient samples. The rFVIIa-mediated
prolongation of clot lysis time could be completely abolished by the addition of a
specific inhibitor of activated TAFI (CPI). Figure 1B shows mean clot lysis times for the
17 patient samples at increasing concentrations of rFVIIa. At rFVIIa concentrations of
31.3 U/ml and higher the increase in clot lysis time was statistically significant (p<0.01).
From the rFVIIa titration curves the concentrations of rFVIIa required for half maximal
prolongation of clot lysis time (Clys½-VIIa) were determined as shown in figure 1C.
Awide variation of Clys½-VIIa values was observed as shown in figure 2A (median 73.0
U/ml; range 10.7-250.0). Clys½-VIIa values were similar in plasma samples from
patients without (median 73.0 U/ml; range 17.4-185.9) and with (median 81.8 U/ml;
range 10.7-250.0) inhibitory antibodies. To examine whether the antifibrinolytic
potential of rFVIIa remained constant over time in a single patient, Clys½-VIIa
values of two unrelated patients were determined in 4 plasma samples collected at
Figure 2. Variability in antifibrinolytic and procoagulant effect of rFVIIa in 17 plasma samples
from patients with severe haemophilia A. Panel A: Clys½-VIIa values were determined in plasma
samples from 17 patients with severe haemophilia A following the example in figure 1B. Panel B:
Cclot½-VIIa values were determined in plasma samples from 17 patients with severe haemophilia A
following the example in figure 1C. The horizontal line indicates medians.
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intervals of approximately 3 months. These experiments showed that Clys½-VIIa values
remained constant in a period of 1 year (patient 1: range 238-267 U/ml, patient 2:
range 91-150 U/ml).
To investigate the effect of tissue factor concentration on Clys½-VIIa values, clot lysis
assays were performed using plasma of a single patient in which coagulation was
initiated by increasing amounts of tissue factor. Clys½-VIIa was 85 U/ml at the
tissue factor dilution used throughout this study. When the tissue factor
concentration was doubled or quintupled, Clys½-VIIa values decreased to 26 and 11
U/ml, respectively.
Correlation of Clys½-VIIa values with levels of several plasma proteins
To study possible parameters that influence Clys½-VIIa values, levels of several plasma
proteins were measured and the correlation with Clys½-VIIa values was determined.
Clys½-VIIa values were not correlated with TFPI activity (r=0.190, p=0.468), TAFI
antigen (r=0.089, p=0.729), soluble thrombomodulin antigen (r=0.032, p=0.895),
fibrinogen (r=0.054, p=0.861), factor II activity (r=0.071, p=0.785), factor VII activity
(r=0.286, p=0.265), factor X activity (r=0.302, p=0.238), and plasminogen activity
(r=0.032, p=0.902) levels.
To exclude the possibility that differences in trace amounts of factor VIII activity left in
the plasma samples account for the large variation in Clys½-VIIa values, an experiment
was performed using a plasma sample from a patient with severe haemophilia A due to
an intron 22 gene inversion, who did not receive any treatment for over a year. The
plasma in this patient was considered to completely lack factor VIII activity. Clys½-
VIIa values were determined in this plasma sample in the presence of the polyclonal
inhibitory antibody in the absence or presence of 1 mU/ml factor VIII, which
represents 0.1% of the factor VIII found in pooled normal plasma. Clys½-VIIa did not
change upon addition of factor VIII, indicating sufficient inhibition of 0.1% factor
VIII by the antibody (data not shown).
Improvement of clot formation requires around 10-fold less rFVIIa than improvement of
fibrinolysis
In all patients, a significant reduction in clotting time on addition of rFVIIa was
observed. A typical example of the effect of rFVIIa on clotting time is shown in figure
1D. Cclot½-VIIa values were defined as the concentration of rFVIIa required to half-
maximally reduce clotting time. Cclot½-VIIa values were approximately 10-fold lower
than Clys½-VIIa values as shown in figure 2B (median 8.4 U/ml; range 1.7-22.5). Cclot½-
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VIIa values were not correlated with Clys½-VIIa values (r=0.187, p=0.470). Cclot½-VIIa
for pooled normal plasma was 9.9 U/ml.
Cclot½-VIIa values correlate with endogenous factor VII levels
Cclot½-VIIa values were positively correlated with endogenous factor VII levels as shown
in figure 3 (r=0.653, p<0.005). Cclot½-VIIa values were not correlated with plasma levels
of factor X (r=0.311, p=0.223), factor II (r=0.164, p=0.530), and fibrinogen (r=0.206,
p=0.499).
Tissue factor dependency of clot formation in haemophilic plasma
To investigate whether clot formation in factor VIII-deficient plasma was completely
dependent on tissue factor, clot lysis assays were performed using plasma samples
from 4 patients (all with inhibitory antibodies against factor VIII) in the presence of
increasing concentrations of rFVIIa and in the presence or absence of an inhibitory
antibody against tissue factor (500 lg/ml). As shown in figure 4, clot formation was
significantly inhibited (clotting time >30 min) on inhibition of tissue factor. When
rFVIIa was added to the plasma, clotting did occur during the time span of our
experiment when tissue factor was inhibited. Inhibition of tissue factor attenuated clot
formation at all rFVIIa concentrations tested. However, at 125 and 250 U/ml rFVIIa the
increase in clotting time upon inhibition of tissue factor was no longer statistically
significant.
Figure 3. Correlation between Cclot½-VIIa levels and endogenous factor VII levels.
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Effects of modulation of TFPI on Clys½-VIIa and Cclot½-VIIa values
The effect of TFPI on Clys½-VIIa and Cclot½-VIIa values was investigated in all patient
samples. As shown in figure 5A, addition of rFL-TFPI resulted in an increase in Clys½-
VIIa values (median 119.2 U/ml; range 12.3-375 U/ml), but this did not reach statistical
significance. Inhibition of TFPI by an inhibitory antibody resulted in a significant
decrease of Clys½-VIIa values (median 2.6 U/ml; range 0-86.9, p<0.05).
As shown in figure 5B, addition of rFL-TFPI did not change Cclot½-VIIa values (median
7.2 U/ml; range 2.2-20.5). Also addition of a blocking antibody against TFPI did not
change Cclot½-VIIa values (median 8.8 U/ml; range 2.6-34.6). However, clotting times
in the absence of rFVIIa were decreased by addition of a blocking antibody against
TFPI, whereas clotting times in the absence of rFVIIa increased by addition of rFL-
TFPI (data not shown).
Figure 4. Effect of the inhibition of tissue factor on the clotting time in plasma from four patients
with severe haemophilia A at different rFVIIa concentrations. Clotting times were determined
using the same conditions as used for the clot lysis assay in the absence (open circles) or presence
(closed circles) of a polyclonal inhibitory antibody against tissue factor. Error bars indicate
standard deviation. * indicates p<0.05.
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Discussion
This in vitro study shows that rFVIIa both accelerates clot formation and inhibits
fibrinolysis by activation of TAFI in factor VIII-deficient plasma. In agreement with
previous studies we have shown a lack of TAFI activation in plasma from patients
with severe haemophilia A at low tissue factor concentrations, implicating that
haemophilia is a disorder of both clot formation and down-regulation of clot
Figure 5. Effect of TFPI on antifibrinolytic and procoagulant potential of rFVIIa. Panel A shows
Clys½-VIIa values of the 17 plasma samples as shown in figure 2A (No additions), and Clys½-VIIa
values of the same samples in the presence of 100 ng/ml rFL-TFPI (+ TFPI), or an inhibitory
antibody against TFPI (+ a-TFPI). Panel B shows Cclot½-VIIa values of the 17 plasma samples
as shown in figure 2B (No additions), and Cclot½-VIIa values of the same samples in the presence
of 100 ng/ml rFL-TFPI (+ TFPI), or an inhibitory antibody against TFPI (+ a-TFPI).
51
Chapter 2
breakdown. In a previous study we have shown that as little as 0.01% of the amount of
factor VIII present in pooled normal plasma completely restores TAFI-mediated down-
regulation of fibrinolysis in factor VIII-deficient plasma201. Here, we showed that high
rFVIIa levels are required for inhibition of fibrinolysis. Values required for half maximal
effect range from therapeutical (10.7 U/ml) to supratherapeutical (250 U/ml) levels.
We have not been able to determine specific factors, which determine Clys½-VIIa values.
We speculate that the antifibrinolytic potential of rFVIIa is determined by a combination
of both thrombin-generating capacity and plasma fibrinolytic potential.
We have shown that the amount of rFVIIa required to restore fibrinolysis is dependent
on the concentration of tissue factor. The efficacy of a certain dose of rFVIIa in a patient
is probably highly dependent on the site of injury and the extent of vascular damage. It is
likely that also in vivo rFVIIa is more effective in downregulation of the fibrinolytic
system at wounds where large amounts of tissue factor are exposed. Another
important factor in the efficacy of rFVIIa is the amount of thrombomodulin present.
Thrombomodulin is capable of enhancing TAFI activation by approximately 3 orders
of magnitude66. However, a high concentration of thrombomodulin down-regulates
TAFI activation by protein C activation67. Thus, it is likely that both tissue factor and
thrombomodulin present at the site of injury determine the antifibrinolytic potential of
rFVIIa in a patient with haemophilia A.
The regulatory effect of TFPI in rFVIIa-mediated inhibition of fibrinolysis becomes
evident on evaluation of Clys½-VIIa values, which are determined in the presence of a
blocking antibody against TFPI. In the absence of the inhibitory activity of TFPI,
little rFVIIa is needed to restore fibrinolysis, and in some patients fibrinolysis was
already maximally inhibited in the absence of rFVIIa. The addition of rFL-TFPI did
not lead to a significant inhibition of the antifibrinolytic effect of rFVIIa, probably
because TFPI concentrations present in plasma were nearly saturating at the low tissue
factor concentrations used in our assay.
The effect of rFVIIa on clot formation was more pronounced than the effect on TAFI
activation; the levels of rFVIIa required to half maximally reduce clot formation were
approximately 10-fold lower than those required to half maximally inhibit fibrinolysis.
Moreover Clys½-VIIa values were not correlated with Cclot½-VIIa values. This indicates
that primary and secondary thrombin formation in factor VIII-deficient plasma are
differently regulated processes. This phenomenon is supported by the observation that
modulation of TFPI activity clearly effects Clys½-VIIa values, whereas Cclot½-VIIa values
are unchanged. The inhibitory activity of TFPI on clot formation is overruled by rFVIIa.
This might be due to kinetic limitations combined with the rate-limiting concentration of
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factor Xa. The thrombin generation that occurs after formation of the fibrin clot is
efficiently inhibited by TFPI even in the presence of rFVIIa, as inhibition of TFPI
markedly reduces Clys½-VIIa values.
The hypothesis that primary and secondary thrombin formation in our system are
differently regulated processes is further supported by the observation that
endogenous factor VII levels positively correlate with Cclot½-VIIa but not with Clys½-
VIIa values. The correlation of endogenous factor VII levels with Cclot½-VIIa
corresponds to the inhibitory activity of zymogen factor VII on tissue factor-induced
coagulation as described by van ’t Veer et al.183 Apparently this inhibitory activity is
not important for secondary thrombin generation.
In conclusion, the efficacy of rFVIIa infusion in patients with haemophilia who
developed inhibitory antibodies may be explained by a combination of the following
factors: 1) enhancement of clot formation via the tissue factor pathway, possibly by
overruling the inhibitory activity of zymogen factor VII, and 2) down-regulation of
fibrinolysis by TAFI activation, which contributes to the stability of the clot. However,
until now we have no evidence that the antifibrinolytic effect of rFVIIa also occurs in the
in vivo situation. More sophisticated techniques for TAFI activation in vivo will be
required to adress this question. Whether the in vitro variations in antifibrinolytic
potential of rFVIIa may have clinical relevance (e.g., in predicting clinical efficacy of
rFVIIa in patients with severe haemophilia) will be investigated in future studies.
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Recombinant factor VIIa (rFVIIa, NovoSeven, Novo Nordisk, Bagsværd, Denmark)
has recently become available for the treatment of patients with inhibitor-complicated
haemophilia
195
. rFVIIa has been shown to be safe and effective in the treatment of
bleeding episodes, and prophylactically during surgery148,196.
The mechanism of action of rFVIIa in patients with haemophilia is still a matter of
debate. It has been proposed that tissue factor (TF)-dependent enhancement of
coagulation is responsible for the therapeutic effect of rFVIIa in haemophilia182. This
was supported by the in vitro observation that endogenous zymogen factor VII is a
physiological inhibitor of coagulation, and that rFVIIa overcomes the inhibitory effect
of zymogen VII by competing for TF binding183. Alternatively, it has been proposed that
the therapeutic efficacy of rFVIIa could be explained by a mechanism involving tissue
factor-independent thrombin generation triggered by rFVIIa directly bound to
activated platelets or monocytes188,189.
If this latter mechanism of action would have physiological relevance, genetically
modified analogues of rFVIIa with enhanced intrinsic (i.e., TF independent) activity,
might be beneficial in treating haemophilia patients. Recently, several mutant rFVIIa
molecules with substantially enhanced intrinsic activity have been described213,214. In
the presence of TF, these mutants displayed similar proteolytic activity compared to
wild type rFVIIa.
It has been hypothesized that haemophilia is not only a disorder of coagulation, but that
accelerated fibrinolysis due to a lack of activation of thrombin activatable fibrinolysis
inhibitor (TAFI) also contributes to the bleeding diathesis of these patients200,201. In a
previous publication, we have shown that rFVIIa does not only have procoagulant but
also antifibrinolytic properties in plasma from patients with severe haemophilia A215.
These antifibrinolytic properties were attributable to enhancement of activation of
thrombin activatable fibrinolysis inhibitor (TAFI) as a consequence of enhanced
thrombin generation. However, in our assay system, the procoagulant potential of
rFVIIa was much more pronounced than its antifibrinolytic activity.
We have compared the procoagulant and antifibrinolytic potential of two analogues of
rFVIIa with substantially increased TF-independent activity with those of wild-type
rFVIIa in plasma from patients with severe haemophilia A using a plasma-based clot
lysis assay as described previously215. We investigated M298Q-rFVIIa, which had a 7-
fold increased intrinsic proteolytic activity compared to wild type, and K337A/V158D/
E296V/M298Q-rFVIIa (K337A-rFVIIaIIa), which had a 56-fold increased proteolytic
activity compared to wild type213. In short, in a 96-well microtitre plate, plasma was
allowed to clot by the addition of tissue factor (Innovin, Dade Behring GmbH,
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Marburg, Germany, 1:100.000 times diluted), calcium chloride (17 mM), and
phospholipid vesicles (10 lM), fibrinolysis was induced by addition of tPA
(Chromogenix, Mo¨lndal, Sweden, 30 U/ml). Coagulation and clot lysis were
monitored by continuous turbidity measurements at 405 nm, and clotting times and
clot lysis times were determined as described215. Titration curves of wild type and
mutant rFVIIa were made in plasma from 6 different patients with severe haemophilia
A, who had an inhibitor titre >1 BU/ml at the time of sampling. From these titration
curves, rFVIIa concentrations required for half maximal reduction of coagulation time
(Cclot½-VIIa) and rFVIIa concentrations required for half maximal increase in clot lysis
time (Clys½-VIIa) were calculated.
As shown in figure 1, the rFVIIa analogues had a significantly larger procoagulant
potential compared to wild-type rFVIIa (Cclot½-VIIa: median [range], wt-rFVIIa: 363
[130-604] ng/ml, M298Q-rFVIIa: 70 [34-190] ng/ml, K337A-rFVIIaIIa: 17 [10-31] ng/
ml, p<0.01 wt vs mutants, paired ANOVA with Dunnett’s post test). Also, the amount
of rFVIIa analogues required for downregulation of fibrinolysis was substantially
decreased compared to wild type (Clys½-VIIa: median [range], wt-rFVIIa: 5288 [1000-
10120] ng/ml, M298Q-rFVIIa: 641 [220-1367] ng/ml, K337A-rFVIIaIIa: 101 [49-379]
ng/ml, p<0.01 wt vs mutants, paired ANOVA with Dunnett’s post test).
Figure 1. Enhanced procoagulant and antifibrinolytic potential of rFVIIa analogues compared to
wild-type in factor VIII deficient plasma. In plasma from 6 patients with severe haemophilia A, the
rFVIIa concentrations required for half maximal reduction of clotting time (Cclot½-VIIa) and the
rFVIIa concentrations required for half maximal prolongation of clot lysis time (Clys½-VIIa) were
determined. Horizontal bars indicate medians.
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Next, the TF dependency of clot formation was investigated in plasma from a single
patient with severe haemophilia A (George King Bio-Medical, Inc., Overland Park,
KS). Titration curves of wild type and mutant rFVIIa were made in absence or
presence of an inhibitory antibody against TF as described previously (figure 2)215. In
the absence of TF activity, no clot formation was observed during the time-course of
the experiment. Clotting did occur in the absence of TF, when as little as 20 ng/ml wild
type or mutant rFVIIa was added to the plasma. At lower concentrations of rFVIIa,
clotting was significantly slower when TF activity was blocked. However, at increasing
concentrations of rFVIIa clotting times were no longer significantly affected by
inhibition of TF. On inhibition of TF, the rFVIIa analogues displayed a similar
increase in procoagulant potential compared to the situation in which TF activity was
present.
With these experiments we show that the superactive rFVIIa variants do not only display
a substantially enhanced procoagulant potential compared to wild type, but that the
antifibrinolytic potential of the mutants is also significantly enhanced. This confirms
our earlier observations that rFVIIa-mediated thrombin generation in our assay
system is at least partially tissue factor-independent215. However, when lower
concentrations of either wild type or mutant rFVIIa is used, the presence of TF is
required for expression of full procoagulant potential.
In conclusion, should a TF-independent mechanism be involved in the efficacy of rFVIIa
in patients with haemophilia, the herein described superactive VIIa analogues might
offer improved clinical benefit as both procoagulant and antifibrinolytic potential are
significantly enhanced compared to wild type.
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Figure 2. Procoagulant effect of wt-rFVIIa (panel A), M298Q-rFVIIa (panel B), and K337A-
rFVIIaIIa (panel C) in presence (closed symbols) or absence (open symbols) of an inhibitory
antibody against tissue factor. Wild type or mutant VIIa was added in different concentrations to
plasma from a single patient with severe haemophilia A, and clotting times were determined. TF
activity was inhibited by a polyclonal antibody (500 lg/ml, 45 minutes preincubation at room
temperature). Shown are mean values of 3 independent experiments. Error bars indicate
standard error of mean.
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1) Introduction
Haemostasis consists of a complicated sequence of events designed to prevent excessive
blood loss in case of vessel wall injury. The haemostatic system is in a delicate balance
between pro- and antihaemostatic processes. Alterations in the system may lead to either
a bleeding diathesis or thrombotic disorder.
Liver failure is accompanied by multiple changes in the haemostatic system. As many
proteins involved in haemostasis are synthesized by the liver, reduced plasma levels are
found when the synthesis function of the liver becomes compromised. The diseased liver
also has a reduced capacity to clear activated haemostatic proteins or protein-inhibitor
complexes from the circulation. Finally, the number and function of platelets can be
affected in patients with liver disease. In this review the haemostatic changes occurring
in patients with chronic or acute hepatic failure will be discussed. Furthermore, the
occurrence and treatment of bleeding complications in these patients will be reviewed.
2) Normal haemostasis – current insights
Primary haemostasis
Blood platelets are of crucial importance in preventing blood loss upon vessel wall
damage. Platelets are produced from megakaryocytes in the bone marrow. Platelet
production is regulated by thrombopoietin, a hormone synthesized by the liver. When
subendothelial components are exposed to the bloodstream, platelets rapidly adhere
and aggregate to form a primary haemostatic plug. The formation of a platelet plug
starts when platelets from the circulation are slowed down by transient binding of
platelet glycoprotein Ib to von Willebrand factor (vWF) bound to subendothelial
collagen (figure 1A). Subsequently, a stationary contact between platelet and
subendothelium is accomplished by binding of one or more platelet receptors to their
ligands in the subendothelium (figure 1B). After adhesion, platelets become activated
by a number of agonists including collagen and thrombin. Platelet activation is
propagated by excretion of thromboxane A2, which is synthesized and excreted by the
platelet upon stimulation, and by ADP excreted from platelet a-granules (figure 1C).
Platelet activation results in activation and clustering of the integrin aIIbb3, which
subsequently can bind fibrinogen and vWF. Bridging of fibrinogen and vWF between
two platelets results in aggregation, which leads to the formation of a stable platelet
plug (figure 1D).
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Secondary Haemostasis
Blood coagulation, or the process of fibrin formation, consists of a sequence of enzymatic
reactions, eventually leading to thegenerationof thrombin.Thrombin isnotonly involved
in platelet activation, but can also cleave fibrinogen into fibrin. Fibrin spontaneously
polymerizes and forms an insoluble mesh, which stabilizes the platelet plug.
Currently, it is believed that fibrin formation is initiated by the exposure of tissue factor
to the bloodstream. Factor VII binds to tissue factor and is rapidly activated by plasma
proteases. The physiological relevant activator of factor VII presumably is coagulation
factor Xa. The tissue factor-VIIa complex activates factors IX and X, which then
assemble with their cofactors VIIIa and Va onto an anionic phospholipid surface. The
resulting tenase and prothrombinase complexes activate factor X and II
(prothrombin), respectively. Prothrombin amplifies its own generation by activating
Figure 1. Schematic representation of platelet adhesion to subendothelium under flow conditions
(see text for details). A) Rolling of platelets over collagen-bound vWF mediated by GPIb. B) Firm
attachment mediated by a2b1 and glycoprotein VI (GP VI) binding to collagen, and by aIIbb3
binding to collagen-bound vWF. C) Platelet activation, secretion, and spreading. D) Aggregate
formation.
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cofactors V and VIII, and also by activating factor XI, which once activated can also
activate factor IX (figure 2).
The regulation of thrombin formation proceeds through a number of plasma inhibitors
of coagulation. The tissue factor pathway is regulated by the kunitz type inhibitor TFPI
(tissue factor pathway inhibitor). TFPI binds activated factor X, and the TFPI-Xa
complex subsequently binds to the TF-VIIa complex resulting in a fully inhibited
quaternary TFPI-Xa-TF-VIIa complex. Antithrombin (AT) is a serine protease
inhibitor present in plasma, which inactivates thrombin and factors IXa, Xa, and XIa.
Its inhibitory action is potentiated by heparin or glycosaminoglycans present on the
vessel wall. Other plasma thrombin inhibitors are heparin cofactor II (HCII) and a2-
macroglobulin (a2-M). The inhibitory activity of HCII is also enhanced by heparin.
HCII exclusively inhibits thrombin. a2-M is a more general serine protease inhibitor,
also able (among other proteins) to inhibit factor Xa and plasmin. Activated protein
C, which is activated by thrombomodulin-bound thrombin, together with its cofactor
protein S inhibits thrombin generation by inactivating coagulation cofactors Va and
VIIIa. Protein C circulates in plasma in zymogen form, and is activated by
thrombomodulin-bound thrombin. Finally, the protein Z-dependent protease inhibitor
(ZPI) inactivates factor Xa with protein Z as mandatory cofactor.
Figure 2. Schematic overview of tissue factor induced coagulation. (See text for details).
Uninterrupted lines indicate activation, interrupted lines indicate inhibition.
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Fibrinolysis
The dissolution of a fibrin clot is facilitated by plasmin, an enzyme formed from the
plasma protein plasminogen. The physiological activator of plasminogen is
presumably tissue type plasminogen activator (tPA). tPA circulates in plasma in low
levels in complex with its plasma inhibitor plasminogen activator inhibitor-1 (PAI-1).
tPA is synthesized and both constitutively excreted and stored by endothelial cells, and
the tPA released locally from endothelial cells is thought to be responsible for plasmin
activation in vivo. Both tPA and plasminogen need to bind to fibrin, in order to
accelerate plasminogen activation.
Fibrinolysis is regulated by a number of plasma inhibitors. Firstly, plasminogen
activation is regulated by PAI-1, a stoichiometric inhibitor of tPA, which is
synthesized and constitutively extreted by endothelial cells. PAI-1 is also present in
substantial amounts in platelet a-granules. Histidine rich glycoprotein (HRG) has also
been implicated in regulation of plasmin activation, by its ability to bind to lysine
residues on plasminogen, thereby preventing binding to fibrin and hence delaying its
activation. The physiological relevance of HRG is unclear at present. The proteolytic
activity of plasmin is regulated by the circulating inhibitor a2-antiplasmin.
Fibrin clots are made more resistant to fibrinolysis by two mechanisms involving
thrombin. Firstly, thrombin activates factor XIII, which stabilizes the fibrin clot by
crosslinking gamma or alpha chains in adjacent fibrin molecules by introducing e(c-
glutamyl)lysyl isopeptide bonds. Activated factor XIII also crosslinks a2-antiplasmin
to the fibrin clot, thereby contributing to the inhibition of fibrinolysis. Secondly,
thrombin (or thrombomodulin bound thrombin) can activate thrombin activatable
fibrinolysis inhibitor (TAFI). Activated TAFI cleaves C-terminal lysine and arginine
residues from partially degraded fibrin, thereby preventing tPA and plasminogen
binding (figure 3).
3) Defects in primary haemostasis in liver disease
Thrombocytopenia and platelet function defects
Mild tomoderate thrombocytopenia (i.e., platelet counts between 50.000 and 150.000 per
ml) can be seen in both chronic and acute liver failure216,217. In patients with cirrhosis, the
major cause for thrombocytopenia is thought to be increased platelet sequestration in the
spleen due to congestive splenomegaly218.Decreased production of thrombopoietin (tpo)
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by the diseased liver has been suggested to contribute to the low platelet count in patients
with chronic or acute liver failure. However, both decreased219,220, increased221 and
normal222,223 plasma tpo levels in patients with chronic liver failure have been reported.
A recent publication showed that the return to normal platelet count after liver
transplantation was accompanied by an increase in plasma tpo levels, and that the
peripheral platelet count increased irrespective of spleen size, indeed suggesting that
decreased platelet production as a consequence of low levels of tpo might be an
important cause of the low platelet count in end stage liver disease224. A reduced
platelet half life has been shown in some patients225, and autoimmune mechanisms may
be involved226. In patients with alcohol-induced cirrhosis, the reduced platelet count may
also be a consequence of folic acid deficiency227 or decreased platelet production due to
direct toxic effects of ethanol on megakaryocytopoiesis228. Another suggested cause of
thrombocytopenia in liver disease is the presence of chronic (low-grade) disseminated
intravascular coagulation (DIC)229. However, the presence of DIC in patients with
hepatic failure is still a matter of controversy230.
Platelet function defects are often encountered in patients with chronic or acute liver
disease. In vitro platelet aggregation in response to ADP, arachidonic acid, collagen,
and thrombin has been shown to be defective231,232. Also, platelet-vessel wall
interaction studied under flow conditions has been shown to be impaired233. Impaired
Figure 3. Schematic representation of the fibrinolytic system and its link with the coagulation
system (see text for details). Uninterrupted lines indicate activation, interrupted lines indicate
inhibition
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aggregation might be caused by defective platelet signal transduction mechanisms234, an
acquired storage pool deficiency235, and decreased levels of arachidonic acid (required
for thromboxane A2 production) in the platelet membrane
236. Furthermore, increased
production of prostacyclin and nitric oxide (both powerful platelet inhibitors) by
endothelial cells may contribute to impaired platelet function in vivo237,238. Finally,
platelet-vessel wall interaction may be defective in patients with liver disease due to
proteolysis of platelet receptors by plasmin239,240, or due to the presence of a reduced
haematocrit241.
Von Willebrand factor
Plasma levels of vWF are substantially increased in patients with liver failure,
presumably due to endothelial dysfunction, which may be triggered by
endotoxemia242. Although reduced levels of the vWF cleaving protease, which cleaves
high molecular weight multimers of vWF in less reactive smaller multimers, have been
found in cirrhotic patients243, the multimeric structure of vWF is found to be either
normal242, or defective in high molecular weight multimers244. Other proteases (such as
plasmin and elastase, see section on fibrinolysis) have been implicated in increased
proteolytic degradation of vWF244. Studies on vWF function in patients with cirrhosis
are conflicting. Both normal242 and reduced231 platelet agglutination to ristocetin have
been found, and in one study hyperagglutination of platelets towards botrocetin was
observed245.
4) Defects in secondary haemostasis in liver disease
Defects in procoagulant pathways
As the liver is assumed to be the site of synthesis for all proteins involved in thrombin
generation, decreased plasma concentrations for all proteins except for factor VIII are
observed in patients with hepatic failure. Although the liver is probably the principle
site of synthesis for factor VIII, as haemophilia can be resolved by liver
transplantation246, other tissues have also been shown to produce factor VIII mRNA,
and protein synthesis in these tissues may be stimulated by liver disease247. Another
possibility is that, as factor VIII is not only produced by hepatocytes, but also by
sinusoidal endothelial cells, the latter cell type sustains its capacity for factor VIII
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synthesis even when liver function becomes impaired247. Alternatively, reduced
clearance might lead to elevated factor VIII levels.
Besides low levels of clotting factors due to impaired synthesis capacity, also
dysfunctional proteins are found in patients with liver failure. Factors II, VII, IX, and
X as well as the anticoagulant factors protein C, protein S, and protein Z (see below)
contain c-carboxyglutamic acid (gla) residues which facilitate binding to anionic
phospholipids. Gla residues are introduced into the protein by a vitamin K dependent
carboxylase present in the hepatocyte248, which catalyses the attachment of a second
carboxyl group to specific N-terminal glutamic acid residues. It has been shown that in
liver disease part of the circulating prothrombin249 and protein C250 lack their gla
residues, and this is presumably also true for the other gla containing proteins.
Abnormal c-carboxylation might be the consequence of an intrinsic enzymatic defect,
or to a vitamin K deficiency.
Factor V, a vitamin K independent coagulation factor is also reduced in both chronic
and acute hepatic failure. Factor V levels in acute liver failure has been shown to
correlate with survival251.
Fibrinogen is believed to be synthesized exclusively in the liver. Fibrinogen levels are
within the normal range in patients with stable chronic liver disease, but decreased
levels are found in patients with advanced cirrhosis or acute hepatic failure252.
Accelerated clearance and consumption due to intravascular coagulation may also
contribute to the hypofibrinogenemia seen in these patients. Both in chronic and acute
liver failure, abnormal fibrinogen molecules are commonly found253. These
dysfibrinogens are characterised by an excessive content of sialic acid residues, which
lead to impaired fibrin polymerisation254. The exact cause of fibrinogen
hyperglycosilation is not clear, but it might be a consequence of elevated tissue levels
of glycosyltransferases255.
Defects in anticoagulant pathways
Plasma levels of TFPI in patients with liver disease are found to be normal256, although
also significantly decreased levels have been reported257. As endothelial cells (and not
hepatocytes) are considered the primary site of synthesis of TFPI258, normal levels
would be expected.
AT levels are decreased in liver failure252, as are HCII and a2-M levels
259, thus resulting
in reduced thrombin inhibition.
Decreased levels of both protein C and S are found in patients with liver disease as a
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consequence of reduced synthesis. Moreover, protein C and S molecules lacking c-
carboxylation may be produced.
Reduced levels of protein Z have been reported in patients with liver failure260, but to our
knowledge ZPI levels have not been measured in this patient population.
Low levels of anticoagulant proteins might not only compensate for the defective
thrombin generating capacity due to low levels of procoagulant proteins in patients
with liver failure, reduced thrombin inhibition might also facilitate thrombosis. The
clinical consequence of the concomitant reduction in both pro- and anticoagulant
proteins is unknown. Although patients with hepatic failure in general are thought to
have a bleeding tendency, there are also thrombotic complications, such as portal vein
thrombosis known to occur in this patient population261. Although these thrombotic
complications are rare, they are considered serious events.
5) Disorders of the fibrinolytic system
All proteins involved in fibrinolysis, except for tPA and PAI-1 are synthesized in the
liver, and indeed reduced plasma levels of plasminogen225, a2-antiplasmin
212, HRG262,
factor XIII263 and TAFI212 have been found in patients with liver disease. Plasma tPA264
levels are often elevated in patients with liver failure, which may be a result of either
enhanced secretion from endothelial cells or diminished clearance by the diseased liver.
PAI-1 levels are slightly elevated in plasma from patients with liver disease and do not
seem to balance the elevated plasma tPA levels265,266, except in acute hepatic failure, in
which plasma PAI-1 levels are dramatically increased267.
The net effect of the changes in the fibrinolytic system in patients with chronic liver failure
is thought to be a hyperfibrinolytic state (reviewed in 268). In contrast, in patients with
acute hepatic failure, a shift towards hypofibrinolysis is observed, presumably as a
consequence of substantially elevated plasma PAI-1 levels212,267. Already in 1914 it was
reported that clotted whole blood of patients with liver disease showed premature
fibrinolysis in vitro269. Hyperfibrinolysis was subsequently shown to be present in at
least part of the patients with liver failure by many studies, in which different clot lysis
assays were used. These assays include thromboelastography using whole blood230,
diluted whole blood clot lysis assays265,270, and assays in which the euglobulin fraction
of plasma is used (euglobulin clot lysis time and fibrin plate method)271. However, these
commonly used in vitro fibrinolysis assays have major drawbacks, and caution should be
taken in interpreting shortened clot lysis times. For example, classical
thromboelastography assays whole, nonanticoagulated blood, and caution must be
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taken in interpreting this assay as clot formation is initiated by (non physiological)
contact activation. More recent variations on this technique make use of tissue factor-
induced coagulation of citrated whole blood, but to our knowledge tissue factor-
induced thromboelastrography has not yet been used for determination of fibrinolytic
potential in patients with liver failure. The dilute whole blood clot lysis time is
performed in the absence of calcium, and a clot is formed by addition of thrombin. Clot
lysis time is therefore independent of coagulation and, as a consequence, independent of
TAFI. Finally, accelerated clot lysis times in clot lysis assays using the euglobulin fraction
from plasma (such as the euglobulin clot lysis time and fibrin plate method) must be
interpreted with caution. As the euglobulin fraction does not contain inhibitors of
fibrinolysis, enhanced clot lysis times presumably only reflect elevated tPA levels.
Recently, our group has used a plasma-based clot lysis assay in which coagulation was
initiated by tissue factor, and exogenously added tPA was used to induce clot lysis to
investigate fibrinolytic potential in patients with liver disease. In a large group of
patients with cirrhosis of different severity and etiology, we could not demonstrate
accelerated fibrinolysis compared to lysis in plasma clots from healthy volunteers212.
However, the absence of platelets in our assay makes it difficult to refute a
hyperfibrinolytic state in vivo based on our experiments, as the reduced platelet count
in patients with cirrhosis might affect fibrinolysis by a reduced availability of platelet
derived PAI-1272.
A different line of evidence supporting the concept of a hyperfibrinolytic state in patients
with liver failure is the appearance of elevated levels of indicators of fibrinolysis such as
plasmin-a2-antiplasmin complexes
273, fibrin(ogen) degradation products274, and D-
Dimers275 in plasma from patients with cirrhosis. However, accumulation of these
molecules may also be a reflection of a reduced capacity of the diseased liver to clear
these substances.
The presence of hyperfibrinolysis in cirrhosis has been suggested to be coupled to
activation of the coagulation system, presumably triggered by endotoxemia276,277. The
presence of low-grade disseminated intravascular coagulation (DIC) in liver disease
has been proposed to be responsible for ongoing fibrinolysis, but the presence of DIC
in liver disease is highly controversial230. Although DIC-like laboratory features
(elevated markers of coagulation and fibrinolysis, such as thrombin-antithrombin
complexes, plasmin-a2-antiplasmin complexes and D-Dimers
273) are observed, this
might be due to a reduced clearance capacity of the diseased liver. Furthermore,
autopsy studies have shown little evidence for fibrin deposition in organs, which is the
hallmark of ‘classical’ DIC278.
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The in vivo significance of hyperfibrinolysis in cirrhosis have been shown by Francis and
Feinstein270, and by Violi and coworkers279, who reported an increased occurrence of
bleeding in patients in whom hyperfibrinolysis was detected in vitro. However, it could
be that the presence of in vitro hyperfibrinolysis is merely a reflection of a greater severity
of the disease. Another argument against the presence of hyperfibrinolysis in liver
disease, is that these patients do not show a typical hyperfibrinolytic bleeding
tendency, i.e., delayed bleeding after trauma or surgery, as observed in a2-
antiplasmin280 or PAI-1281 deficiency. Bleeding problems in patients with cirrhosis,
e.g., after liver biopsy, is usually immediate282.
6) Bleeding complications associated with defective haemostasis in liver disease
Table 1 summarizes the pro and anti haemostatic changes observed in patients with liver
disease. The net outcome of these alterations in the haemostatic system is a bleeding
diathesis, although thrombosis of the portal vein is also frequently seen in patients
with cirrhosis261. However, the development of thrombosis might also be a
consequence of local disturbances, such as a reduced blood flow in the portal vein.
As liver disease has multiple effects on the haemostatic system, it is difficult to determine
which factors contribute most to the bleeding diathesis. Bleeding problems in patients
Haemostatic changes impairing haemostasis Haemostatic changes promoting haemostasis
. Low platelet count
. Impaired platelet function and platelet vessel
wall interaction
. Enhanced platelet inhibition by nitric oxide
and prostacyclin
. Low levels of coagulation factors II, V, VII,
IX, X, XI
. Quantitative and qualitative abnormalities in
fibrinogen
. Low levels of a2-antiplasmin, TAFI, HRG
. Elevated levels of plasma tPA, which are not
balanced by PAI-1 levels
. Elevated levels of factor VIII and vWF
. Decreased levels of protein C, protein S,
protein Z, antithrombin, a2-macroglobulin,
and heparin cofactor II
. Low levels of plasminogen
Table 1.
Changes in the haemostatic system promoting bleeding (left) and counteracting bleeding (right)
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with liver failure may be a consequence of the disbalanced haemostatic system. However,
also bleeding due to mechanical reasons, such as bleeding from esophageal varices,
occurs frequently in patients with cirrhosis283. The contribution of the haemostatic
defects to variceal bleeding is unclear, but it has been suggested that laboratory signs
of hyperfibrinolysis are associated with an increased risk to variceal bleeding284.
The relative contribution of the changes in platelet number and function, coagulation,
and fibrinolysis to the bleeding tendency in these patients is unclear. The mild to
moderate thrombocytopenia is of little clinical relevance, but the low platelet count is
often accompanied by poorly defined platelet function defects, and this combination
might contribute to some extent to the bleeding diathesis in liver failure. The
substantially reduced levels of procoagulant proteins in these patients is probably a
major contributor to the bleeding tendency, even though the defects in procoagulant
potential is partly compensated for by decreased levels of anticoagulant proteins. The
contribution of alterations in the fibrinolytic system to the bleeding problems in liver
disease is uncertain. Although associations between in vitro hyperfibrinolysis and
bleeding in patients with cirrhosis have been demonstrated, this association might not
be causal, as described in the previous section.
The bleeding diathesis in patients with acute hepatic failure or advanced cirrhosis
manifests itself by epistaxis, gingival bleeding, ecchymoses, and gastrointestinal
bleeding. Patients undergoing small invasive procedures, such as liver biopsy have a
small but significant bleeding risk282, and it is recommended that if a serious
coagulopathy is detected, it is corrected by transfusion of platelets or plasma before
the procedure. A larger bleeding risk is encountered in patients undergoing major
abdominal surgery, including liver transplantation. During liver transplantation major
changes in the already disturbed haemostatic system occur, and despite major
improvements in the surgical techniques and available pro-haemostatic agents, liver
transplantation may be accompanied by substantial intraoperative bleeding285.
7) Treatment of bleeding complications in liver disease
Patients in whom platelet count is above 50.000/ll are usually not at risk for acute
bleeding or bleeding during small invasive procedures286. Whenever platelet counts are
below 50.000/ll, platelet transfusion is indicated during bleeding episodes or prior to
invasive procedures (e.g., liver biopsy)287. The increase in platelet count upon platelet
transfusion may be markedly less in a patient with liver failure compared to patients
with intact liver function as a consequence of sequestration of the transfused platelets
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in the enlarged spleen, and platelet count should always be measured before a procedure
is initiated. Splenectomy has been shown to improve platelet count, but this procedure is
contraindicated in patients with portal hypertension and hypersplenism, due to high
surgery-related morbidity and mortality288. The prolonged bleeding time in patients
with liver failure may be corrected by infusion of 1-deamino-8-D-arginine vasopressin
(DDAVP), but the exact mechanism as well as the clinical relevance of this finding is
unclear289. DDAVP has failed to prove efficacy in acute variceal bleeding in cirrhotic
patients290, and the clinical usefulness of DDAVP in other procedures has not been
demonstrated yet.
The deficiencies in coagulation factors may be corrected by administration of fresh
frozen plasma (FFP) or prothrombin complex concentrates (PCC). Disadvantages of
FFP are the large volumes required for correction of a severe coagulopathy and the
brief duration of action because of the short biological half life of some clotting
factors, in particular factor VII. Fluid overload may be a complication upon FFP
administration. Disadvantages of PCC’s, which contain only the vitamin K dependent
coagulation factors, are the fact that the coagulopathy is only partially corrected and the
risk of thromboembolic complications, including DIC291. In patients with acute liver
failure and haemostatic complications, plasmapheresis has been used as adjunctive
therapy to correct haemostasis and to prevent fluid overload, but this procedure is not
routinely used292.
A novel approach to treat the coagulopathy in patients with liver disease is the
administration of recombinant factor VIIa (rFVIIa). rFVIIa has been shown to correct
a prolonged prothrombin time in patients with stable cirrhosis293, or patients who are
actively bleeding from esophageal varices294. It must be stressed, however, that
prolongation of the prothrombin time by rFVIIa does not necessarily reflect
haemostatic efficacy. Anecdotal reports do support the haemostatic potential of
rFVIIa in patients with liver disease295,296. Moreover, rFVIIa has been shown to
significantly reduce transfusion requirements during liver transplantation297. A
limitation of this study, however, was the comparison of the rFVIIa treated patients
with a historic control group.
Antifibrinolytic agents such as e-aminocaproic acid (eACA), tranexamic acid, and
aprotinin may be administered if a hyperfibrinolytic state is shown. However, since a
hyperfibrinolytic state in patients with chronic liver failure is still somewhat
controversial, and because of the risk for thromboembolic complications, the general
therapeutic value of antifibrinolytics in these patients remains uncertain. On the other
hand, both aprotinin298 and tranexamic acid299 have been shown effective in reducing
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transfusion requirements during liver transplantation. However, whether the efficacy of
these agents is exclusive due to their antifibrinolytic capacity, or that other mechanisms
(such as modulation of vascular tone) are involved is unclear300.
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Thrombin activatable fibrinolysis inhibitor deficiency in
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Abstract
Background & aims
Thebleeding tendencyofpatients suffering fromcirrhosis is inpart ascribed toaccelerated
fibrinolysis. In this study, the role of the recently discovered inhibitor of fibrinolysis,
thrombin activatable fibrinolysis inhibitor (TAFI) in cirrhosis was examined.
Methods
In 64 patients with cirrhosis of varying severity, TAFI antigen levels were measured by
ELISA, and compared with TAFI levels in control subjects. Furthermore, a plasma-
based fibrinolysis assay was performed in the presence and absence of a specific
inhibitor of activated TAFI.
Results
TAFI levels were decreased in cirrhosis. Mean TAFI levels were 66% in Child’s A, 55% in
Child’s B, 47% in Child’s C cirrhosis, and 26% in acute liver failure. Decreased TAFI
antigen levels were highly correlated with antithrombin and a2-antiplasmin activity
levels. Clot lysis times and clot lysis ratio (defined as ratio between clot lysis time in the
absence and presence of a specific inhibitor of activated TAFI) of cirrhotics were not
significantly different from healthy controls.
Conclusions
Despite decreased levels of TAFI and other components of the fibrinolytic system, no
evidence of increased plasma fibrinolytic potential in cirrhosis is observed using the
plasma-based assay of this study. The reduction of antifibrinolytic factors in cirrhosis
is compensated by the concomitant reduction in profibrinolytics.
Introduction
Bleeding problems are frequently encountered in cirrhotic patients and can be ascribed
to a defective haemostasis, or to complications of portal hypertension such as esophageal
varices301. Spontaneous bleeding associated with haemostatic abnormalities is not
common, but patients may bleed severely during invasive procedures like liver biopsy,
dental extraction or venipuncture. An even greater challenge to haemostasis is
encountered during liver transplantation, which can be accompanied by severe blood
loss302.
76
TAFI and cirrhosis
Frequently encountered haemostatic abnormalities present in cirrhosis include
thrombocytopenia and platelet function defects, deficiencies in clotting factors,
deficiencies of inhibitors of coagulation, dysfibrinogenemia, and abnormalities in the
fibrinolytic system216,303,304. Moreover, clearance of activated coagulation factors and
enzyme-inhibitor complexes may be reduced. An imbalance of the fibrinolytic system
has been observed using in vitro clot lysis assays, which show accelerated fibrinolysis in
part of the patient population230,270,271. In vivo indications for hyperfibrinolysis
includes increased plasmin-a2-antiplasmin (PAP) complexes, increased D-Dimer levels
and fibrin(ogen) degradation products in plasma from cirrhotics (for a review see
Leebeek268). However, increased levels of PAP, D-Dimer, and fibrin(ogen) degradation
products may also be a consequence of impaired clearance. The nature of enhanced
fibrinolysis in cirrhosis is not completely clear. An imbalance between t-PA and PAI-1
activity in favor of t-PA, accompanied by reduced levels of a2-antiplasmin leading to
decreased binding of a2-antiplasmin to fibrin might explain the apparent
hyperfibrinolytic state of these patients266. Hyperfibrinolysis in cirrhosis might be a
primary phenomenon, but could be secondary to disseminated intravascular
coagulation (DIC), which might be triggered by endotoxemia277. However, controversy
on the presence of (low-grade) DIC in cirrhosis exists230.
In this study, the role of the recently discovered inhibitor of fibrinolysis, thrombin
activatable fibrinolysis inhibitor (TAFI)305, which is also known as plasma
procarboxypeptidase B306, procarboxypeptidase U307 or procarboxypeptidase R,308
was examined. Activated TAFI inhibits fibrinolysis by cleaving C-terminal arginine
and lysine residues from partially degraded fibrin, thereby inhibiting t-PA-mediated
plasminogen activation64. TAFI is synthesized as zymogen in the liver306 and can be
activated by relatively high levels of thrombin305. TAFI can also be activated by the
thrombin-thrombomodulin complex. This reaction is approximately 1200 times more
efficient than the activation of TAFI by thrombin alone66. Both in vitro and in vivo
experiments indicate that the thrombin required for TAFI activation is formed via
thrombin-mediated activation of factor XI65,309. This factor XI feedback loop
generates additional thrombin after formation of the fibrin clot resulting in down-
regulation of fibrinolysis by activation of TAFI. Tissue factor-induced clots formed
from plasma with deficiencies in factor VIII, IX, X or XI, have been shown to lyse
prematurely because of a lack of TAFI activation, indicating the necessity for an intact
coagulation pathway for down-regulation of fibrinolysis200. The clinical importance of
TAFI is not established so far. However, it has been shown that increased levels of TAFI
are a mild risk factor for venous thrombosis310. Also, inhibition of TAFI has been shown
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to improve thrombolytic therapy in animal thrombosis models, indicating in vivo
importance of down-regulation of the fibrinolytic system by TAFI311,312.
Because TAFI is synthesized in the liver, we hypothesized that TAFI levels are decreased
in patients with cirrhosis. Premature fibrinolysis in cirrhosis might be explained in part
by a defective down-regulation of fibrinolysis by activated TAFI as a consequence of
both reduced levels of TAFI and reduced thrombin generation caused by deficiencies
in the thrombin-generating system. In this study, we examined TAFI antigen levels of
patients with cirrhosis of varying severity. Moreover, plasma clot lysis assays were
performed in the presence of exogenous t-PA to examine the contribution of TAFI to
the inhibition of fibrinolysis in cirrhosis.
Materials and methods
Patients
Sixty-four patients in stable condition with biopsy-proven cirrhosis of various etiology –
alcohol abuse (18), viral hepatites (26), autoimmune hepatites (2), primary biliary
cirrhosis (4), cryptogenic cirrhosis (10), and others (4) – were included in this study.
The patients were classified according to Pugh’s modification of the Child’s
classification313. Nineteen patients with Child’s A cirrhosis, 20 patients with Child’s B
cirrhosis, and 25 patients with Child’s C cirrhosis were studied. In addition, 4 patients
with acute liver failure were included in this study. Twenty healthy volunteers from our
laboratory served as a control group. Pooled normal plasma was obtained by combining
plasma from 40 healthy volunteers. Plasma from a patient with a congenital homozygous
functional a2-antiplasmin deficiency (a2-antiplasmin Enschede) was also used in the
study280. This patient has normal antigen levels of a2-antiplasmin, but a2-antiplasmin
activity is < 4%.
Blood samples were obtained by venipuncture from the antecubital vein into 3.2%
sodium citrate (9:1, v/v). To obtain platelet poor plasma, the samples were centrifuged
twice at 2000g for 15 minutes. Plasma samples were stored at –708C until use.
Materials
Fresh frozen plasma was obtained from the local blood bank. Tissue type plasminogen
activator (t-PA) was from Chromogenix (Mo¨lndal, Sweden). Recombinant human tissue
factor (Innovin) was from Dade Behring GmbH (Marburg, Germany), and
carboxypeptidase inhibitor from potato (CPI) was purchased from Calbiochem (La
Jolla, CA). Recombinant active plasminogen activator inhibitor 1 (PAI-1) was a
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generous gift from Dr. Thomas M. Reilly (DuPont Pharmaceuticals Company,
Wilmington, DE). Antithrombin deficient plasma, and purified plasminogen were
obtained from American Diagnostica Inc. (Greenwich, CT).
Phospholipid vesicles consisting of 40% L-a-dioleoylphosphatidylcholine, 20% L-a-
dioleoylphosphatidylserine and 40% L-a-dioleoylphosphatidylethanolamine (all from
Sigma, St. Louis, MO) were prepared according to Brunner209 with minor
modifications as described by van Wijnen210. Total phospholipid content of the vesicles
was determined by phosphate analysis according to Rouser211.
TAFI was purified from fresh frozen plasma by immunoaffinity chromatography
followed by further purification on protein G-Sepharose and Q-Sepharose as
described314. TAFI antigen levels were determined by a sandwich-type ELISA, using a
monoclonal capturing antibody and a polyclonal detection antibody as described206.
TAFI levels were expressed as percentage of pooled normal plasma. TAFI deficient
plasma was prepared by passing plasma over a Sepharose column to which
monoclonal antibody NIK 9H10 was coupled. Undiluted flow-through fractions were
shown to be deficient in TAFI by ELISA.
Plasminogen deficient plasma was prepared by passing plasma over a lysine-Sepharose
column. Since this procedure also resulted in a partial depletion of TAFI from the
plasma, purified TAFI was added to the plasma to reach a final concentration of
100%. The concentration of a2-antiplasmin in the plasminogen-depleted plasma was
104%.
Antithrombin was purified from human plasma using DEAE-Sepharose
chromatography followed by heparin-Sepharose chromatography according to de
Swart315. Levels of a2-antiplasmin were determined using the Coamatic plasmin
inhibitor kit from Chromogenix (Mo¨lndal, Sweden). Antithrombin levels were
measured with the Coamatic thrombin inhibitor kit from Chromogenix (Mo¨lndal,
Sweden). PAI-1 antigen levels were determined using the PAI-1 ELISA kit from
Technoclone GmbH (Vienna, Austria). D-Dimer levels were determined using the
Asserachrom D-dimer ELISA kit from Boehringer Mannheim GmbH (Mannheim,
Germany).
Clot lysis assay
Lysis of a tissue factor-induced clot by exogenous t-PA was studied by monitoring
changes in turbidity during clot formation and subsequent lysis essentially as described
previously198. A mixture of tissue factor (diluted Innovin, final dilution 105 times), CaCl2
(final concentration 17 mM), t-PA (final concentration 30 U/ml; 56 ng/ml) and
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phospholipid vesicles (final concentration 10 lM) was added to 75 ll of citrated plasma.
The volume was adjusted to 150 ll with Hepes buffer (25 mM Hepes, 137 mM NaCl, 3.5
mM KCl, 3 mM CaCl2, 0.1% BSA, pH 7.4), resulting in a final plasma concentration of
50%. After thorough mixing, 100 ll of this mixture was transferred to a microtiter plate
and turbidity at 405 nm was measured in time at 37ºC in a Spectramax 340 kinetic
microplate reader (Molecular Devices Corporation, Menlo Park, CA, USA). Clot lysis
time was defined as the time from the midpoint of the clear to maximum turbid
transition, which characterizes clot formation, to the midpoint of the maximum turbid
to clear transition, which represents clot lysis. To assess the contribution of TAFI
activation to clot lysis time, experiments were performed in which CPI (25 lg/ml), a
specific inhibitor of activated TAFI199, was added to the plasma. The contribution of
TAFI to the clot lysis assay was quantified by calculating the clot lysis ratio, which is
defined as the ratio between clot lysis time in absence and presence of CPI. To assess
the influence of PAI-1 on clot lysis times, clot lysis experiments were performed with
pooled normal plasma to which different amounts of active PAI-1 were added. To
examine the influence of a2-antiplasmin on clot lysis times, clot lysis experiments were
performed with plasma from a patient with severe a2-antiplasmin deficiency, which
was mixed with different amounts of pooled normal plasma. Clot lysis times with
varying plasminogen concentrations were determined by mixing plasminogen-deficient
plasma with different amounts of purified plasminogen. The contribution of
antithrombin to clot lysis times was assayed using antithrombin-deficient plasma to
which different amounts of purified antithrombin was added. The effect of a 50%
reduction of both TAFI and antithrombin on clot lysis time was assayed by mixing
equal amounts of TAFI and antithrombin-deficient plasma.
Statistical analysis.
Statistical analysis was performed using the GraphPad InStat (San Diego, USA)
software package. Differences in TAFI antigen levels were assayed by standard one-
way analysis of variance (ANOVA) using the Tukey-Kramer test. As clot lysis times
and clot lysis ratio showed Gaussian distribution with significant differences between
standard deviations between groups, statistical analysis on clot lysis times and clot
lysis ratios was performed using Kruskal-Wallis ANOVA test, with Dunn’s post test. P
values <0.05 were considered statistically significant. Correlations between TAFI
antigen levels and antithrombin or a2-antiplasmin levels were determined by Pearson’s
correlation coefficient.
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Results
TAFI antigen levels are decreased in cirrhosis
TAFI antigen levels were determined in plasma samples from 64 patients with cirrhosis
of varying severity. Also, TAFI antigen levels in 4 patients with acute liver failure were
determined. TAFI levels were significantly reduced in plasma from patients with Child’s
A (66+13%; mean+sd), Child’s B (55+22%), as well as Child’s C (47+18%) cirrhosis
compared with TAFI levels in the control group, in which mean TAFI level was
103+20% (p<0.001, for mild, moderate, and severe cirrhosis compared with control).
As shown in figure 1, TAFI levels decreased significantly with increasing severity of the
disease (mild vs. severe cirrhosis p<0.05). In 4 patients studied who suffered from acute
liver failure, mean TAFI levels were 26+11% (p<0.001 compared to control).
Correlation of TAFI antigen levels with antithrombin and a2-antiplasmin activity levels
TAFI antigen levels correlated with antithrombin (r=0.701, p<0.0001) and a2-
antiplasmin (r=0.730, p<0.0001) activity levels as shown in figure 2.
Figure 1. TAFI antigen levels of patients with Child’s A (A), Child’s B (B) or Child’s C (C) cirrhosis
and of patients suffering from acute liver failure (Acute) compared with TAFI antigen levels in
healthy controls (Control). TAFI levels were determined by ELISA and are expressed as a
percentage of pooled normal plasma. The horizontal line represents the mean of each group.
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Clot lysis assay
Clot lysis times were determined by measuring the turbidity profile in time of a tissue
factor-induced clot, which was lysed by exogenous t-PA. Clot lysis times were
determined for all patients and controls both in the presence and absence of the TAFI
inhibitor CPI. Figure 3 shows typical examples of clot lysis curves in plasma of healthy
subjects (panel A) and in plasma of cirrhotic patients (panel B). Despite decreased TAFI
levels and decreased thrombin formation, down-regulation of fibrinolysis by TAFI is
seen in cirrhotic plasma because clot lysis times can be significantly reduced by the
Figure 2. Correlation of TAFI antigen levels with antithrombin (A) and a2-antiplasmin (B) activity
levels.
Figure 3. Typical example of a clot lysis curve in normal (panel A) and cirrhotic (panel B) plasma in
the absence (uninterrupted line) or presence (interrupted line) of CPI. Coagulation was initiated by
tissue factor (105 diluted Innovin), phospholipid vesicles (10 lM), and calcium chloride (17 mM).
Fibrinolysis was initiated by the addition of tPA (30 U/ml). Fibrin formation and subsequent lysis
were measured in time as the change in turbidity at 405 nm.
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addition of CPI. As shown in figure 4A, clot lysis times do not differ between cirrhotic
patients and controls. A few patients showed almost no lysis during the time span of our
experiment. These plasma samples contain high PAI-1 levels (data not shown), which
can cause complete inhibition of clot lysis in our assay (see below). When clot lysis
results are expressed as clot lysis ratio, i.e., the ratio of clot lysis time in absence and
presence of CPI, a specific inhibitor of activated TAFI, no differences between the
patient groups and the control group are seen (figure 4B). Because all clot lysis ratios
are significantly higher than 1, TAFI activation occurs in all plasma samples obtained
from cirrhotic patients. In 3 of 4 plasma samples from patients with acute liver failure,
no lysis could be detected during the time course of our experiment, both in presence and
absence of CPI. This can most likely be attributed to very high PAI-1 levels in these
plasma samples (data not shown).
Elevated D-Dimer levels in cirrhosis
To investigate if the patient population used in this study was comparable to patient
populations used in previous studies in which patients with cirrhosis are found to be
hyperfibrinolytic, D-Dimer levels were measured in patients and controls. As shown in
figure 5, D-Dimer levels increase with increasing severity of the disease. A
hyperfibrinolytic state (i.e., D-Dimer levels above 500 ng/ml) was detected in 47% of
the patient with Child’s A, 75% of the patients with Child’s B, and 100% of the
patients with Child’s C cirrhosis.
Figure 4. A. Clot lysis times of patients with Child’s A (A), Child’s B (B) or Child’s C (C) cirrhosis
and in patients suffering from acute liver failure (Acute) compared with clot lysis times in healthy
controls (Control). B. Clot lysis ratio of patient samples as shown in panel A. Clot lysis ratio is
defined as clot lysis time divided by clot lysis time in the presence of CPI. Because 3 of 4 plasma
samples from patients with acute liver failure did not lyse at all during the time course of the
experiment both in presence and absence of CPI, no clot lysis ratios are given for this group.
Horizontal lines represent medians of each group.
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PAI-1, a2-antiplasmin, plasminogen and antithrombin levels influence both clot lysis time
and clot lysis ratio
As TAFI levels decrease with increasing severity of the disease, clot lysis times and ratios
were also expected todecrease.However, as clot lysis times and ratios in different stages of
cirrhosis did not differ from those inhealthy controls,we examined the effect of PAI-1,a2-
antiplasmin, plasminogen and antithrombin on clot lysis time and ratio.
To determine the effect of PAI-1 on clot lysis time, increasing concentrations of active
PAI-1 were added to pooled normal plasma, and clot lysis times were determined in
presence and absence of CPI. As shown in figure 6A, PAI-1 dose dependently prolongs
clot lysis time. PAI-1 levels of 500 ng/ml or higher completely inhibit clot lysis during the
time span of the experiment (4 hours). On inhibition of activated TAFI, a decrease in
fibrinolysis time is seen at PAI-1 concentrations up to 500 ng/ml. Clot lysis ratio
increases at PAI-1 levels up to 500 ng/ml. At higher PAI-1 levels no lysis is seen even in
the presence of CPI.
To assay the effect of a2-antiplasmin on clot lysis times, plasma from a patient with a
severe a2-antiplasmin deficiency (TAFI antigen level of 82%) was mixed with pooled
normal plasma, and the clot lysis assay was performed in the presence and absence of
CPI. As shown in figure 6B, the clot lysis time increases with increasing amounts of
Figure 5. D-Dimer levels in patients with Child’s A (A), Child’s B (B) or Child’s C cirrhosis and of
patients suffering from acute liver failure (Acute) compared to D-Dimer levels in healthy controls.
D-Dimer levels >500 ng/ml were considered to represent hyperfibrinolysis. The horizontal line
represents the mean of each group.
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functional a2-antiplasmin. Moreover, clot lysis ratio increases with increasing
concentrations of functional a2-antiplasmin.
The effect of plasminogen on clot lysis time was determined by addition of purified
plasminogen to plasminogen deficient plasma. As shown in figure 6C, when plasminogen
concentration is reduced to 60% of normal, no effect on clot lysis time is observed.
Figure 6. A. The effect of PAI-1 on clot lysis time in the absence (open circles) or presence (closed
circles) ofCPI. Different amounts of active PAI-1 were added to pooled normal plasma and the clot
lysis times were determined. Lysis times >200 min mean no detectable lysis in the time span of the
experiment. B. The effect of a2-antiplasmin on clot lysis time in the absence (open circles) or
presence (closed circles) of CPI. Plasma from a patient with a dysfunctional a2-antiplasmin
molecule was mixed with pooled normal plasma and clot lysis times were determined. C. The
effect of plasminogen on clot lysis time in absence (open circles) or presence (closed circles) of
CPI. Purified plasminogen was added to plasminogen depleted plasma, and clot lysis times were
determined. Lysis time >200 min means no detectable lysis in the time span of the experiment. D.
Antithrombin moderately accelerates clot lysis in normal plasma. Clot lysis assays were performed
in antithrombin depleted plasma, which was reconstituted with different amounts of purified
antithrombin. Clot lysis times were determined in the absence (open circles) and presence (closed
circles) of CPI.
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However, when plasminogen concentration is reduced to 40% or less, a dramatic increase
in clot lysis time is seen, and on complete depletion of plasminogen no lysis is seen at all.
The influence of thrombin inhibition by antithrombin on clot lysis time was assayed in
antithrombin-deficient plasma (TAFI antigen level of 83%) to which different amounts
of purified antithrombin were added. As shown in figure 6D, increasing amounts of
antithrombin moderately decrease clot lysis time, as well as clot lysis ratio.
A reduction of both TAFI and antithrombin does not affect clot lysis time
Because TAFI levels are decreased in cirrhosis, a decrease in clot lysis times in cirrhotics
compared to controls would have been expected. However, clot lysis time is influenced by
both the level of antithrombin and the levels of fibrinolytic proteins. It was hypothesized
that clot lysis times of cirrhotics are not decreased compared to controls because of
compensatory mechanisms for the decrease in antifibrinolytics. For example,
decreased TAFI levels might be counterbalanced by decreased levels of antithrombin.
To assay the effect of a 50% reduction of both TAFI and antithrombin in normal
plasma, mixing experiments were performed with TAFI-deficient, antithrombin-
deficient, and pooled normal plasma. As shown in figure 7, the decrease in clot lysis
time due to a decrease in TAFI levels to 50% can be balanced by a simultaneous
decrease of antithrombin levels to 50%.
Figure 7. A simultaneous reduction of TAFI and antithrombin to 50% of pooled normal plasma
levels does not affect clot lysis time, whereas reduction of either TAFI or antithrombin to 50%
results in a reduction or an increase in clot lysis time, respectively. Values shown represent
means+standard deviation (n=3).
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Down-regulation of fibrinolysis in cirrhotic plasma is TAFI mediated
To show that activation of TAFI indeed results in a down-regulation of fibrinolysis in
cirrhotic plasma, different concentrations of TAFI were added to TAFI-depleted
plasma from a single cirrhotic patient who suffered from Child’s C cirrhosis. As shown
in figure 8, increasing amounts of TAFI prolong clot lysis times in both normal (panel A)
and cirrhotic (panel B) plasma. However, in plasma from the patient with cirrhosis no
clear prolongation of clot lysis time is seen at TAFI concentrations above 100% of
pooled normal plasma, whereas in normal plasma prolongation of clot lysis time is
seen with TAFI concentrations up to 200% of pooled normal plasma.
Discussion
This study shows reduced plasma levels of TAFI antigen in a large group of patients
suffering from cirrhosis, which is related to the severity of the disease. We hypothesized
that reduced TAFI levels might contribute to the bleeding diathesis seen in cirrhotic
patients, which is partly ascribed to accelerated fibrinolysis268,270. However, despite
reduced TAFI levels and a reduced ability to generate thrombin, as characterized by a
prolonged prothrombin and activated partial thromboplastin time, we still observed
down-regulation of fibrinolysis by activated TAFI in our fibrinolysis assay because
clot lysis times could be significantly reduced by addition of a specific inhibitor of
activated TAFI. Apparently, sufficient ‘free’ thrombin is generated to activate TAFI,
Figure 8. Effect of TAFI concentration on clot lysis time in normal (panel A) or cirrhotic (panel B)
plasma. Different concentrations of purified TAFI were added to TAFI depleted plasma from a
healthy volunteer or TAFI depleted plasma from a patient suffering from Child C cirrhosis after
which clot lysis times were determined. TAFI concentrations are expressed as percentage of pooled
normal plasma.
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most probably caused by reduced antithrombin levels in these patients. This hypothesis
is supported by the observation that depletion of antithrombin from normal plasma
moderately prolongs clot lysis time. In summary, we find no indication of accelerated
plasma fibrinolysis in patients suffering from cirrhosis because clot lysis times do not
differ from healthy controls.
Although the concept of a hyperfibrinolytic state in cirrhosis is widely accepted, the
evidence from the literature is not convincing. In vitro indications for hyperfibrinolysis
in cirrhosis are based on decreased clot lysis times in fibrinolysis assays, such as dilute
whole blood clot lysis time265, euglobulin clot lysis time271 and thromboelastography230.
It has been proposed that increased t-PA activity relative to PAI-1 activity, accompanied
by decreased a2-antiplasmin levels cause accelerated fibrinolysis in cirrhosis
266.
Commonly used fibrinolysis assays have major drawbacks, and caution should be taken
in interpreting shortened clot lysis times. For example, the dilute whole blood clot lysis
time is performed in the absence of calcium, and a clot is formed by addition of
thrombin. Clot lysis time is therefore independent of coagulation and, as a consequence,
independent of TAFI. Because the euglobulin fraction used in fibrinolysis assays, such as
euglobulin clot lysis timeandfibrin platemethod, donot contain inhibitors offibrinolysis,
these tests only assay increased plasma t-PA levels. Although thromboelastography
assays whole, nonanticoagulated blood, caution must be taken in this assay as the clot
formed is initiated by (nonphysiological) contact activation.
The appearance of indicators of fibrinolysis in plasma like D-Dimers275 fibrin(ogen)
degradation products274, and PAP complexes273 has been used as in vivo evidence for a
hyperfibrinolytic state in patients with cirrhosis. This study confirms the presence of
elevated levels of D-Dimers in plasma of patients with cirrhosis. The appearance of D-
Dimers in our patient population is consistent with the concept of accelerated fibrinolysis
preceded by clotting activation276. The appearance of elevated plasma levels of
prothrombin fragment 1+2277 and thrombin-antithrombin complexes273 has been used
as evidence for in vivo clotting activation in cirrhosis. However, accumulation of
indicators of both clotting activation and fibrinolysis could also be the consequence of
a reduced clearance of these molecules by the diseased liver.
Clinically, the bleeding manifestations in cirrhotic patients do not resemble bleeding
problems seen in a clear hyperfibrinolytic state like a2-antiplasmin
280 or PAI-1281
deficiency, in which, among other bleeding manifestations, delayed bleeding after
trauma or surgery is observed. In cirrhotic patients, bleeding complications after
invasive procedures like biopsy are immediate, whereas delayed bleeding is uncommon.
Using a plasma-based clot lysis assay, in which coagulation is initiated by the
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physiological initiator of coagulation (i.e., tissue factor), we have found no evidence of
accelerated plasma fibrinolysis in cirrhosis. Because our assay uses exogenous t-PA to
initiate fibrinolysis, slightly enhanced endogenous t-PA levels are not detected. Because
vessel wall injury immediately leads to massive release of t-PA from the endothelium, this
assay set up more accurately reflects the physiological condition than do fibrinolysis
assays in which endogenous t-PA is responsible for clot lysis.
The lack of hyperfibrinolysis in cirrhotic plasma is most likely explained by a balance of
profibrinolytic and antifibrinolytic factors. Defective inhibition of fibrinolysis by
reduced levels of TAFI and a2-antiplasmin is balanced by a defective fibrinolytic
activation caused by reduced plasminogen levels and increased PAI-1 levels.
Moreover, we have shown that antithrombin also functions as profibrinolytic agent
because of its ability to inhibit thrombin activity and thus TAFI activation and that
decreased antithrombin levels are able to counterbalance decreased TAFI levels with
respect to clot lysis time. This balance is also observed on evaluation of clot lysis ratio
of cirrhotic plasma. Because PAI-1, a2-antiplasmin, plasminogen and antithrombin
levels all have an effect on clot lysis ratio, no decrease in clot lysis ratio is seen with
increasing severity of the liver damage. This decrease would be expected if clot lysis
ratio was solely dependent on TAFI levels.
Whether the absence of plasma hyperfibrinolysis can be translated to the in vivo
situation remains uncertain. Platelets have also been shown to contribute to inhibition
of fibrinolysis by PAI-1 release and by PAI-1-independent mechanisms68,272. Because
patients with cirrhosis also suffer from thrombocytopenia and platelet function
defects, it is possible that impaired platelet-mediated inhibition of fibrinolysis
contributes to the development of a hyperfibrinolytic state in vivo.
In conclusion, in this study we do not observe plasma hyperfibrinolysis in patients with
cirrhosis. Our data implicate that despite decreased levels of TAFI, accompanied by
deficiencies in the thrombin-generating system, down-regulation of fibrinolysis by
TAFI can take place in patients with cirrhosis. Abnormalities in coagulation, platelet
number, and platelet function may be more important in the bleeding diathesis of
cirrhotics, although the contribution of platelet defects to a hyperfibrinolytic state
cannot be ruled out.
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Abstract
Cirrhosis is associated with a bleeding tendency, which is particularly pronounced
during orthotopic liver transplantation (OLT). A novel approach to treat the bleeding
diathesis of patients with cirrhosis is administration of recombinant factor VIIa
(rFVIIa). This study examined whether the efficacy of rFVIIa in cirrhosis might be
explained in part by enhanced down-regulation of fibrinolysis by thrombin activatable
fibrinolysis inhibitor (TAFI). Addition of therapeutic or supratherapeutic doses of
rFVIIa to plasma of 12 patients with stable cirrhosis did not result in a prolongation of
clot lysis time, though clotting times were significantly reduced. Also, clot lysis assays of
plasma samples taken during and after OLT, which was performed with or without a
single bolus dose of rFVIIa, did not show any effect of rFVIIa on plasma fibrinolytic
potential. In conclusion, this study shows no evidence for an antifibrinolytic effect of
rFVIIa in cirrhotic patients or in patients undergoing OLT.
Introduction
Cirrhosis results in severe changes in the haemostatic system. The haemostatic defects in
cirrhosis include thrombocytopenia and platelet function defects, deficiencies of clotting
factors and inhibitors, dysfibrinogenemia, and deficiencies of fibrinolytic
proteins216,266,303. Bleeding complications in cirrhosis may be a consequence of a
defective haemostatic system, but patients may also bleed due to complications of
portal hypertension such as esophageal varices301. The bleeding diathesis of cirrhotic
patients becomes strikingly apparent during orthotopic liver transplantation (OLT),
which is frequently accompanied by excessive blood loss302.
Management of bleeding in patients with cirrhosis includes the administration of vitamin
K, fresh frozen plasma, fibrinogen concentrate and platelet concentrates. Whenever a
hyperfibrinolytic state is shown, treatment with antifibrinolytic drugs such as e-
aminocaproic acid, tranexamic acid or aprotinin is an option. Both tranexamic acid
and aprotinin have been shown to reduce blood loss during liver transplantation298,299.
A novel approach to treat the haemostatic defects in cirrhosis is administration of
recombinant factor VIIa (rFVIIa; NovoSeven). rFVIIa was shown to normalise a
prolonged PT in stable cirrhotic patients
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, and in patients with alcoholic cirrhosis who
are bleeding from esophageal varices294. Also, rFVIIa was shown to be effective in
inducing haemostasis during small invasive procedures295. A recent report showed that
rFVIIa reduced the need for transfusion of red blood cells and plasma during OLT169.
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rFVIIa was originally developed for the treatment of haemophiliacs with inhibitors
during bleeding episodes or surgery, in whom it was shown to be safe and
effective145,146,195. rFVIIa exerts its pro-haemostatic effect via enhancement of the
extrinsic coagulation pathway in a tissue factor-dependent manner182. The ability of
high-dose rFVIIa to overcome the inhibitory effect of plasma factor VII on
coagulation might play a role in the enhancement of thrombin generation by rFVIIa183.
Alternative mechanisms for the therapeutic effects have been proposed. A possible
alternative mechanism involves thrombin formation on activated platelets or
monocytes independently of tissue factor188,189. Another mechanism for the efficacy of
rFVIIa might be down-regulation of the fibrinolytic system via (enhanced) activation of
thrombin activatable fibrinolysis inhibitor (TAFI). We have previously shown that
rFVIIa serves as an antifibrinolytic agent in factor VIII deficient plasma by enhancing
secondary thrombin generation required for TAFI activation215. Whether this
mechanism also applies to cirrhotic plasma remains speculative304.
TAFI is activated by high concentrations of thrombin305 or by the thrombin-
thrombomodulin complex66. Activated TAFI down-regulates fibrinolysis by cleaving C-
terminal lysine and arginine residues from partially degraded fibrin64. These lysine and
arginine residues are essential cofactors in tissue-type plasminogen activator (t-PA)
mediated fibrinolysis. We previously observed significantly reduced levels of TAFI
antigen in patients with cirrhosis212. However, despite reduced levels of TAFI antigen
accompanied by a reduced ability to generate thrombin, optimal TAFI activation could
be demonstrated in a plasma-based fibrinolysis assay. Even more, plasma clot lysis times
were not significantly shorter in cirrhotic plasma compared to plasma of control subjects.
In this report, we investigated a possible (further) TAFI-mediated down-regulation of
fibrinolysis by rFVIIa in non-bleeding cirrhotic patients and in patients undergoingOLT.
Materials and methods
Patients
Twelve patients in stable condition with biopsy-proven cirrhosis of different etiologies -
viral hepatitis (6), alcohol abuse (4), auto-immune hepatitis (1), and cryptogenic cirrhosis
(1)- were included in this study. The patients were classified according to Pugh’s
modification of the Child classification313. Four patients with Child A, 4 patients with
Child B, and 4 patients with Child C cirrhosis were studied. Twelve healthy volunteers
from our laboratory served as a control group. Pooled normal plasma was obtained by
combining plasma from 40 healthy laboratory volunteers.
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Twelve patients with Child B and C cirrhosis who underwent OLT were also included in
this study. Six of them underwent a transplantation after receiving a single bolus dose of
rFVIIa (80 lg/kg; 4000 U/kg), whereas 6 others served as a control group. The clinical
evaluation of these patients has been described by Hendriks et al.169. Patients and
controls were matched according to expected blood loss and transfusion
requirements. Baseline characteristics of patients and controls were similar.
Transfusion of red blood cells, platelets, plasma and fibrinogen concentrate was
performed according to predefined criteria, and treatment with rFVIIa significantly
reduced transfusion requirements as described previously169. No antifibrinolytic drugs
such as aprotinin were administered. Plasma samples from 6 time points during and
after surgery were studied; 30 minutes after induction of anaesthesia (A), 30 minutes
after the start of the anhepatic phase (B), 30 minutes after reperfusion (C), at the end
of surgery (D), 24 hours after the end of surgery (E) and at day 5 after surgery (F).
rFVIIa was given 10 minutes before to start of the surgery (i.e., between time-points
A and B). In the rFVIIa-treated group time-point B corresponds to 4.5 hours
(median; range 4-5.75), time point C to 7 hours (range 5.5-8.5), and time point D to 9
hours (range 7.75-11.75) after rFVIIa infusion. The duration of the different phases in
the control group was similar.
Blood was collected in 3.8% sodium citrate (9:1, v/v) as the anticoagulant. To obtain
platelet poor plasma, samples were centrifuged twice at 2000 g for 10 minutes. Plasma
samples were stored at -808C until use.
Materials
Tissue type plasminogen activator (t-PA) was from Chromogenix (Mo¨lndal, Sweden).
Recombinant human tissue factor (Innovin) and the prothrombin fragment 1+2 kit
(Enzygnost) were from Dade Behring GmbH (Marburg, Germany). Carboxypeptidase
inhibitor from potato (CPI) was purchased from Calbiochem (La Jolla, CA, USA).
Trypsin inhibitor from corn (CTI; >30.000 trypsin inhibitory units/ml) was purchased
from Fluka Chemie GmbH (Buchs, Switzerland). Recombinant factor VIIa was a
generous gift of Novo Nordisk (Bagsvaerd, Denmark). Recombinant hirudin was a
generous gift from R. Wallis (Ciba Geigy, Horsham, UK).
Phospholipid vesicles consisting of 40% L-a-dioleoylphosphatidylcholine, 20% L-a-
dioleoylphosphatidylserine and 40% L-a-dioleoylphosphatidylethanolamine (all from
Sigma, St. Louis, MO, USA) were prepared according to Brunner209 with minor
modifications as described by van Wijnen210. Total phospholipid content of the vesicles
was determined by phosphate analysis according to Rouser211.
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Plasminogen activator inhibitor-1 (PAI-1) antigen levels were determined using the PAI-
1 ELISA kit from Technoclone GmbH (Wien, Austria). TAFI antigen levels were
determined by a sandwich type ELISA, using a monoclonal capturing antibody and a
polyclonal detection antibody as described206. TAFI levels were expressed as
percentage of pooled normal plasma. Antithrombin levels were measured using the
Coamatic thrombin inhibitor kit from Chromogenix (Mo¨lndal, Sweden).
Clot lysis assay
Lysis of a tissue factor-induced clot by exogenous t-PA was studied by monitoring
changes in turbidity during clot formation and subsequent lysis essentially as
described198. Fifty microliters of plasma was pipetted into Immulon-2 flatbottom
microtiter plates (Dynatech Laboratories Inc, Chantilly, VA). These plates do not
support contact activation316. To further suppress contact activation CTI, a potent
inhibitor of coagulation factor XIIa317 was added to the plasma throughout this study.
Fifty microliters of a mixture containing tissue factor (diluted Innovin, final dilution 105
times), CaCl2 (final concentration 17 mM), t-PA (final concentration 30 U/ml; 56 ng/ml),
phospholipid vesicles (final concentration 10 lM), and CTI (final dilution 1:25) diluted
in Hepes buffer (25 mM Hepes, 137 mM NaCl, 3.5 mM KCl, 3 mM CaCl2, 0.1% BSA,
pH 7.4) was added. After thorough mixing, turbidity at 405 nm was measured in time at
378C in a Spectramax 340 kinetic microplate reader (Molecular Devices Corporation,
Menlo Park, CA, USA). Coagulation time was defined as the time to reach the
midpoint of clear to maximal turbid transition. Clot lysis time was defined as the time
from the midpoint of the clear to maximum turbid transition, which characterises clot
formation, to the midpoint of the maximum turbid to clear transition, which
represents clot lysis. To assess the contribution of activated TAFI to clot lysis time,
experiments were performed in which CPI (25 lg/ml), a specific inhibitor of activated
TAFI199, was added to the plasma. To assay the influence of rFVIIa on clot lysis in
cirrhotic plasma, 60 U/ml of rFVIIa, which represents the double amount of peak
values of rFVIIa observed in cirrhotic patients who received a bolus dose of 80 lg/kg
(4000 U/kg) rFVIIa293, was added to the plasma.
Prothrombin fragment 1+2 measurement during clot lysis assay
Prothrombin activation during the clot lysis assay was monitored by performing a clot
lysis assay not in 96-well microtitre plates, but in eppendorf tubes. Coagulation was
induced in cirrhotic plasma or pooled normal plasma in the presence or absence of
rFVIIa (60 U/ml). At different time intervals, thrombin formation was terminated by
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the addition of 100 ll of HEPES buffer containing 20 mM EDTA and 50 U/ml hirudin.
After thorough mixing for 1 minute, the clot was spun down (2 minutes, 15.000 g).
Prothrombin activation was quantified by assaying the concentration of prothrombin
fragment 1+2 in the supernatant by ELISA.
Statistical analysis
Statistical analysis was performed using the GraphPad InStat (San Diego, USA)
software package. The statistical significance of differences in coagulation or clot lysis
time upon addition of rFVIIa was evaluated using a paired Student’s t-test. A P value
of <0.05 was considered statistically significant.
Results
Effect of rFVIIa on coagulation during the clot lysis assay in cirrhotic and control plasma.
In 12 patients with cirrhosis of varying severity and in 12 controls, a clot lysis assay was
performed in presence and absence of rFVIIa (60 U/ml). As shown in figure 1,
coagulation times in cirrhotics, which were derived from the turbidity profiles of the
clot lysis assay, were similar to those in healthy controls. Upon addition of rFVIIa, a
significant decrease in clotting time was seen in both cirrhotic and control plasma
(p<0.0001 for controls; p<0.0001 for cirrhotics, paired t-test).
Figure 1. Coagulation times in cirrhotic and control plasma derived from clot lysis turbidity profiles
in absence or presence of recombinant factor VIIa (rFVIIa; 60 U/ml). Coagulation was initiated by
addition of calcium (17 mM), phospholipids (10 lM) and tissue factor (Innovin; 105 times diluted).
Corn trypsin inhibitor was added to the reaction mixture to suppress contact activation.
Horizontal bars represent means.
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Effect of rFVIIa on clot lysis time in cirrhotic and control plasma.
As shown in figure 2, addition of 60 U/ml rFVIIa had no effects on clot lysis time in both
cirrhotic and control plasma. Addition of supratherapeutic doses of rFVIIa (up to 400
U/ml) to cirrhotic plasma also did not result in a prolongation of clot lysis time (data not
shown). Also, clot lysis times did not differ between cirrhotics and controls, despite a
pronounced difference in TAFI antigen levels (controls 102+22% (mean+SD);
cirrhotic patients 62+23%). In both groups a down-regulation of fibrinolysis by
activated TAFI was present, since clot lysis times could be significantly reduced by an
inhibitor of activated TAFI (CPI).
Prothrombin fragment 1+2 formation during the clot lysis assay
Prothrombin activation during the clot lysis assay was quantified by measurement of
prothrombin fragment 1+2 (F1+2) at different time points after initiation of the clot
lysis assay. As shown in figure 3, only a very small amount of prothrombin was
activated when the plasma started to clot (which is at approximately 5 minutes) for
both cirrhotic and pooled normal plasma. The bulk of the thrombin was formed after
clot formation. On addition of rFVIIa to both cirrhotic and pooled normal plasma,
Figure 2. Clot lysis times of cirrhotic and control plasma. Coagulation was initiated by addition of
calcium (17 mM), phospholipids (10 lM) and tissue factor (Innovin; 105 times diluted), fibrinolysis
was induced by the addition of tissue-type plasminogen activator (t-PA; 30 U/ml). Clot lysis times
were determined in plasma spiked with buffer, recombinant factor VIIa (rFVIIa; 60 U/ml), or
carboxypeptidase inhibitor (CPI; 25 lg/ml). Corn trypsin inhibitor (CTI) was added to the
reaction mixture to suppress contact activation. Horizontal bars represent means.
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prothrombin activation increased in the first 15 minutes, but was not increased at later
time-points, when all available prothrombin had been converted. The amount of F1+2
formed in cirrhotic plasma was much smaller than that in pooled normal plasma, due
to the low prothrombin level in the cirrhotic plasma.
TAFI antigen levels during and after OLT
Figure 4A shows TAFI antigen levels at 6 selected time-points during and after OLT of
six patients who did not receive rFVIIa. TAFI levels decreased during the anhepatic and
post-reperfusion phases, and rapidly normalized after surgery. Figure 4B shows TAFI
antigen levels in 6 patients undergoing OLT after a single bolus dose of rFVIIa.
Although basal levels of TAFI were lower in this group, a similar pattern of the course
of TAFI antigen levels during and after the transplantation was observed in both groups.
The course of TAFI antigen levels was comparable to levels of other proteins involved in
coagulation and fibrinolysis such as antithrombin (figures 4C and D) plasminogen and
a2-antiplasmin (data not shown), and represent the improvement of the synthesis
function of the liver.
Figure 3. Prothrombin fragment 1+2 formation during clot lysis assay in pooled normal plasma
(squares) or cirrhotic plasma (circles) in absence (open symbols) and presence of recombinant
factor VIIa (rFVIIa; 60 U/ml; closed symbols).
98
rFVIIa in liver disease and liver transplantation
Clot lysis times during and after OLT
Clot lysis times were determined in plasma samples taken at 6 time-points during and
after OLT in the presence or absence of a specific inhibitor of activated TAFI. Figure
5A shows clot lysis times of patients who did not receive rFVIIa. Clot lysis times
decreased during the anhepatic and post-reperfusion phase, indicating the
development of a hyperfibrinolytic state. At the end of surgery, clot lysis times
increased, and most samples showed no lysis at all during the time course of our
experiment. The inhibition of clot lysis during this phase was associated by a transient
Figure 4. TAFI antigen and antithrombin activity levels during and after OLT performed without
(panels A and C) or with (panels B and D) a single bolus dose of recombinant factor VIIa (rFVIIa;
80 lg/kg; 4000 U/kg). TAFI and antithrombin levels were measured in samples taken 30 minutes
after the induction of anesthesia (A), 30 minutes after the start of the anhepatic phase (B), 30
minutes after reperfusion (C), at the end of surgery (D), at day 1 (E), and day 5 after surgery (F).
rFVIIa was injected 10 minutes before the start of the surgery (between time points A and B). In the
rFVIIa-treated group time point B corresponds to 4.5 hours (median; range 4-5.75), time point C to
7 hours (range 5.5-8.5), and time point D to 9 hours (range 7.75-11.75) after rFVIIa infusion. The
duration of the different phases in the control group was similar. The horizontal bars represent
medians.
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Figure 5. Clot lysis times during and after OLT performed without (panel A) or with (panel B) a
single bolus dose of recombinant factor VIIa (rFVIIa; 80 lg/kg; 4000 U/kg) in the absence (open
symbols) or presence (closed symbols) of the specific TAFIa inhibitor CPI. Clot lysis times were
determined in samples taken 30 minutes after the induction of anesthesia (A), 30 minutes after the
start of the anhepatic phase (B), 30 minutes after reperfusion (C), at the end of surgery (D), at day 1
(E), and day 5 after surgery (F). The horizontal bars represent medians.
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increase in plasminogen activator inhibitor-1 (PAI-1) levels as shown in figure 6. In a
previous report we have shown that very high PAI-1 levels can completely inhibit clot
lysis212. At day 5 after surgery clot lysis times were still above basal levels. As shown in
figure 5B, the rFVIIa treated patients showed the same pattern of clot lysis time during
and after OLTas the control group, except for clot lysis times during the postreperfusion
phase, which were longer in the rFVIIa treated group (not significant). In all samples,
except for those who did not show any lysis during our experiment, clot lysis times
could be significantly shortened by addition of a specific inhibitor of activated TAFI
(CPI).
Discussion
The mechanism behind the efficacy of rFVIIa in patients suffering from cirrhosis295 as
well as patients undergoing OLT169 is still unclear. We have explored the potential of
rFVIIa to serve as an antifibrinolytic agent in plasma from non-bleeding cirrhotic
patients. Also, the fibrinolytic potential of plasma samples taken during and after
OLT, which was performed with or without the use of rFVIIa was assayed. This study
shows, by using a plasma-based clot lysis assay, no evidence for enhanced activation of
TAFI by therapeutic or even supratherapeutic doses of rFVIIa in these patient groups.
On the other hand, rFVIIa does result in enhancement of the rate of clot formation, as
reflected by a shortening of the clotting times.
Two separate stages of thrombin formation during tissue factor-induced coagulation can
Figure 6. Plasminogen activator inhibitor type 1 (PAI-1) antigen levels during and after OLT
performed without (panel A) or with (panel B) a single bolus dose of recombinant factor VIIa
(rFVIIa; 80 lg/kg; 4000 U/kg). PAI-1 levels were determined in samples taken 30 minutes after
the induction of anesthesia (A), 30 minutes after the start of the anhepatic phase (B), 30 minutes
after reperfusion (C), at the end of surgery (D), at day 1 (E), and day 5 after surgery (F). The
horizontal bars represent medians.
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be distinguished. The primary formation of thrombin results in cleavage of fibrinogen,
and activation of factor XIII, leading to the assembly of a stable fibrin clot. After the
fibrin clot is formed, thrombin formation continues via thrombin-mediated activation
of factor XI and subsequent thrombin generation via the intrinsic pathway198. This
secondary burst of thrombin results in the activation of TAFI65.
In both control and cirrhotic plasma, primary thrombin formation was accelerated by
the addition of rFVIIa. Acceleration of primary thrombin formation was observed
both as a shortening of coagulation time as well as an increase in prothrombin
fragment 1+2 release in the first 10 minutes of incubation. Basal coagulation times in
our experimental set-up were similar in patient and control plasma, though
prothrombin times of the patient plasma were significantly prolongued. The assay
performed in this study is a very dilute prothrombin time assay. On dilution of the
tissue factor source, clotting time is no longer dependent only on levels of the
procoagulant proteins, but also on the levels of anticoagulants like antithrombin. It is
likely that in our assay the decreases in procoagulant factors in cirrhotic plasma are
compensated by the decreases in anticoagulant factors, resulting in clotting times
comparable to control levels.
Our results show that secondary thrombin formation was already optimal for TAFI
activation in both control and cirrhotic plasma because addition of rFVIIa did not
result in an increase in clot lysis time. All available prothrombin is already converted
after 30 minutes of incubation in both control and cirrhotic plasma in the absence or
rFVIIa.
Although we have questioned the presence of a hyperfibrinolytic state in non-bleeding
cirrhotic patients212, we did observe development of a hyperfibrinolytic state in
patients undergoing OLT, consistent with previous studies285,318. In this study we
showed accelerated fibrinolysis during the anhepatic and postreperfusion phase of
OLT. During these critical phases of OLT, TAFI levels, which were already decreased
at baseline, decreased even more. However, TAFI was still contributing to down-
regulation of fibrinolysis during these phases, as clot lysis times significantly decreased
on addition of a specific TAFI inhibitor (CPI). At the end of surgery, a transient
strong increase in plasma PAI-1 levels was seen, which leads to a complete inhibition
of clot lysis. Clot lysis times in OLT patients who received a single bolus dose of
rFVIIa were similar to those in controls, except in the postreperfusion phase in which
a trend towards higher clot lysis times in the rFVIIa treated group was seen. Because
rFVIIa levels during this phase had almost returned to baseline169, this apparent
difference is unlikely to be a consequence of a direct rFVIIa effect.
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In this study we did not find any evidence for a rFVIIa-mediated downregulation of
fibrinolysis in cirrhosis, both in stable patients as well as in patients undergoing OLT.
The beneficial effect of rFVIIa during OLT can probably be mainly ascribed to its
potential to enhance fibrin formation. The reduced thrombin inhibition due to low
levels of antithrombin in cirrhotic patients facilitates enhancement of fibrin formation
by rFVIIa. As treatment with rFVIIa does not alter the development of a
hyperfibrinolytic state during anhepatic and post-reperfusion phase, a combination of
rFVIIa and antifibrinolytics during OLT might be an option. However, it should be
considered that this combination might increase the risk of thrombosis, particularly of
the donor liver vessels. The absence of hyperfibrinolysis in cirrhotics limits the rational
use of antifibrinolytics in stable cirrhosis.
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Abstract
Tissue factor-induced coagulation leads to the generation of a small amount of thrombin
via tenase and prothrombinase activity, resulting in the formation of a fibrin clot. After
the fibrin clot has formed, thrombin generation continues via a factor XI-dependent
pathway. The resulting secondary burst of thrombin activates TAFI (thrombin
activatable fibrinolysis inhibitor), leading to downregulation of fibrinolysis.
In this study the effect of anticoagulant drugs targeting different steps in the coagulation
cascade on clot formation and subsequent breakdown was investigated using a plasma-
based clot lysis assay. All drugs tested significantly delayed clot formation. However,
only those drugs targeting factor Xa (tissue factor pathway inhibitor, the
pentasaccharide compound fondaparinux sodium, and low molecular weight heparin)
accelerated fibrinolysis. Anticoagulant drugs targeting tissue factor (active site
inactivated factor VIIa) or thrombin (hirudin and the low molecular weight compound
PPACK) did not affect clot lysis time. In accordance with these findings, it was shown
that total thrombin generation, as quantified by the endogenous thrombin potential, was
only affected by anticoagulant drugs targeting factor Xa when all drugs were used in a
concentration with an equal potential to inhibit clot formation.
Induction of hyperfibrinolysis by anticoagulant drugs directed against factor Xa might
be beneficial as increased clot breakdown might facilitate thrombolysis or prevent
reocclusion. On the other hand, the induction of hyperfibrinolysis by these compounds
might increase the risk of bleeding complications.
Introduction
Numerous approaches for the treatment or prevention of venous and arterial
thromboembolism have become available in the last decades. Among those are
inhibitors of platelet function319, inhibitors of coagulation320, and a diversity of
thrombolytic agents321. Inhibition of thrombin generation is considered an important
aspect of antithrombotic treatment. Traditionally, heparin or low molecular weight
heparins have been used to downregulate the coagulation system. These agents function
by enhancing the activity of antithrombin towards both factor Xa and thrombin.
Recently, a synthetic pentasaccharide (Org31540/SR90107A, fondaparinux sodium,
Arixtra, PENTA), which selectively inhibits factor Xa in an antithrombin dependent
manner has been introduced as an alternative to traditional low molecular weight
heparins (LMWH’s)126. Alternative strategies aiming at downregulation of
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coagulation include direct inhibition of thrombin, by low molecular weight inhibitors
such as D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone (PPACK)127 or
hirudin128, or inhibition of the tissue factor pathway by active site inactivated factor
VIIa (ASIS, FFRck-VIIa)130 or recombinant full length tissue factor pathway
inhibitor (rFL-TFPI)131.
The application of the different novel anticoagulants in the clinic has not been fully
established yet. An important complication of anticoagulant treatment is the
development of bleeding complications322. Phase II and III studies have indicated
differences between anticoagulant drugs with respect towards in vivo anticoagulant
potency and risk to benefit ratio323-325. Anticoagulant-related bleeding can occur
spontaneously, at sites of previous vascular damage (e.g., after surgery). Alternatively,
it may be associated with concomitant drug use or comorbid disease such as cancer.
Insight into the mechanism by which the different anticoagulants affect the
coagulation system may assist treatment in case of bleeding complications.
A thus far underestimated consequence of anticoagulant treatment is its effect on the
stability of the fibrin clot, and its resistance to breakdown by the fibrinolytic system.
A recently discovered important determinant in clot resistance to fibrinolysis in in
vitro sytems is the activation of thrombin activatable fibrinolysis inhibitor (TAFI)63.
TAFI is activated by high concentrations of thrombin, which is generated after clot
formation via thrombin-mediated activation of factor XI65. Alternatively, TAFI may
be activated by the thrombin-thrombomodulin complex. The latter reaction is
approximately 1200 times more efficient than the activation of TAFI by thrombin
alone66.
In vivo relevance of TAFI has been demonstrated in animal thrombosis models, in which
inhibition of TAFI by carboxypeptidase inhibitor from potatoe resulted in facilitation of
thrombolysis311,326. However, TAFI deficiency in mice failed to show an altered
phenotype compared to control mice when challenged in different thrombosis models105.
The effects of the different anticoagulants on the haemostatic system are usually
investigated in laboratory assays, which have clot formation as the primary endpoint.
However, at the time of clot formation, very little thrombin has been generated41. In
this study, the effects of different anticoagulants, inhibiting tissue factor (VIIai), the
TF-VIIa complex and Xa (TFPI), factor Xa (PENTA), factor Xa and thrombin
(LMWH), or thrombin (PPACK and Hirudin) on secondary thrombin generation (i.e.,
the thrombin generated after clot formation) and TAFI activation have been
investigated in an in vitro clot lysis assay. The outcome of these clot lysis experiments
were confirmed by investigating total thrombin generation as measured by the
107
Chapter 6
endogenous thrombin potential327 in the presence of the mentioned anticoagulants.
Materials and methods.
Plasma samples
Pooled normal plasma was obtained by combining plasma from 10 healthy volunteers.
Blood samples were obtained by venipuncture from the antecubital vein into 3.2%
sodium citrate (9:1, v/v). To obtain platelet poor plasma, the samples were centrifuged
twice at 2000g for 15 minutes. Plasma samples were stored at –708C until use.
Materials
Tissue type plasminogen activator (t-PA) was from Chromogenix (Mo¨lndal, Sweden).
Recombinant human tissue factor (Innovin) was from Dade Behring GmbH
(Marburg, Germany). Trypsin inhibitor from corn (CTI; >30.000 trypsin inhibitory
units/ml) was purchased from Fluka Chemie GmbH (Buchs, Switzerland). The
fluorogenic substrate Z-GGR-AMC was from Bachem (Bubendorf, Switzerland).
Phospholipid vesicles consisting of 40% L-a-dioleoylphosphatidylcholine, 20% L-a-
dioleoylphosphatidylserine and 40% L-a-dioleoylphosphatidylethanolamine (all from
Sigma, St. Louis, MO, USA) were prepared according to Brunner209 with minor
modifications as described by van Wijnen210. Total phospholipid content of the vesicles
was determined by phosphate analysis according to Rouser211.
Anticoagulant drugs
Active site inactivated factor VIIa and recombinant full length TFPI (rFL-TFPI) were
generous gifts from Drs. M. Kjalke and U. Hedner, TF/VIIa research, Novo Nordisk
(Ma˚løv, Denmark). Org31540/SR90107A was from NV Organon (Oss, The
Netherlands). LMWH (Fragmin) was from KabiVitrum AB (Stockholm, Sweden).
PPACK was obtained from Bachem (Bubendorf, Switzerland). Recombinant
desulphato hirudin was a generous gift from Dr. R. Wallis (Ciba Geigy, Horsham, UK).
Clot lysis assay
Lysis of a tissue factor-induced clot by exogenous t-PA was studied by monitoring
changes in turbidity during clot formation and subsequent lysis essentially as
described, except that a different tissue factor concentration was used198. Fifty
microliters of plasma was pipetted into Immulon-2 flatbottom microtiter plates
(Dynatech Laboratories Inc, Chantilly, VA). These plates do not support contact
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activation316. To further suppress contact activation CTI, a potent inhibitor of
coagulation factor XIIa317 was added to the plasma throughout this study. Fifty
microliters of a mixture containing tissue factor (diluted Innovin, final dilution 1000
times), CaCl2 (final concentration 17 mM), t-PA (final concentration 30 U/ml; 56 ng/
ml), phospholipid vesicles (final concentration 10 lM), and CTI (final dilution 1:25)
diluted in Hepes buffer (25 mM Hepes, 137 mM NaCl, 3.5 mM KCl, 3 mM CaCl2,
0.1% BSA, pH 7.4) was added. After thorough mixing, turbidity at 405 nm was
measured in time at 378C in a Spectramax 340 kinetic microplate reader (Molecular
Devices Corporation, Menlo Park, CA, USA). Coagulation time was defined as the
time to reach the midpoint of clear to maximal turbid transition. Clot lysis time was
defined as the time from the midpoint of the clear to maximum turbid transition,
which characterises clot formation, to the midpoint of the maximum turbid to clear
transition, which represents clot lysis.
Endogenous thrombin potential
The endogenous thrombin potential was determined essentially as described by Hemker
et al327. In a 96-wells microtitre plate, 80 ll plasma was pipetted. A mixture of tissue
factor (1/1000 dilution of innovin), phospholipids vesicles (final concentration 10 lM),
CTI (final dilution 1:25), and one of the anticoagulant drugs was added in a total volume
of 20 ll. The reaction was started by adding 20 ll of a solution containing 100 mM
CaCl2, and 5 mM of the fluorogenic substrate Z-GGR-AMC. Fluorescence was
monitored in time in a microtiter plate fluorometer Fluoroskan Ascent, type 374
(Labsystems, Helsinki, Finland) with the excitation filter at 390 nm and the emission
filter at 460 nm. The endogenous thrombin potential was determined as described328.
Statistical analysis
Statistical analyses were performed using the GraphPad InStat (San Diego, USA)
software package. Statistical significance of differences in clotting and clot lysis times
upon addition of increasing concentrations of anticoagulants was determined by
standard ANOVA with Dunnett’s post-test. P<0.05 was considered statistically
significant.
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Results
Effect of different anticoagulant drugs on clot formation and clot lysis
Clot lysis assays were performed with increasing concentrations of active site inactivated
factor VIIa. Clotting times and clot lysis times were derived from the obtained turbidity
profiles. Figure 1A shows a dose dependent increase in clotting time upon addition of
VIIai, which was statistically significant at VIIai concentrations of 5 ng/ml and higher
(p<0.01 vs no VIIai). Clot lysis times showed a small decrease at higher concentrations
of VIIai, but this was not statistically significant (p>0.05 for 5000 ng/ml VIIai vs no
VIIai).
Figure 1B shows clotting times and clot lysis times obtained in the presence of increasing
concentrations of recombinant full length tissue factor pathway inhibitor. Clotting times
dose dependently increased, and a statistically significant increase in clotting time was
observed at rFL-TFPI concentrations of 1 and 2 mg/ml (p<0.05 and p<0.01,
respectively). Clot lysis times dose dependently decreased, with a statistically
significant decrease at rFL-TFPI concentrations of 1 and 2 mg/ml (p<0.01).
In figure 1C, the effect of PENTA on clotting times and clot lysis times are shown.
Clotting times were dose dependently increased, with statistical significance at a
concentration of 1.6 anti Xa Units/ml (p<0.05) and higher (p<0.01). The clot lysis time
was dose dependently decreased, with statistical significance at 0.8 anti Xa Units/ml and
higher (p<0.01).
Effects of the low molecular weight heparin Fragmin on clotting and clot lysis times are
shown in figure 1D. Clotting times dose dependently increased upon addition of
LMWH. Statistical significance was reached at LMWH concentrations of 0.25 anti Xa
U/ml and higher (p<0.01). A dose dependent decrease in clot lysis time was observed,
which reached statistical significance at LMWH concentrations of 0.125 anti Xa U/ml
and higher (p<0.01).
The thrombin inhibiting chloromethlyl ketone peptide PPACK dose dependently
inhibited clotting time (figure 1E), with statistical significance reached at a
concentration of 0.25 lM or higher (p<0.01). PPACK had no effect on clot lysis time
in the range of concentrations tested.
Hirudin, the other thrombin inhibitor tested, showed similar results as PPACK. Clotting
times were significantly prolonged at hirudin levels of 6.125 U/ml or higher (p<0.01),
whereas no effect on clot lysis time was observed (figure 1F).
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Figure 1. Effects of VIIai (A), rFL-TFPI (B), PENTA (C), LMWH (D), PPACK, and hirudin (E)
on clot formation (closed symbols) and clot lysis time (open symbols). Coagulation was initiated in
pooled normal plasma by the addition of tissue factor (Innovin, 1:1000), calcium chloride (17 mM),
and phospholipid vesicles (10 lM), and fibrinolysis was induced by the addition of tPA (30 U/ml).
Clot lysis profiles were measured for increasing concentrations of the different anticoagulants.
Shown are the mean values obtained from three independent experiments. Error bars indicate
standard deviation.
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Endogenous thrombin potential in the presence of anticoagulant drugs
We next tested the 6 anticoagulants using a fixed concentration of each anticoagulant
which results in an approximate doubling of coagulation time as derived from clot lysis
curves (figure 2A). Under these conditions, clot lysis times are significantly decreased for
TFPI, PENTA, and LMWH, but not for VIIai, PPACK, and Hirudin (figure 2B).
Similarly, as shown in figure 2C, endogenous thrombin potential (ETP) is decreased by
TFPI (77+12% of ETP in absence of anticoagulant drug), PENTA (26+6%), and
LMWH (54+9%), whereas the ETP did not significantly change by VIIai (110+17%),
PPACK (90+30), and hirudin (98+14%). The thrombin generation curve did show a
shift to the right for all anticoagulants, confirming that clot formation was inhibited
for all compounds.
Discussion
This in vitro study shows that anticoagulant drugs targeting factor Xa induce
enhancement of plasma fibrinolytic potential due to attenuation of TAFI activation.
Anticoagulant drugs exclusively inhibiting tissue factor or thrombin do not show an
effect on fibrin clot lysis in the assay set-up employed in this study. All drugs tested
are potent inhibitors of clot formation, for which only a relatively small amount of
thrombin is required. The bulk of the thrombin is generated after formation of the
fibrin clot39,41. The generation of the thrombin burst after clot formation is required
for TAFI activation. Direct inhibition of tissue factor or thrombin apparently fails to
prevent or diminish this secondary thrombin generation, and thereby fails to induce
hyperfibrinolysis.
The effect of the different anticoagulants on secondary thrombin generation was
investigated by measurements of the (extrinsic) endogenous thrombin potential
(ETP)327. The ETP measures the total amount of ‘active’ thrombin formed in a plasma
sample upon activation. Indeed, as hypothesized from the clot lysis experiments, only the
drugs targeting factor Xa resulted in a significant decrease in ETP when concentrations
of the drugs were used which were equally potent in delaying clot formation. In these
experiments we found an excellent correlation between acceleration of TAFI-
dependent clot lysis and the ETP, but it is uncertain whether these two parameters are
exchangeable in all situations. It is not yet known how much active thrombin at what
stage during clot lysis is required for TAFI activation, and it is therefore conceivable
that in certain situations discrepancies between clot-lysis experiments and ETP values
may occur.
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Figure 2. A. From figures 1 A-F, a single concentration of each anticoagulant, which resulted in an
approximate equal prolongation of coagulation time, was selected. B. Clots lysis times under these
conditions were significantly shortened for TFPI, LMWH, and PENTA, but not for VIIai,
PPACK, and hirudin. C. The endogenous thrombin potential was determined for the different
anticoagulants at a single concentration. Shown are mean values of three independent
experiments. Error bars indicate standard deviation.
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Why does only inhibition of factor Xa affect secondary thrombin generation? Inhibition
of the TF pathway does not attenuate secondary thrombin generation as this process
depends on factor XIa mediated activation of the intrinsic pathway of coagulation198.
Once a small amount of thrombin is generated via the TF pathway, thrombin amplifies
its own generation in a TF-independent manner. The reason why direct thrombin
inhibitors fail to inhibit secondary thrombin generation is, at first sight, less obvious.
Most likely, the inhibitory activity of direct thrombin inhibitors towards in situ
generated thrombin is simply not fast enough to prevent explosive thrombin
generation as already suggested by Lindhout et al.329, who did observe a decrease in
thrombin potential upon addition of hirudin to normal plasma, but high
concentrations were required. In addition, Mohri and coworkers previously described
a complete lack of effect of hirudin on thrombin potential330.
Although the physiological relevance of TAFI activation and its inhibition by
anticoagulant drugs targeting factor Xa remains uncertain, our findings may have
clinical consequences. On one hand, induction of hyperfibrinolysis by anticoagulant
drugs may be beneficial in certain clinical conditions as prevention or treatment of
thrombus formation is accomplished by two mechanisms (i.e., prevention of clot
formation and facilitation of clot breakdown). On the other hand, the induction of
hyperfibrinolysis could lead to an increased risk of bleeding. This could imply that
bleeding episodes induced by factor Xa inhibitors could be managed by antifibrinolytic
agents like aprotinin or e-aminocaproic acid.
In conclusion, we have shown that anticoagulant drugs targeting factor Xa have both
anticoagulant and profibrinolytic properties. The clinical relevance of this finding
warrants further investigation.
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Abstract
Org31540/SR90107A (fondaparinux sodium, PENTA) is a synthetic pentasaccharide,
which selectively inhibits factor Xa. PENTA has recently been registered in Europe and
the United States for prevention of venous thromboembolism following hip fracture, hip
replacement, and knee replacement surgery. However, an antidote in case bleeding
complications occur has not yet been established. In this study, we have explored the
effects of recombinant factor VIIa on the defects in both clot formation and TAFI-
mediated downregulation of fibrinolysis induced by PENTA in vitro. In vitro clot lysis
assays were performed in plasma from healthy volunteers to which PENTA was added.
Addition of PENTA to pooled normal plasma significantly delayed clot formation
whereas clot lysis was significantly enhanced due to decreased activation of thrombin
activatable fibrinolysis inhibitor (TAFI). Addition of recombinant factor VIIa
corrected the defect in clot formation induced by PENTA, and the defective TAFI
activation was partially restored. On addition of PENTA to individual plasma samples
of 35 healthy volunteers, a heterogeneous response with respect to clot lysis time was
observed. The decrease in clot lysis time on addition of PENTA was correlated with
endogenous factor VII levels. In conclusion, recombinant factor VIIa might be a good
therapeutic option in patients treated with PENTA who develop bleeding
complications, since both clot formation as well as fibrinolytic resistance are improved.
Introduction
The synthetic pentasaccharide Org31540/SR90107A (Fondaparinux sodium, Arixtra,
PENTA; Sanofi-Synthelabo, Paris, and NV Organon, Oss, The Netherlands) is a
novel, chemically synthesized antithrombotic drug, which exerts its antithrombotic
effect by selective inhibition of coagulation factor Xa activity in an antithrombin
dependent manner331. Recent clinical studies suggested that PENTA has superior
qualities over other low-molecular-weight heparins with respect to risk-benefit ratio in
preventing venous thromboembolism after hip replacement surgery332,333, hip-fracture
surgery325, and elective major knee surgery334, for which PENTA has been recently
registered in Europe and the United States. Also, PENTA was shown to be effective
for treatment of proximal vein thrombosis335, as adjunctive therapy in acute
myocardial infarction336, and to prevent abrupt vessel closure during percutaneous
transluminal coronary angioplasty337.
A possible adverse event associated with the administration of heparin-like
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anticoagulants is the risk of bleeding322. Therapeutical options in patients treated with
PENTAwho develop bleeding complications are until now limited. We hypothesize that
the administration of recombinant factor VIIa (rFVIIa) could reverse the anticoagulant
effects of PENTA. rFVIIa has been originally developed for patients with haemophilia A
or B with inhibitory antibodies195. Recently, however, it has been suggested that rFVIIa
could become a general haemostatic agent as it has shown to be effective in arresting
bleedings or limit blood loss in various clinical settings162,169,174,180,338.
In a previous study we have shown that rFVIIa, in addition to its procoagulant
properties, can function as an antifibrinolytic agent when added to plasma from
patients with severe haemophilia A by means of enhancing the activation of thrombin
activatable fibrinolysis inhibitor (TAFI)215. As TAFI is activated by high
concentrations of thrombin65, we speculated that PENTA might not only function as
an anticoagulant but also as a profibrinolytic agent by attenuating TAFI activation.
In this study, we investigated the effect of rFVIIa on clot formation and on TAFI
mediated down-regulation of fibrinolysis in plasma from healthy individuals to which
PENTA was added.
Materials and methods
Plasma samples
Pooled normal plasma was obtained by combining plasma from 40 healthy volunteers.
Individual plasma samples from 35 healthy laboratory volunteers were also used in this
study.
Blood samples were obtained by venipuncture from the antecubital vein into 3.2%
sodium citrate (9:1, v/v). To obtain platelet poor plasma, the samples were centrifuged
twice at 2000g for 15 minutes. Plasma samples were stored at –808C until use.
Materials
Recombinant factor VIIa (NovoSeven) was a generous gift from Novo Nordisk A/S
(Bagsvaerd, Denmark). Fondaparinux sodium was from NV Organon (Oss, The
Netherlands). Tissue type plasminogen activator (t-PA) was from Chromogenix
(Mo¨lndal, Sweden). Recombinant human tissue factor (Innovin) was from Dade
Behring GmbH (Marburg, Germany), and carboxypeptidase inhibitor from potato
(CPI) was purchased from Calbiochem (La Jolla, CA). Phospholipid vesicles consisting
of 40% L-a-dioleoylphosphatidylcholine, 20% L-a-dioleoylphosphatidylserine and 40%
L-a-dioleoylphosphatidylethanolamine (all from Sigma, St. Louis, MO) were prepared
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according van Wijnen
210
. Total phospholipid content of the vesicles was determined by
phosphate analysis according to Rouser211. Factor VII, factor V, factor X, and factor II
activity levels were determined by a one-stage clotting assay using factor VII deficient
plasma from Helena Laboratories (Beaument, TX, USA), and factor V, X and II
deficient plasma from Boeringer Mannheim GmbH (Mannheim, Germany). In these
assays, thromborel S (Dade-Behring, Mannheim, Germany) was used as tissue factor
source. Antithrombin levels were determined using the Coamatic antithrombin kit from
Chromogenix (Mo¨lndal, Sweden). TAFI antigen levels were determined by a sandwich-
type ELISA as described206.
Clot lysis assay
Lysis of a tissue factor-induced clot by exogenous t-PA was studied by monitoring
changes in turbidity during clot formation and subsequent lysis essentially as described
previously212, except for a change in tissue factor concentration. Fifty microliters of
plasma was pipetted into a microtiter plate. Fifty microliters of a mixture containing
tissue factor (diluted Innovin, final dilution 1000 times), CaCl2 (final concentration 17
mM), t-PA (final concentration 30 U/ml; 56 ng/ml), and phospholipid vesicles (final
concentration 10 lM), diluted in Hepes buffer (25 mM Hepes, 137 mM NaCl, 3.5 mM
KCl, 3 mM CaCl2, 0.1% BSA, pH 7.4) was added. After thorough mixing, turbidity at
405 nm was measured in time at 378C in a Spectramax 340 kinetic microplate reader
(Molecular Devices Corporation, Menlo Park, CA, USA). Coagulation time was
defined as the time to reach the midpoint of clear to maximal turbid transition. Clot
lysis time was defined as the time from the midpoint of the clear to maximum turbid
transition, which characterises clot formation, to the midpoint of the maximum turbid
to clear transition, which represents clot lysis. To assess the contribution of TAFI
activation to clot lysis time, experiments were performed in which CPI (25 lg/mL), a
specific inhibitor of activated TAFI199, was added to the plasma.
Statistical analysis
Statistical analysis was performed using the GraphPad InStat (San Diego, USA)
software package. Differences in clotting time and clot lysis time in pooled normal
plasma was determined by standard t-test. Differences in clotting time and clot lysis
time in the 35 individual samples were assayed by repeated measures one-way analysis
of variance (ANOVA) using the Tukey-Kramer post-test. Statistical significance of
linear correlations was determined by Pearson’s correlation coefficient. P values <0.05
were considered statistically significant.
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Results
PENTA delays clot formation and accelerates clot breakdown in pooled normal plasma
The effect of PENTA in a plasma system in which coagulation was initiated with a
diluted prothrombin reagent as tissue factor source was investigated. As shown in
figure 1A, PENTA dose-dependently inhibited clot formation in pooled normal
plasma (open circles). In the same assay, the effect of PENTA on clot lysis induced by
exogenous t-PA was investigated. Figure 1B shows that PENTA dose-dependently
decreased clot lysis time (open circles). Simultaneous experiments were performed in
which CPI, a specific inhibitor of activated TAFI, was added to the plasma (figure 1B,
squares). PENTA only affected clot lysis time in the presence of TAFI activity.
rFVIIa accelerates clot formation and enhances TAFI-mediated down-regulation of
fibrinolysis in plasma containing PENTA
On addition of rFVIIa (40 nM) to pooled normal plasma to which PENTA was added,
clotting times were significantly lowered over the whole range of PENTA tested (figure
1A, closed circles). Clot lysis time in PENTA-containing plasma was prolongued by
rFVIIa (figure 1B closed circles). A significant prolongation of clot lysis time was
observed for PENTA levels above 1.4 lg/ml.
Figure 1. Defective clot formation and TAFI-mediated down-regulation of fibrinolysis induced by
PENTA can be improved by rFVIIa. Panel A shows the effect of PENTA on clotting time in
absence (open symbols) or presence (closed symbols) of rFVIIa (40 nM). Panel B shows the
effect of PENTA on clot lysis time in absence (circles) or presence (squares) of CPI, and in
absence (open symbols) or presence (closed symbols) of rFVIIa (40 nM). The mean of 3
independent experiments is shown. Error bars indicate standard deviation.
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The profibrinolytic potential of PENTAvaries between individuals; effects of rFVIIa
The effect of addition of PENTA (3.5 lg/ml), rFVIIa (40 nM), and a combination of
both on clot formation and fibrinolytic potential was investigated in plasma samples
from 35 healthy volunteers. We observed that addition of a fixed concentration of
PENTA reduced clot lysis time in some, but not all plasma samples. Therefore, we
separately analysed samples that gave more than 5% reduction of clot lysis time on
addition of 3.5 lg/ml PENTA (high responders; figure 2, panels A and C), and samples
Figure 2. Effect of PENTA (3.5 lg/ml), rFVIIa (40 nM), a combination of PENTA and rFVIIa, and
CPI (25 lg/ml) on clot lysis time and clotting time in plasma of 35 healthy volunteers. Panels A and
C show clot lysis times and clotting times, respectively, of plasma samples which gave a more than
5% reduction of clot lysis time on addition of PENTA. Panels B and D show clot lysis times and
clotting times, respectively, of plasma samples which showed a less than 5% reduction of clot lysis
time on addition of PENTA. Panels B and D also show the effect of a high concentration of
PENTA (10.5 lg/ml), and of a combination of a high concentration of PENTA in combination
with rFVIIa (40 nM) on clot lysis time and clotting time.
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that gave less than 5% reduction of clot lysis time on addition of 3.5 lg/ml PENTA (low
responders; figure 2, panels B and D).
Figure 2A shows clot lysis times from the high responders. The decrease in clot lysis time
on addition of PENTAwas statistically significant (Control 80+13 min, PENTA 65+15
min; mean+SD, p<0.001). On addition of rFVIIa to PENTA anticoagulated plasma in
this group, a significant increase in clot lysis time was seen (PENTA 65+15 min, PENTA
+ rFVIIa 72+13 min, p<0.01). Addition of rFVIIa in the absence of PENTA had no
effect on clot lysis time. On addition of CPI, clot lysis times decreased to 38+7 min,
indicating that PENTA only partially decreased TAFI activation.
In plasma samples from the low responders, addition of rFVIIa to plasma containing 3.5
lg/ml PENTA did not change clot lysis time (figure 2B). However, when 10.5 lg/ml
PENTA was added to low responder plasma, a decrease in clot lysis time was seen,
which could be partially corrected by the addition of rFVIIa (figure 2B, right panel;
10.5 lg/ml PENTA 43+7 min, 10.5 lg/ml PENTA + rFVIIa 47+10, p=0.02).
In both groups, addition of rFVIIa significantly decreased clotting time, clotting time
increased significantly on addition of PENTA, and a combination of rFVIIa and
PENTA resulted in clotting times comparable to the control situation.
On evaluation of clotting times of the two groups we found that in the high responder
group, clotting times in the control situation were significantly higher compared to
clotting times in the low responder group (4.07+0.86 min vs. 3.08+0.53 min,
p<0.001). Clotting times were significantly correlated with the percentage of reduction
of clot lysis time on addition of PENTA (r=0.6076, p=0.0001).
Endogenous factor VII levels determine the extent of acceleration of fibrinolysis by
PENTA in individual plasma samples
Plasma levels of factors V, X, II, antithrombin and TAFI were not correlated with the
percentage of reduction of clot lysis time on addition of PENTA. Also, no correlation
was found between plasma levels of factors V, X, II and antithrombin and clotting
time in the control situation.
Only plasma levels of factor VII were significantly correlated with the percentage of
reduction of clot lysis time on addition of PENTA (r= -0.4069, p=0.015). Moreover,
plasma levels of factor VII were significantly correlated with clotting time in the
control situation (r= -0.3680, p=0.03).
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Discussion
Addition of PENTA to plasma from healthy volunteers leads to a delay of tissue factor
induced clot formation, and to acceleration of fibrinolysis due to diminished TAFI
activation.
The observation that inhibition of coagulation factor X results in inhibition of TAFI
activation is in accordance with a previous study by Broze and Higuchi, who showed
premature fibrinolysis in plasma deficient in either one of the intrinsic coagulation
factors200. It was postulated that haemophilia is not only a disorder of coagulation,
but that defective TAFI activation might also cause part of the bleeding tendency
observed in these patients. Likewise, part of the bleeding diathesis of patients
anticoagulated with heparin derivatives, may be due to induction of hyperfibrinolysis
as a consequence of defective activation of TAFI.
In this study, we have shown that addition of rFVIIa to plasma containing PENTA not
only leads to a profound acceleration of clot formation, but also to an improvement of
TAFI-mediated inhibition of fibrinolysis.
Interestingly, the extent of reduction of clot lysis time induced by PENTAvaried strongly
between samples of healthy individuals. On addition of a fixed concentration of PENTA,
accelerated fibrinolysis was seen in some (high responders), but not all (low responders)
plasma samples from healthy volunteers, and an effect of rFVIIa on clot lysis time was
only observed in those plasma samples in which PENTA accelerated clot lysis. This high
responder/lowresponderphenomenonappeared tobecorrelatedwithclotting times in the
absence of PENTA (i.e., basal thrombin generating capacity). A larger basal thrombin
generating capacity indicated less inhibition of TAFI activation by the fixed
concentration of PENTA. The basal clotting time and thus the pro-fibrinolytic capacity
ofPENTAwas correlated toplasma levels of factorVII.Thus, it seems that the capacityof
a plasma sample to generate thrombindetermines the extent of accelerationoffibrinolysis
by PENTA (i.e., higher levels of factor VII increase basal thrombin generating capacity
and consequently decrease inhibition of TAFI activation). Therefore, the bleeding risk
associated with the administration of PENTA might be increased in patients with a low
basal thrombin generating capacity, as this determines the extent of inhibition of TAFI
activation by PENTA. On the other hand, PENTA dosage might have to be increased to
reach an optimal therapeutic effect in patients with a high basal thrombin generating
capacity (for example caused by classical thrombophilic factors such as FVLeiden,
FIIG20210A, and high levels of FVIII).
In conclusion, rFVIIa may be a useful therapeutic option in those instances where
patients treated with PENTA develop bleeding complications as both clot formation
and fibrinolytic resistance of a clot are improved.
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Abstract
A novel approach to treat bleeding episodes in patients with Glanzmann’s
thrombasthenia (GT) and perhaps also in patients receiving aIIbb3-inhibitors, is the
administration of recombinant factor VIIa (rFVIIa). The mechanism of action of
rFVIIa in these patients is, however, still unclear. We studied the effect of rFVIIa-
mediated thrombin formation on adhesion of aIIbb3-deficient platelets under flow
conditions. Adhesion of aIIbb3-deficient platelets to the extracellular matrix (ECM) of
stimulated human umbilical vein endothelial cells or to collagen type III was studied
using a model system with washed platelets and red cells. When aIIbb3-deficient
platelets were perfused over the surface at arterial shear rate for 5 minutes, a low
surface coverage was observed (GT platelets: mean+SEM 37.5+5.0%, normal
platelets preincubated with an RGD-containing peptide: 7.4+2.1%). When rFVIIa,
together with factors X and II was added to the perfusate, platelet deposition
significantly increased (GT platelets: mean+SEM 67.0+4.3%, normal platelets
preincubated with an RGD-containing peptide 48.2+2.9%). The same effect was
observed when normal platelets were pretreated with the commercially available anti-
aIIbb3 drugs abciximab, eptifibatide, or tirofiban. It was shown that tissue factor-
independent thrombin generation (presumably induced by binding of rFVIIa to
adhered platelets) was responsible for the increase in platelet deposition. In conclusion,
defective adhesion of aIIbb3-deficient platelets to ECM can be restored by tissue factor-
independent rFVIIa-mediated thrombin formation. The enhanced generation of platelet
procoagulant surface facilitates fibrin formation, so that lack of platelet aggregate
formation might be compensated for.
Introduction
Platelets play a crucial role in hemostasis and in thrombotic processes. Upon vessel wall
injury, platelets adhere to the subendothelium through the interaction of glycoprotein Ib
with von Willebrand factor (vWF) bound to subendothelial collagen. Stable adhesion is
subsequently accomplished by binding of platelet integrin receptors such as aIIbb3, a2b1,
a5b1, a6b1, and avb3 to their ligands present in the subendothelium. When stable
adhesion is accomplished, secretion and activation of the platelets takes place,
followed by aggregation through bridging of vWF or fibrinogen to aIIbb3 on two
different platelets11.
The importance of aIIbb3 in platelet functioning is demonstrated by the bleeding
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tendency of patients with Glanzmann’s thrombasthenia (GT), who have a congenital
qualitative or quantitative defect in this receptor339. Also, inhibition of aIIbb3 by anti-
platelet drugs such as abciximab, eptifibatide, and tirofiban is of proven benefit to
patients suffering from acute coronary artery disease340. Although these aIIbb3-
antagonists are highly effective in preventing reocclusion after thrombolysis, stenting,
or angioplasty, administration of these compounds also induces bleeding in a
significant number of patients341.
Traditionally, platelet concentrates are administered to patients with GT during
bleeding episodes, or prophylactically during surgery. However, platelet concentrates
carry the risk of alloimmunisation to human leukocyte antigens or to aIIbb3, making
further administration of donor platelets ineffective. Bleeding complications in
patients receiving anti-aIIbb3 drugs may be controlled simply by withdrawing infusion
of the drug. Due to the relatively short half-life of these compounds340, the induced
platelet defect is rapidly reversed. When urgent bleeding problems occur, platelet
transfusion has been shown to reverse abciximab’s inhibitory effect. However, in case
of eptifibatide and tirofiban, which are dosed in a way the peak concentration is very
high relative to the amount of aIIbb3 molecules present in circulation, transfused
platelets are also inhibited rapidly after infusion by free circulating drug340.
A novel approach to treat patients with GT during bleeding episodes or surgery is the
administration of recombinant factor VIIa (rFVIIa, NovoSeven, Bagsværd,
Denmark)
162,342
. rFVIIa was originally developed for the treatment of inhibitor-
complicated haemophilia A and B145,343. Currently, novel indications for rFVIIa,
including its use in patients with liver disease169,293, thrombocytopenia344 and platelet
function defects162,163, and in patients without coagulation disorders who are bleeding
as a result of extensive surgery or major trauma174,180, are explored in clinical trials.
The use of rFVIIa in patients with GT appears to be safe and effective, although
randomised controlled clinical trials have not been performed in this small patient
group. The apparent success of rFVIIa in GT may possibly be translated to patients
who suffer from uncontrollable bleeding as a consequence of administration of anti-
aIIbb3 drugs. A single case in which rFVIIa was used for bleeding management of a
patient treated with tirofiban has recently been reported18.
The mechanism of action of rFVIIa in platelet related bleeding disorders is still a matter
of debate. To explain the efficacy of rFVIIa in haemophilia, both tissue factor-dependent
and independent enhancement of thrombin generation has been suggested to play a
role182,183,189,215. At first sight, the efficacy of rFVIIa in platelet-related bleeding
disorders is curious, because of the presence of a fully competent coagulation system in
125
Chapter 8
these patients. However, it has been suggested that enhancement of thrombin generation
may enhance recruitment of defective platelets to the site of injury as well as enhance
fibrin deposition, thereby compensating for the platelet defect190. Thrombin has
multiple actions on platelets, which are, at present, not fully understood. It has been
proposed that the glycoprotein Ib/V/IX complex is an important thrombin receptor on
platelets345,346. Thrombin binding to this complex initiates signalling events by
enhancing activation of the classical thrombin receptor (PAR-1)17, and it has been
proposed to facilitate the cleavage of glycoprotein V from the complex, resulting in a
hyperresponsive platelet347,348. Also, thrombin binding to GPIb appears essential for
thrombin-mediated induction of platelet procoagulant activity346. Furthermore,
thrombin is able to activate the low affinity thrombin receptor (PAR-4)349, but
whether binding to the glycoprotein Ib/V/IX complex also enhances PAR-4 cleavage is
not known.
In this study we have generated a model to study the effect of rFVIIa-mediated thrombin
generation on platelet adhesion under flow conditions in a model system using aIIbb3-
inhibited platelets. Using a model system of isolated platelets and red cells, and
purified clotting factors, we show an enhancement of platelet adhesion to
subendothelial material. Important denominators in thrombin-mediated enhancement
of platelet deposition in our system were subsequently investigated.
Materials and methods
Proteins, antibodies, and anti-aIIbb3 drugs
rFVIIa (NovoSeven), a goat polyclonal inhibitory antibody against tissue factor, and a
monoclonal antibody against factor VIIa were generous gifts from Dr. U. Hedner (Novo
Nordisk, Ma˚løv, Denmark). Factor X was purified from fresh frozen plasma by
immunoaffinity chromatography followed by Q-sepharose chromatography as
previously described
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or purchased from Kordia B.V. (Leiden, The Netherlands).
Prothrombin was purified from fresh frozen plasma according to Koedam et al.351.
Collagen type III was from Sigma (St. Louis, Mo). Recombinant hirudin was a
generous gift from R. Wallis (Ciba Geigy, Horsham, UK). Recombinant annexin V
was a generous gift from Dr. W.L. van Heerde (University Medical Centre St.
Radboud, Nijmegen, the Netherlands).
Inhibitory antibodies against glycoprotein Ib (AK-2, ascites fluid) and von Willebrand
factor (RAG-35, ascites fluid) were generous gifts from Dr. M. Berndt (Baker Institute,
Melbourne, Australia) and Dr. J.A. van Mourik (CLB, Amsterdam, The Netherlands),
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respectively. Fab fragments of a monoclonal antibody, which specifically inhibits
thrombin binding to glycoprotein Ib (LJIb-10) were a generous gift from Dr. Z.M.
Ruggeri (The Scripps Research Institute, La Jolla, CA). Fluorescein isothiocyanate
(FITC) labeled goat anti mouse IgG was purchased from Calbiochem (La Jolla, CA).
The RGD containing peptide D-arginyl-glycyl-L-aspartyl-L-tryptophane (dRGDW)
was generously provided by Dr. J. Bouchaudon (Rhoˆne Poulenc Rorer, Chemistry
Department, Centre de Recherche de Vitry, Vitry sur Seine, France).
Abciximab (ReoPro) was from Centocor (Malvern, PA). Eptifibatide (Integrilin) was
purchased from COR Therapeutics (South San Francisco, CA). Tirofiban (Aggrastat)
was from Merck (White House Station, NJ).
Cell culture
Human umbilical vein endothelial cells were isolated and grown to confluence as
described352. Cells of the second passage were seeded on gelatin coated thermanox
coverslips. The cells were stimulated overnight with phorbol myristate acetate (PMA,
Sigma, St. Louis, MO; 20 ng/ml final concentration) for 16 hours. After stimulation,
the endothelial cell matrix was isolated by removing the cells with 0.1 mol/L NH4OH
for 15 minutes at room temperature, and subsequently the matrices were washed 3
times with phosphate buffered saline (PBS, 10 mmol/L phosphate buffer, 150 mmol/L
NaCl, pH=7.4).
Collagen coated surfaces
Collagen type III was solubilized in 50 mM acetic acid and sprayed on thermanox or
glass coverslips (the latter were used for immunofluorescence studies) using a
retouching airbrush (Badger model 100, Badger Brush Co, Franklin Park, Il.) at a
density of 30 lg/cm2. After the spraying procedure, coverslips were blocked for 1 hour
at room temperature with 4% human albumin in PBS.
Blood collection
Blood was drawn from healthy volunteers who denied ingestion of aspirin or other
NSAID’s for the preceding 10 days into 1/10 volume 3.4% sodium citrate. For selected
experiments, blood from six unrelated patients with type 1 GT was used.
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Perfusion studies
Perfusions were carried out in a single pass perfusion chamber as described previously353.
Perfusions were carried out with reconstituted blood, which was prepared as follows.
Platelet rich plasma (PRP) was prepared from whole blood by centrifugation (10
minutes at 200g at room temperature). The PRP was acidified by addition of 1/10
volume of ACD (2.5% trisodiumcitrate, 1.5% citric acid, and 2% D-glucose), and the
platelets were spun down (500g, 15 min). The platelet pellet was resuspended in
HEPES-Tyrode buffer (137 mM NaCl, 2.68 mM KCl, 0.42 mM NaH2PO4, 1.7 mM
MgCl2, 5 mM d-glucose, pH= 7.35). Prostacyclin (PGI2, 10 ng/ml) was added to
prevent platelet activation during the subsequent washing step. Platelets were spun
down and resuspended in a small volume of HEPES-Tyrode buffer. The platelets were
diluted in human albumin solution (HAS; 4% human albumin, 4 mM KCl, 124 mM
NaCl, 20 mM NaHCO3, 2 mM Na2SO4, 1.5 mM MgCl2, 5 mM d-glucose, pH 7.35).
Red cells were washed twice with 0.9% NaCl containing 5 mM d-glucose (2000g, 5
min), and finally cells were packed (2000g, 15 min).
Platelets were mixed with red cells to obtain reconstituted blood containing 200.000
platelets/ll and a haematocrit of 40%. The reconstituted blood was preincubated with
buffer or clotting factors for 5 minutes at 378C and perfused for 5 minutes at a shear
rate of 1600 s-1. After perfusion, slides were washed with HEPES buffer (10 mM
Hepes, 150 mM NaCl, pH=7.35) and fixed in 0.5% glutaraldehyde in PBS.
Subsequently, slides were dehydrated in methanol and stained with May-Gru¨nwald
and Giemsa as described previously354. Platelet adhesion was evaluated using
computer-assisted analysis with OPTIMAS 6.0 software (DVS, Breda, The
Netherlands), and was expressed as the percentage of the surface covered with platelets.
Immunofluorescence microscopy
To investigatedirect bindingof rFVIIa toplatelets adheredunderflowconditions,washed
platelets and red cellswereperfusedover a collagen-coated surface (5minat a shear rate of
1600 s-1) inpresence andabsenceof rFVIIa (1.2lg/ml) andcalciumchloride (5mM).After
perfusion, the coverslips were washed with HEPES buffer containing 5 mM calcium
chloride and fixed with 3% paraformaldehyde and 0.002% glutardialdehyde in PBS.
Subsequently, coverslips were washed with PBS, and blocked with 1% BSA, 0.1%
glycine in PBS for 10 minutes at room temperature. Coverslips were incubated with a
monoclonal anti FVII antibody (10 lg/ml in PBS) for 45 minutes at 378C. After washing
and subsequent blocking, coverslips were incubated with FITC-labeled goat anti mouse
IgG (1:20 diluted in PBS) for 45 minutes at 378C. After washing, coverslips were mounted
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in Mowiol 40-80 containing 0.1% paraphenylenediamine. Bound rFVIIa was visualized
using confocal laser scanning microscopy using Leica TCS 4D (Heidelberg, Germany)
equipment.
Statistical analysis
Statistical analysis was performed using the GraphPad InStat (San Diego, USA)
software package. Comparison of mean surface coverage values were undertaken by
standard Student’s t-test. P<0.05 was considered statistically significant.
Results
Enhancement of deposition of aIIbb3-deficient platelets to PMA-stimulated endothelial cell
matrix (PMA-ECM) upon addition of coagulation factors VIIa, X, and II
Washed platelets and red cells obtained from 6 unrelated patients with type I GT were
perfused over PMA-ECM at 1600 s-1 for 5 minutes. In figure 1A, the morphological
appearance of a typical experiment performed with GT platelets to PMA-ECM is
presented. The surface coverage was 37.5+5.0%. (mean+SEM of 16 coverslips; with 4
patients experiments were performed in triplicate, with the other 2 patients, experiments
were performed in duplicate). No platelet aggregates were observed. Upon addition of a
thrombin-generating system, consisting of rFVIIa (1.2 lg/ml), factor X (10 lg/ml), and
Figure 1. The effect of coagulation factors VIIa, X, and II on adhesion of platelets from patients
with type I GT to the subendothelial matrix of PMA-stimulated endothelial cells under flow
conditions. Washed platelets and red cells (200.000 platelets/ll; haematocrit 40%) were perfused
over PMA-ECM for 5 minutes at 1600 s-1 in absence (panel A) or presence (panel B) of a
thrombin-generating system (1.2 lg/ml rFVIIa, 10 lg factor X, 20 ng/ml prothrombin, 3 mM
CaCl2). Shown is a typical example from one GT patient.
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prothrombin (20 ng/ml), a significant increase in platelet adhesion was observed
(67.0+4.3%; mean+SEM of 16 coverslips, p<0.0001, figure 1B shows a typical
example of the morphology). Platelet aggregates were still not formed.
Enhancement of platelet deposition to PMA-ECM in a model for GT upon addition of
coagulation factors VIIa, X and II.
In order to study the mechanism by which addition of coagulation factors VIIa, X, and II
lead to a significant increase in adhesion of aIIbb3 deficient platelets to PMA-ECM, a
model system for GT was created. Perfusion experiments were performed with
platelets from healthy volunteers pretreated with a peptide containing the RGD
sequence in order to block ligand binding to aIIbb3. In absence of the RGD-containing
peptide, perfusion of washed platelets and red cells over PMA-ECM at 1600 s-1 resulted
in a high surface coverage (69.2+3.0%, mean+SEM of 6 coverslips), and extensive
aggregate formation was observed (figure 2A). Addition of the dRGDW peptide (200
lM, final concentration in platelet suspension) resulted in an extensive reduction in
platelet adhesion (7.4+2.1%; mean+SEM of 18 coverslips), whereas aggregate
formation was completely absent (figure 2B). Upon addition of purified coagulation
factors VIIa, X, and II to aIIbb3-inhibited platelets, a significant enhancement of
platelet adhesion was observed (48.2+2.9%; mean+SEM of 18 coverslips, p<0.0001,
figure 2C). When only rFVIIa was added to the perfusate, no increase in platelet
adhesion was observed (data not shown). The morphologic appearance of GT platelets
adhered to PMA-ECM was similar to that observed in the dRGDW-model, although the
Figure 2. Development of a model system for adhesion of thrombasthenic platelets to
subendothelial structures under flow conditions and the effect of the thrombin generating
system. Washed normal platelets and red cells (200.000 platelets/ll; haematocrit 40%) were
perfused over PMA-ECM for 5 minutes at 1600 s-1 in absence (panel A) or presence (panels B
and C) of an RGD-containing peptide (rRGDW; 200 lM). Panel C shows the effect of the
thrombin-generating system (1.2 lg/ml rFVIIa, 10 lg factor X, 20 ng/ml prothrombin, 3 mM
CaCl2) on adhesion of RGD-inhibited platelets.
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surface coverage observed with GT platelets was slightly higher than that of dRGDW-
inhibited normal platelets.
Enhancement of deposition of platelets treated with aIIbb3 -blocking drugs to PMA-ECM
upon addition of coagulation factors VIIa, X, and II.
When normal platelets were pretreated with the registered anti-aIIbb3 drugs abciximab
(10 lg/ml), eptifibatide (10 lg/ml), and tirofiban (1 lg/ml), a similar morphological
pattern of adhesion was seen compared to the studies using dRGDW to block aIIbb3.
As shown in table 1, a low adhesion was observed when platelets treated with an anti-
aIIbb3 drug were perfused over PMA-ECM. Upon addition of the thrombin-generating
system, platelet deposition was significantly enhanced.
Additions Surface coverage (%+SEM)
Abciximab
Abciximab + VIIa/X/II
Eptifibatide
Eptifibatide + VIIa/X/II
Tirofiban
Tirofiban + VIIa/X/II
5.6+1.2 (n=6)
46.8+1.9* (n=6)
13.0+3.0 (n=6)
46.3+1.0* (n=6)
7.9+1.8 (n=6)
57.9+1.4* (n=6)
Table 1. Effects of VIIa-mediated thrombin generation on platelet adhesion to PMA-ECM in the
presence of aIIbb3-blocking drugs. Washed platelets were preincubated with abciximab, eptifibatide
or tirofiban for 30 minutes at room temperature. After addition of washed red cells, platelets were
perfused over PMA-ECM for 5 minutes at a shear rate of 1600 s-1. * p<0.001 vs drug in the absence
of VIIa/X/II. n indicates the number of evaluated coverslips.
The generation of thrombin independently of tissue factor results in enhancement of platelet
deposition in the GT model
When hirudin (5 U/ml) was added to a dRGWD-inhibited platelet suspension together
with the thrombin generating system, the increase in platelet deposition to PMA-ECM
induced by the thrombin generating system was completely abolished (table 2).
Similarly, addition of annexin V (50 lg/ml) to dRGDW-inhibited platelets completely
abrogated the enhancement in adhesion induced by the thrombin generating system.
However, when all tissue factor activity in the system was neutralized by an inhibitory
polyclonal antibody (500 lg/ml in PBS, both the PMA-ECM as well as the platelet
suspension were treated for 45 minutes at room temperature), addition of the
thrombin generating system still enhanced platelet deposition to the same extent as in
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the absence of tissue factor blockade (table 2). The inhibitory capacity of the antibody
was demonstrated using a standard prothrombin time assay and by a factor Xa
generation assay on PMA-ECM. Preincubation of the tissue factor source with the
antibody prolonged the prothrombin time from 12 to over 200 seconds, and
preincubation of PMA-ECM with the antibody completely abolished rFVIIa-induced
Xa generation in a static assay.
Additions Surface coverage (%+SEM)
None
+ VIIa/X/II
+ VIIa/X/II + Hirudin
+ VIIa/X/II + Annexin V
+ VIIa/X/II + anti-TF
7.4+2.1* (n=18)
48.2+2.9 (n=18)
6.7+0.9* (n=7)
10.1+2.0* (n=6)
58.8+4.1 (n=8)
Table 2. Tissue factor-independent thrombin generation on procoagulant surface enhances
deposition of aIIbb3-inhibited platelets to PMA-ECM under flow conditions. Washed platelets
and red cells were preincubated with the RGD containing peptide dRGDW and perfused over
PMA-ECM at a shear rate of 1600 s-1 for 5 minutes. Hirudin or annexin V was added to the
perfusate right before perfusion. Both the platelet suspension and the surface were preincubated
with the anti-TF antibody for 45 minutes at room temperature. * p<0.001 vs addition of VIIa/X/II.
n indicates the number of evaluated coverslips.
Thrombin-mediated enhancement of platelet deposition in the GT model is dependent on the
GPIb-vWF interaction and on thrombin binding to GPIb
When the platelets were pretreated with an inhibitory antibody against either GPIb or
vWF (45 min at room temperature, both antibodies were used in a dilution of 1:250),
the enhancement in adhesion induced by the thrombin generating system was
completely inhibited (table 3).
If platelets were pretreated with Fab fragments of an antibody which specifically blocks
the binding of thrombin to GPIb (LJIb-10; 50 lg/ml), the enhancement of platelet
adhesion induced by the thrombin generating system was completely abolished (table
3). The antibody did not affect platelet adhesion to purified vWF (not shown).
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Additions Surface coverage (%+SEM)
None
+ VIIa/X/II
+ VIIa/X/II + anti GPIb
+ VIIa/X/II + anti vWF
+ VIIa/X/II + LJIb-10
7.4+2.1* (n=18)
48.2+2.9 (n=18)
6.7+1.5* (n=8)
2.5+1.3* (n=4)
8.3+1.1* (n=7)
Table 3. Increased adhesion of aIIbb3-inhibited platelets to PMA-ECM by VIIa mediated thrombin
generation is dependent on the GPIb-vWF interaction and on thrombin binding to GPIb. Washed
platelets and red cells were preincubated with the RGD containing peptide dRGDWand perfused
overPMA-ECMata shear rateof 1600 s-1 for 5minutes. Plateletswerepreincubatedwithantibodies
against GPIb, vWF, or the thrombin binding site on GPIb (LJIb-10) for 45 minutes at room
temperature. * p<0.001 vs addition of VIIa/X/II. n indicates the number of evaluated coverslips.
Tissue factor-independent thrombin generation enhances platelet deposition to collagen
type III upon aIIbb3 blockade
To confirm that rFVIIa is able to generate thrombin independently of tissue factor in our
model, experiments were performed using a tissue factor-poor adhesive surface. Platelet
adhesion to collagen (type III) in presence of dRGDW was low (6.4+2.0%, mean+SEM
of 12 coverslips), presumably due to the absence of vWF in the perfusate, which is
necessary for reduction of the velocity of the platelets. Aggregate formation was
completely absent (figure 3A). Upon addition of the thrombin-generating system to
Figure 3. Adhesion of aIIbb3-inhibited platelets to collagen type III under flow conditions; increased
adhesion by the thrombin generating system is independent of tissue factor. Washed normal
platelets and red cells (200.000 platelets/ll; haematocrit 40%) were perfused over collagen type
III for 5 minutes at 1600 s-1 in presence of an RGD-containing peptide (rRGDW; 200 lM) in the
absence (panel A) or presence (panels B and C) of the thrombin-generating system (1.2 lg/ml
rFVIIa, 10 lg factor X, 20 ng/ml prothrombin, 3 mM CaCl2). In panel C both the surface and
the platelet suspension was preincubated with inhibitory tissue factor IgG.
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aIIbb3-inhibited platelets, the adhesion to collagen was significantly increased
(57.0+1.4%, mean+SEM of 12 coverslips, p<0.001, figure 3B). Pretreatment of both
the surface and the platelet suspension with anti-tissue factor IgG (500 lg/ml) did not
abolish the enhanced platelet deposition induced by the thrombin-generating system
(54.7+1.3, mean+SEM of 12 coverslips, figure 3C), confirming that the thrombin
generation also occurred independently of tissue factor.
rFVIIa binds to collagen-adhered platelets under flow conditions
To investigate direct binding of rFVIIa to platelets adhered and activated under flow
conditions, perfusion experiments were performed in which washed platelets and red
cells were perfused over a collagen-coated surface in presence and absence of rFVIIa
and calcium chloride. After perfusion, platelets were fixed and bound rFVIIa was
visualized using immunofluorescence. As shown in figure 4, intense staining for rFVIIa
was observed. No staining was observed when rFVIIa or the primary antibody (not
shown) was omitted. Also, no fluorescence was observed when annexin V or EDTA
was added to the perfusate (data not shown). Addition of an inhibitory antibody
against tissue factor did not affect the signal (not shown).
Tissue factor-independent thrombin generation is associated with the release of
glycoprotein V from the platelet surface
Thrombin binding to GPIb has been proposed to facilitate the release of a soluble
fragment of GPV from the platelet surface. To investigate whether thrombin
Figure 4. Binding of rFVIIa to collagen-adhered platelets under flow conditions. Washed platelets
and red cells were perfused over a collagen coated glass coverslip in absence (panel A) or presence
(panel B) of rFVIIa (1.2 lg/ml). After perfusion, coverslips were fixed, and bound rFVIIa was
visualized by confocal laser scanning fluorescence microscopy using a monoclonal antibody
against factor VII followed by a FITC-labelled secondary antibody.
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generation in our system also results in the release of GPV, we performed perfusion
experiments with washed platelets and red cells over a collagen-coated surface in the
presence of RGD, and in the presence or absence of purified factors VIIa, X, and II.
The perfusate was collected in 50 mM EDTA (1/10, v/v), cells were removed by
centrifugation, and soluble GPV was measured in the supernatant by ELISA
(asserachrom soluble GPV, Diagnostica Stago, Asnieres, France). Upon addition of
the thrombin-generating system, a significant increase in soluble GPV was found in the
supernatant as shown in figure 5 (control: 56+7 ng/ml, mean+SEM of four
independent experiments in duplicate, in presence of rFVIIa/X/II 116+14 ng/ml,
p=0.002).
Figure 5. Tissue factor-independent thrombin generation is associated with release of a soluble
fragment of GPV from the platelet surface. Washed normal platelets and red cells (200.000
platelets/ll; haematocrit 40%) were perfused over collagen type III for 5 minutes at 1600 s-1 in
presence of an RGD-containing peptide (rRGDW; 200 lM) in the absence or presence of the
thrombin-generating system (1.2 lg/ml rFVIIa, 10 lg factor X, 20 ng/ml prothrombin, 3 mM
CaCl2). The perfusate was collected in EDTA (1/10, v/v), cells were removed by centrifugation,
and soluble glycoprotein V was measured in the supernatant. Shown is the mean of 4
independent experiments performed in duplicate. Error bars indicate SEM.
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Discussion
This study shows that rFVIIa-mediated thrombin generation profoundly enhances
deposition of platelets with a congenital or drug-induced defect in the integrin aIIbb3 to
the extracellular matrix of cultured human umbilical vein endothelial cells and to purified
collagen type III. As the enhancement in platelet deposition by the thrombin generating
system (coagulation factors VIIa, X and II) seems independent of tissue factor, but
dependent on the presence of procoagulant surface, we propose a model in which
thrombin is generated via activation of factor X by rFVIIa bound to adhered platelets.
The generated factor Xa subsequently assembles into a prothrombinase complex, of
which the factor Va in our assay set-up is presumably secreted by already adhered
platelets. Finally, the in situ generated thrombin binds to GPIb on platelets, which are
either in suspension or rolling on the surface, resulting in platelet activation. This
thrombin-mediated activation of platelets somehow results in enhanced platelet
deposition. The exact mechanism, which is responsible for the thrombin induced
enhancement of platelet deposition is at present not clear, but might involve PAR-1
mediated activation, and/or cleavage of glycoprotein V from the GPIb/V/IX complex347.
A tissue factor-independent enhancement of thrombin generation by rFVIIa involving
binding to activated platelets or monocytes has been proposed to explain efficacy of
rFVIIa in haemophilia as well as other haemostatic disorders in which rFVIIa has
been shown beneficial188-190. Previously, it was generally accepted that rFVIIa exerts
its haemostatic effect in a tissue factor-dependent manner182,183. In this study we now
show that rFVIIa is able to generate thrombin on platelets adhered to a collagen
surface under flow conditions without requirement for tissue factor, by binding
directly to the platelet surface, supporting the TF independent mechanism of rFVIIa as
suggested by Monroe et al189. A mechanistic explanation for the efficacy of rFVIIa in
patients with GT is still lacking. Our study suggests that a local enhancement of
thrombin generation, either in a tissue factor dependent or independent manner, may
be able to increase adhesion of aIIbb3-deficient platelets. Although enhancement of
adhesion still does not result in a stable platelet plug, due to the absence of aIIbb3-
mediated platelet-platelet interaction, it does provide an increase of procoagulant
surface at the site of injury. The increased procoagulant surface facilitates a further
enhancement of thrombin generation and subsequent fibrin formation. This
enhancement in fibrin deposition might compensate for the lack of aggregate formation.
The assay set-up employed in this study features some simplifications that require
explanation. Firstly, in this study we compare adhesion of aIIbb3-deficient platelets in
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absence or presence of rFVIIa-mediated thrombin generation. In order to translate this
experiment into the in vivo situation, one must realise that if a patient with aIIbb3
deficiency receives rFVIIa, an increase in thrombin generation at the site of injury will
take place (in contrast to the on/off situation in our experimental set-up), and that the
increase in adhesion is probably more subtle compared to the herein shown in vitro
experiment. Secondly, our thrombin generating system is simplified, as it does not
contain inhibitors of thrombin generation (TFPI, antithrombin and the protein C
system), and factors VIII, IX, and XI are lacking. Due to this simplification, dose-
response experiments with rFVIIa will not provide physiologically relevant
information. Finally, as no fibrinogen was added to the reconstituted blood, the
interplay between platelet deposition and fibrin formation was not studied. Studying
fibrin formation to a tissue factor-rich surface is accompanied by a number of
technical difficulties. In case of perfusion of recalcified blood, thrombin generation is
already initiated before perfusion by activation of the contact activation system.
Moreover, fibrin deposition does not halt when the blood has left the tissue factor-rich
surface, resulting in obstruction of the perfusion chamber with macroscopic clots. Using
low molecular weight heparin anticoagulated blood, which is commonly used to study
fibrin deposition under flow conditions355, endogenous factor VII is partially activated
by factor XIIa generated by the contact system, which is not blocked by LMWH (T.
Lisman, unpublished observations), resulting in an underestimation of the effect of
exogenous added rFVIIa. However, Galan et al. recently reported improvement of
both platelet deposition and fibrin formation under flow conditions using low
molecular weight heparin-anticoagulated blood from patients with GT, which
corresponds to the hypothesized mechanism of action put forward in our current
study356.
In conclusion, in this study we show that a tissue factor-independent generation of
thrombin via rFVIIa profoundly increases adhesion of aIIbb3-deficient platelets under
flow conditions in vitro. We hypothesize that administration of rFVIIa to patients with
GT results in an increased platelet adhesion at the site of injury, followed by an enhanced
deposition of fibrin. The increased fibrin formation might compensate for the lack of
aggregation and therefore explain the therapeutic efficacy of rFVIIa in GT. We
speculate that rFVIIa may also be an effective therapeutic agent for patients who are
bleeding as a consequence of treatment with anti-aIIbb3 drugs, with a mechanism of
action comparable to that proposed here for GT patients.
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Chapter 9
General discussion
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The development of rFVIIa for treatment of patients with inhibitor-complicated
haemophilia has been a major step forward in controlling bleeding episodes or
providing haemostasis during interventional procedures195. Traditional haemostatic
agents used in these patients, i.e., (activated) prothrombin complex concentrates
(aPCC’s and PCC’s) and porcine FVIII, have disadvantages, which are not encountered
with the use of rFVIIa. rFVIIa showed significantly higher efficacy rates compared to
PCC’s137,146-148,150,357,358, and undesirable side effects, in particular thromboembolic
complications133, are much lower. In fact, thromboembolic complications associated
with rFVIIa use are extremely rare. A major complication of the use of porcine FVIII is
the development of inhibitory antibodies96. Antibody formation in haemophilia patients
treated with rFVIIa has not yet been reported. Finally, as rFVIIa is a recombinant
product, which does not contain albumin or other stabilizing proteins, the risk of viral
transmission (e.g., HIVor hepatites) is extremely low143.
The high efficacy rate and virtual absence of serious side effects of rFVIIa in patients with
haemophilia in combination with concepts on the general mechanism of action of the
drug, supported subsequent use of rFVIIa in patients with other haemostatic disorders,
including patients with liver cirrhosis168,169,295, patients with platelet-related bleeding
disorders162,163,344, patients with bleedings induced by anticoagulant drugs18,172, and
patients with uncontrollable hemorrhage in absence of preexisting coagulopathy176,179.
Although the efficacy of rFVIIa in these novel indications has not yet been thoroughly
established, the clinical data available so far, are encouraging. rFVIIa has been
proposed to be a universal haemostatic drug, although efficacy, safety, and cost-
effectiveness remains to be proven for indications outside haemophilia. The major
safety concern remains the risk of thrombotic complications, especially in older patients
with established risk factors for arteriothrombotic disease, and in patients with (non-
overt) DIC.
The precise molecular mechanisms, by which rFVIIa provides haemostasis in
haemophilia or in the novel indications, are at present unknown. Unravelling these
mechanisms might provide a rationale for dosing schedules for the different indications.
Moreover, a better understanding could rationalize a selection of patients thatwill benefit
from treatment.Next to evaluationof apossible procoagulant effect, a risk assessment for
a specific typeofbleeding inpatientswitha specific typeof coagulopathymightbepossible
if more information on the mechanism of action would be available. In this chapter, the
contribution of this thesis to knowledge on mechanism of action of rFVIIa in its different
applications will be discussed. The information obtained in this thesis will be combined
with existing literature to formulate a general hypothesis on the action of rFVIIa in vivo.
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Antifibrinolytic properties of rFVIIa in haemophilia
Previous studies on the mechanism of action of rFVIIa in haemophilia focussed on the
effect on thrombin generation or clot formation183,184,189. As it was previously
hypothesized that the bleeding diathesis in haemophilia not only is a consequence of
defective clot formation, but also of premature breakdown of the clot due to defective
TAFI activation (figure 1)200,201, experiments to investigate a possible antifibrinolytic
effect of rFVIIa were initiated. In chapter 2 of this thesis we showed that rFVIIa is
able to protect plasma clots from patients with haemophilia from premature
fibrinolysis, specifically by inducing activation of TAFI (figure 2). In our assay set-up,
Figure 1. Coagulation in severe haemophilia A. In factor VIII or IX deficiency, clot formation is
delayed due to a lack of tenase activity. Moreover, as factor XI-mediated secondary thrombin
generation does not take place as a result of absence of tenase activity, TAFI activation does not
occur (see figure 5 in chapter 1 for comparison).
Figure 2. High dose rFVIIa restores TAFI activation in plasma from patients with severe
haemophilia A by enhancing thrombin generation required for TAFI activation.
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approximately 10 times more rFVIIa was required for inhibition of fibrinolysis
compared to the amount of rFVIIa required for acceleration of clot formation. This
relatively weak antifibrinolytic potential of rFVIIa in haemophilia might explain the
high plasma levels of rFVIIa required for effective haemostasis.
However, whether defective TAFI activation actually contributes to the bleeding
diathesis of haemophiliacs is still unclear. Even more, the relevance of TAFI for normal
or pathological haemostasis is not yet known. Animal models suggest a role for TAFI
activation in thrombosis; inhibition of TAFI significantly accelerated thrombolysis in
different models311,312,326. These experiments, however, were all performed using a
non-specific carboxypeptidase inhibitor, so effects ascribed to TAFI inhibition could
also be caused by inhibition of other (perhaps unknown) carboxypeptidases.
Furthermore, a lack of phenotype of the TAFI knockout mouse105, and the absence of
identified patients with an isolated TAFI deficiency hamper elucidation of a role for
TAFI in vivo.
Suitable animal models to test the hypothesis on haemophilia being a defect in the
fibrinolytic system rather than a defect in clot formation are, to our knowledge, still
lacking. Moreover, it is clear that differences between murine knockout models and
human disorders exist, both for coagulation defects and for defects in the fibrinolytic
system. It would, however, be interesting to see whether cross-breeding mice with a
defects in one of the intrinsic coagulation factors with the TAFI knockout would lead
to an aggravation of the bleeding diathesis of the single knockout.
If the antifibrinolytic effect of rFVIIa has any relevance in vivo, important consequences
for dosing may arise. Firstly, the dosage of rFVIIa required for effective (long-term)
haemostasis may be dependent on where the injury is localized. The amounts of tissue
factor and thrombomodulin expressed at the site of injury, as well as the local
fibrinolytic activity of the tissue may be important in the amount of rFVIIa required
for cessation or prevention of bleedings. The presence of relatively high amounts of TF
might reduce plasma levels of rFVIIa required for effective haemostasis, as the
antifibrinolytic potential of rFVIIa has been shown to increase with increasing TF.
The role of thrombomodulin expression on the antifibrinolytic potential of rFVIIa is
more complicated. The presence of thrombomodulin may either enhance or inhibit
TAFI activation, presumably depending on its density on the endothelial cell surface67.
It has been demonstrated in vitro that the thrombin-thrombomodulin complex has
antifibrinolytic properties at low concentrations by enhancing TAFI activation. At
higher concentrations, however, thrombin-thrombomodulin preferably activates
protein C, which results in acceleration of fibrinolysis by decreasing thrombin
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generation required for TAFI activation67. Thus, the amount of rFVIIa required for
downregulation of fibrinolysis in a specific area of the vasculature may also depend on
the pro- or antifibrinolytic state of thrombomodulin near the site of injury. Finally, the
fibrinolytic potential of the tissue is probably important with respect to the dose of
rFVIIa required to induce haemostasis. Indeed, preliminary clinical data suggested
that higher plasma levels of rFVIIa are required to treat patients with bleedings in the
oral cavity (in which a high fibrinolytic activity is present). It was shown that treatment
of oral cavity bleeding by continuous infusion had a very low efficacy rate compared to
treatment by repeated bolus injections359. As lower peak levels are reached using
continuous infusion, enhancement of TAFI activation might be insufficient, with
rebleeding as a consequence.
Lack of antifibrinolytic effect of rFVIIa in patients with cirrhosis or during liver
transplantation
After demonstrating an antifibrinolytic effect of rFVIIa in plasma from patients with
haemophilia, we hypothesized that a similar mechanism could also apply in plasma
from patients with liver failure. As patients with liver failure have decreased levels of
all procoagulant proteins (except for factor VIII), we hypothesized both primary (i.e.,
the thrombin required for clot formation) and secondary thrombin generation (i.e., the
thrombin generated after formation of the fibrin clot, which is required for TAFI
activation) to be impaired, similarly to that observed in plasma completely deficient in
either one of the intrinsic coagulation factors. Moreover, a hyperfibrinolytic state is
said to be present in at least part of the patients with stable cirrhosis268, and
development of hyperfibrinolysis is observed during liver transplantation285.
However, using the clot lysis assay described in this thesis, we could not observe
accelerated fibrinolysis in plasma samples from patients with stable cirrhosis (chapter
4). Even though the levels of both the thrombin generating proteins as well as TAFI
were significantly decreased, TAFI activation appeared normal as both clot lysis time
and clot lysis ratio (i.e., ratio of clot lysis time in absence and presence of a specific
inhibitor of activated TAFI) were not significantly different from those found in
healthy volunteers. The deficiencies in antifibrinolytic proteins induced by cirrhosis are
probably compensated for by deficiencies in profibrinolytic proteins. TAFI activation
can proceed relatively normal in plasma from patients with cirrhosis because the defect
in thrombin generating capacity is compensated for by a reduced thrombin inhibition
(e.g., by antithrombin).
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Development of hyperfibrinolysis was seen in samples taken during orthotopic liver
transplantation. However, this hyperfibrinolytic state was not caused by defective
TAFI activation. At the end of surgery, a transient hypofibrinolytic state was detected,
presumably a consequence of massive PAI-1 release. If this temporary hypofibrinolytic
state contributes to post-operative thrombotic complications (e.g., portal vein
thrombosis) is not known.
TAFI activation thus appeared already optimal in plasma from patients with stable
cirrhosis and in samples taken during OLT, implicating that sufficient ‘free’ or ‘active’
thrombin is generated. Consequently, addition of rFVIIa to cirrhotic plasma did not
have an effect on clot lysis time (chapter 5). Measurements of thrombin conversion in
time showed that rFVIIa only accelerated primary thrombin generation (i.e., the small
amount of thrombin required for clot formation), but that the total amount of thrombin
converted during the assay is already maximal in the absence of rFVIIa. In contrast, in
haemophilic plasma both primary and secondary thrombin generation are enhanced by
rFVIIa (unpublished results).
According to the in vitro data obtained in this thesis, the prohaemostatic properties of
rFVIIa in patients with liver disease can not be explained by an effect on the fibrinolytic
system. Rather, enhancement of clot formation and platelet adhesion by rFVIIa could
lead to a more stable haemostatic plug in these patients. As patients with liver failure
have both a qualitative and quantitative defect in platelet function (see chapter 3), it is
conceivable that enhancement of thrombin generation would lead to enhancement of
platelet adhesion, similar to the mechanisms described in chapter 8 (see also below).
The increased procoagulant surface would subsequently result in enhancement of
fibrin deposition.
Enhancement of platelet deposition and activation by rFVIIa, however, could lead to
enhanced secretion of PAI-1 and a2-antiplasmin from platelet a-granules
68,69, thereby
downregulating the fibrinolytic system. This possible antifibrinolytic effect of rFVIIa is
obviously not picked up in our plasma-based assay. Also, a lack of effect of rFVIIa on
TAFI activation in our assay does not necessarily mean that rFVIIa does not enhance
TAFI activation in vivo. The presence of thrombomodulin, flow, (activated) platelets,
etc, could very well influence the effect of rFVIIa on TAFI activation in vivo. Very
little is known about TAFI activation in vivo, and more sophisticated assays (e.g., an
assay to measure plasma levels of the TAFI activation peptide, which could be a
measure for TAFI activation) will be required to get more insight into this phenomenon.
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rFVIIa as a potential haemostatic drug in treatment of bleedings induced by
anticoagulant drugs
One of the most important complications of antithrombotic drugs designed to inhibit the
coagulation system, is the development of bleeding complications322. It is traditionally
believed that the bleeding diathesis induced by anticoagulant drugs is a consequence of
inhibition of clot formation. In chapter 6 we have shown that anticoagulant drugs
completely or partially directed against factor Xa, not only inhibit clot formation, but
also accelerate clot breakdown by inhibition of TAFI activation in vitro. Whether this
phenomenon has any in vivo relevance is still unknown, but would it indeed have
physiological relevance, important consequences arise.
On one hand, anticoagulant drugs targeting factor Xa might be more potent in
prevention or treatment of thrombosis in comparison with thrombin inhibitors or TF
antagonists, as Xa inhibitors induce both an anticoagulant and a profibrinolytic effect.
On the other hand, anticoagulant drugs, which inhibit Xa, might induce a more severe
bleeding tendency for the same reason. The selective Xa inhibitor PENTA, has been
shown to be more effective in preventing venous thromboembolism following knee334,
hip replacement332,333, or hip fracture325 surgery compared to enoxaparin (a low
molecular weight heparin, which inhibits both factor Xa and thrombin). One study
reported an increased number of major bleeds when PENTA was used334, whereas the
other studies did not detect a significant difference in bleeding episodes between
PENTA and enoxaparin. A meta analysis of these 4 randomised double-blind studies
showed that major bleeding occurred more frequently in the fondaparinux-treated
group (p=0.008)360. However, the incidence of bleeding episodes leading to death or
reoperation, or occuring in a critical organ did not differ between fondaparinux and
enoxaparin.
We investigated the effect of rFVIIa on coagulation and clot lysis in plasma containing
PENTA (Chapter 7). rFVIIa was able to completely reverse the anticoagulant effect of
PENTA. Interestingly, the profibrinolytic effect induced by PENTA was only partially
reversed by rFVIIa. Even at supratherapeutic levels rFVIIa did not completely reverse
clot lysis in PENTA containing plasma (unpublished data). This is in contrast with the
situation in factor VIII deficient plasma, in which addition of sufficient rFVIIa
normalized clot lysis time (i.e., clot lysis time in factor VIII deficient plasma with high
dose rFVIIa equalled clot lysis time in the same plasma with 1 U/ml of purified factor
VIII). The reason why PENTA is still able to (partially) inhibit secondary but not
primary thrombin generation in the presence of rFVIIa is unclear. Either the
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concentration of Xa required for secondary thrombin generation is much higher than
that required for clot formation, or inhibition of Xa by PENTA is, in the presence of
rFVIIa, simply not fast enough to delay clot formation.
Our results, as well as data from a phase I PENTA/rFVIIa interaction trial (Dr. M. Levi,
personal communication) indicate that rFVIIa may be effective in reversing the
antithrombotic effects of PENTA in case bleeding complications occur. However,
would the induction of hyperfibrinolysis by PENTA have physiological relevance,
adjunctive treatment with antifibrinolytic drugs might be considered as rFVIIa only
partially reverses this antifibrinolytic effect.
Enhancement of platelet deposition by rFVIIa-mediated thrombin generation
The mechanism by which rFVIIa induces haemostasis in patients with qualitative or
quantitative platelet disorders is poorly understood. As these patients have an intact
coagulation system, it is curious at first sight how enhancement of extrinsic coagulation
by rFVIIa could assist haemostasis. However, the traditional view of platelet function
and clot formation seen as more or less separate processes is out of date. First of all,
thrombin generated by the coagulation system is involved in platelet activation.
Furthermore, platelet adhesion to fibrin361 as well as a possible role of polymerizing
fibrin in platelet activation and aggregation362 may have physiological relevance.
Finally, the expression of procoagulant surface by platelets seems to play a pivotal role
in the propagation of thrombin generation; cell surfaces presumed to be involved in the
initiation of coagulation (e.g., fibroblasts and smooth muscle cells) do not provide a
suitable surface for tenase and prothrombinase-mediated large-scale thrombin
generation49.
Experiments presented in chapter 8 of this thesis have revealed an important role of in-
situ generated thrombin for adhesion of platelets with congenital or acquired aIIbb3
deficiency. The generation of a small amount of thrombin profoundly enhances the
deposition of aIIbb3-deficient platelets to subendothelial matrix of cultured endothelial
cells and to collagen under flow conditions. In fact, we have also shown in the same
model system that also normal platelets show increased platelet deposition (in this case
reflected by the formation of more extensive platelet aggregates) to subendothelial
matrix or to collagen. Furthermore, platelet adhesion and activation (relected by
platelet spreading) to a fibrinogen surface was significantly enhanced by the generation
of thrombin. Increased adhesion and aggregate formation to subendothelial matrix was
also observed under conditions mimicking thrombocytopenia (all unpublished results).
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We hypothesize that platelets from patients with liver failure will respond to rFVIIa
mediated thrombin formation as well, but this hypothesis has not yet been tested.
These results are in accordance with results published by Diaz-Ricart et al., who
observed that thrombin increased adhesion of both normal and aIIbb3-inhibited
platelets to denuded rabbit aorta segments under flow conditions363. In these
experiments, thrombin was either preincubated with the surface, or added to the
perfusate, with similar results.
In our experiments, in which the thrombin was generated via rFVIIa and factor X, it
appeared that the presence of tissue factor was not mandatory for thrombin generation.
Supported by our data and by experiments published by Monroe et al., who observed
direct binding of rFVIIa to platelets in suspension189, we postulate the following
general model for enhancement of platelet adhesion under flow conditions by rFVIIa-
mediated thrombin generation. First, a platelet adheres to subendothelial structures
(e.g., collagen), becomes activated, and consequently expresses procoagulant surface.
rFVIIa can subsequently bind to this already adhered platelet, and activates factor X
on the platelet surface. The formed factor Xa subsequently assembles into a
prothrombinase complex resulting in the generation of thrombin. This thrombin
formed on the platelet surface can result in activation of platelets either from
suspension, or rolling on the surface (figure 3). This activation proceeds via thrombin
binding to GPIb, and may involve cleavage of GPV and/or PAR-1 activation17,348.
Enhancement of platelet adhesion results in an increase in the expression of
procoagulant surface, and this may facilitate further (large-scale) thrombin
generation and subsequent fibrin formation. Enhancement of thrombin generation by
Figure 3. A model for enhancement of platelet deposition by rFVIIa-mediated thrombin
generation. rFVIIa binds to already adhered platelets expressing anionic phospholipids and
converts factor X to Xa. Factor Xa subsequently activates prothrombin, and the thrombin
formed activates platelets, which are either rolling on the surface, or in suspension. Platelet
activation by in situ formed thrombin renders the platelet more reactive towards the surface via
an incompletely understood mechanism, but might involve cleavage of GPV from the GPIb/V/
IX complex and/or PAR-1 activation.
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an increased procoagulant surface might also result in enhanced TAFI activation.
Thus, rFVIIa enhances thrombin generation, leading to increased platelet deposition,
and consequently increased fibrin deposition, resulting in a more stable haemostatic
plug. This mechanism potentially applies to patients with normal platelets, and to
patients with all acquired and drug-induced platelet disorders (e.g., GT, uremia,
cirrhosis, aIIbb3-inhibitors) with only one exception, which is GPIb deficiency. The
scarce clinical evidence available suggests that also in BSS rFVIIa has haemostatic
efficacy, and if this is true, a different mechanism than the one described above would
be applicable.
Platelets deficient in GPIb have a strongly reduced thrombin binding capacity and are
also less responsive to thrombin364. Enhanced thrombin generation by rFVIIa will thus
not lead to an enhanced activation as seen with platelets on which the GPIb/V/IX
complex is present. Moreover, platelets deficient in GPIb poorly adhere to
subendothelial structures365, thereby impairing the expression of procoagulant surface
at the site of injury. It might be that in BSS, platelets are ‘trapped’ in a developing fibrin
network by an aIIbb3-mediated mechanism. Although the development of procoagulant
activity in GPIb deficient platelets may be impaired, rFVIIa-mediated enhancement of
thrombin generation could be possible on BSS platelets, as these platelets already
express procoagulant surface under resting conditions366. Enhancement of thrombin
generation would again lead to enhancement of fibrin deposition and/or improvement
of fibrin structure, thereby inducing haemostasis in the BSS patient.
General model for the mechanism of action of rFVIIa
A number of variables concerning the effects of rFVIIa in vivo in enhancing the
haemostatic potential are still unknown, especially with respect to structure and
composition of the haemostatic plug, and its resistance against the fibrinolytic system.
Both changes in fibrin structure, as well as changes in fibrin-platelet interaction
potentially contribute to stability of the haemostatic plug. However, sufficient in vitro
data are available to postulate a general model for the mechanism of action of rFVIIa.
The central player in this model is thrombin. It is now generally accepted that rFVIIa
administration to any patient (with or without defects in the haemostatic system) will
enhance thrombin formation at the site of injury. The exact mechanism by which this
thrombin is generated is still a matter of debate; the mechanism, which seems most
plausible, taken experimental data available at present, will be discussed below (see
also figure 4). The mechanisms by which enhancement of thrombin generation leads to
the formation of a more stable haemostatic plug (and consequently the induction of ‘long
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term’ haemostasis) are incompletely known, but possible targets will be discussed in this
section.
Enhancement of thrombin generation by rFVIIa may be accomplished by tissue factor-
dependent182,183 or -independent189 mechanisms, or perhaps both. rFVIIa may enhance
initiation of coagulation on a tissue factor-bearing cell (e.g., a fibroblast or a smooth
muscle cell). rFVIIa competes with endogenous zymogen factor VII for binding to
TF183, thereby enhancing Xa and IXa generation on the TF-bearing cell. A relatively
small amount of thrombin generated on the TF-bearing cell subsequently leads to
platelet activation, accompanied by the expression of procoagulant surface, suitable
for large-scale thrombin generation. Enhancement of initiation of coagulation may
Figure 4. A general model for the mechanism of action of rFVIIa. rFVIIa may enhance initiation of
coagulation on the TF-bearing cell by competing with endogenous zymogen factor VII for TF. A
small amount of thrombin formed on the TF-bearing cell can activate platelets; thrombin binding
to GPIb accelerates PAR-1 activation and results in release of sGPV from the complex. Factor IXa
formed on the tissue factor-bearing cell can transfer to the activated platelet, and start generating
large amounts of thrombin. In case of haemophilia, this pathway is not active (grey arrows). Large-
scale thrombin generation on the activated platelet can also occur by direct binding of rFVIIa to the
platelet. Without the requirement for TF, platelet-bound rFVIIa can activate factor X. rFVIIa-
mediated enhancement of thrombin generation on the activated platelet by platelet-associated
TF might also occur. The enhancement of large-scale thrombin generation will affect platelet
activation, fibrin formation, TAFI activation, factor XIII activation and other processes.
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already result in enhancement of platelet deposition, and consequently enhancement of
expression of procoagulant surface.
As the membrane environment on the TF-bearing cell is not suitable for large-scale
thrombin generation, the action has to move towards the activated platelet. Factors
Xa and IIa are probably not able to diffuse to the activated platelet surface. Factor Xa
will be inhibited by TFPI, and both factor Xa and IIa are in solution highly susceptible to
inhibition by antithrombin49. Factor IXa, however, is in solution not rapidly inhibited,
and is thus able to transfer to the activated platelet surface to generate large amounts of
thrombin. Thrombin generation on the platelet surface is further amplified by the
activation of factor XI367. It has been shown that factor XI binding to GPIb enhances
its activation by thrombin, and it is thus conceivable that GPIb-bound thrombin is
responsible for factor XI activation368.
A variation on this model involves the possible transfer of ‘blood borne’ tissue factor to
platelets25,369. If during the haemostatic response encrypted TF is transferred from
leukocytes to platelets, the platelet (or, more precisely, the ‘platelet-TF hybrid’) can be
the surface on which both initiation and propagation of thrombin formation takes place.
An alternative pathway of thrombin generation by rFVIIa, which may be relevant
especially in case of factor VIII or IX deficiency, is the TF-independent thrombin
generation on activated platelets189. rFVIIa has been shown to bind with weak affinity
to activated platelets where it can activate factor X, without the requirement for TF. In
case of haemophilia, large-scale thrombin generation on platelets is absent, because only
factor IXa can transfer from the TF-bearing cell to the platelet, so in absence of intrinsic
tenase activity, platelet thrombin generation is absent. It has been hypothesized that TF-
independent thrombin generation is completely responsible for the haemostatic efficacy
of rFVIIa in haemophilia, and that the same mechanism would also apply in patients
with other haemostatic disorders190.
Enhancement of thrombin generation by rFVIIa potentially results in a variety of events,
which lead to a more stable haemostatic plug.
1) Changes in fibrin structure. It has been shown that the amount and the rate of
thrombin generation influence the structure (e.g., thickness) of the fibrin fibres191,192.
Increased thrombin generation might lead to a more stable, less porous fibrin clot193,
better suitable to resist shear forces in the circulation, and less susceptible to
fibrinolysis.
2) Enhanced or more rapid activation of factor XIII could lead to enhanced or more
efficient fibrin cross-linking, thereby contributing to clot stability and resistance to
breakdown by the fibrinolytic system40.
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3) Enhanced activation of TAFI could directly contribute to downregulation of the
fibrinolytic system (this thesis).
4) More extensive platelet activation could lead to a more densely packed platelet plug.
Also, the expression of procoagulant surface, either by an increased platelet number
at the site of injury, or by a stronger activation signal due to the higher concentrations
of thrombin generated, could lead to further enhancement of thrombin generation
(chapter 8 of this thesis). Finally, increased platelet activation could result in an
increased secretion or excretion of clot stabilizing factors such as PAI-1, and a2-
antiplasmin, and FXIII.
Which of these mechanisms contribute to enhancement of clot stability by rFVIIa in
vivo, and to what extent, remains to be elucidated. Future studies will need to focus on
structure, composition, and stability of haemostatic plugs in physiological relevant
models. Models as described in this thesis provide potentially relevant information,
but have the limitation that the interaction between platelets and the coagulation
system are not included. Thus, extensions of the currently used models could be
employed to get closer to the in vivo situation. In vitro models should incorporate
shear stress, as this plays a significant role in platelet-vessel wall, and platelet-fibrin
interaction. Animal models might also be valuable in investigating physiologically
important determinants of clot stability.
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Haemostase
Haemostase is het proces wat ervoor zorgt dat een beschadiging in een bloedvat snel en
effectief wordt hersteld om overtollig bloedverlies te voorkomen. Het haemostatische
proces is in normale omstandigheden strikt gereguleerd. Een haemostatisch systeem
dat uit balans raakt, kan aanleiding geven tot bloedingen of trombose.
In geval van vaatwandbeschadiging treden een aantal, aan elkaar gekoppelde processen
op, die resulteren in afsluiting van het bloedvat. Allereerst trekt het bloedvat samen,
waardoor de hoeveelheid bloed die door het vat stroomt verminderd wordt.
Vervolgens hechten bloedplaatjes, die in rustende toestand circuleren in het bloed, aan
eiwitten die vlak onder de wand van een bloedvat zitten (zoals collageen). Gehechte
bloedplaatjes worden geactiveerd waardoor deze bloedplaatjes weer andere
bloedplaatjes kunnen binden. Zo ontstaat een prop van bloedplaatjes die voor een
eerste afdichting van het bloedvat zorgt. De bloedplaatjesprop alleen is echter niet
voldoende. Versterking van de plaatjesprop door een fibrinenetwerk is noodzakelijk
voor permanente afsluiting van de vaatwandbeschadiging. De eerste aanzet tot
vorming van een fibrine stolsel is het in contact komen van het eiwit tissue factor (TF)
met de bloedstroom. Tissue factor is een eiwit dat op een groot aantal celtypen aanwezig
is, behalve op celtypen binnen een bloedvat (zoals endotheelcellen). Als tissue factor in
contact komt met het bloed, bindt dit eiwit het proenzym factor VII. Als factor VII
geactiveerd wordt (tot factor VIIa), is het tissue factor-VIIa complex in staat andere
stollingseiwitten te activeren, uiteindelijk leidend tot de vorming van het enzym
trombine. Trombine is vervolgens in staat het plasma eiwit fibrinogeen te knippen tot
fibrine, dat spontaan polymeriseert tot een onoplosbare vorm. Naast het knippen van
fibrinogeen is trombine in staat bloedplaatjes te activeren, activeert het factor XIII wat
vervolgens het fibrinenetwerk versterkt door vertakkingen aan te brengen, en activeert
het TAFI (thrombin activatable fibrinolysis inhibitor door trombine te activeren
fibrinolyseremmer). Geactiveerd TAFI is betrokken bij de bescherming van het fibrine
netwerk tegen afbraak. Afbraak van fibrine verloopt via een proces dat fibrinolyse
genoemd wordt. Als reactie op de vaatwandbeschadiging, stoot het nabijgelegen
endotheel het enzym tPA uit. tPA kan het plasma eiwit plasminogeen activeren tot
plasmine, dat in staat is het fibrinestolsel af te breken. De activatie van plasminogeen is
het effectiefst wanneer tPA en plasminogeen gebonden zijn aan fibrine. Geactiveerd
TAFI verwijdert de bindingsplaatsen voor tPA en plasminogeen van fibrine en remt zo
de fibrine afbraak.
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Afwijkingen in de haemostase leidend tot een bloedingsneiging
Veel eiwitten betrokken bij het haemostase proces zijn ontdekt doordat patie¨nten die
zo’n eiwit missen door een erfelijk defect, een bloedings- of tromboseneiging hebben.
Ook kunnen veranderingen in de haemostase die leiden tot bloedingen of trombose
verworven worden. Dit gaat meestal gepaard met een ziekte die niet gerelateerd aan de
haemostase is, of is de oorzaak van het gebruik van medicijnen die direct of indirect de
bloedstolling beı¨nvloeden
In mensen komen vele erfelijke afwijkingen in bloedplaatjes, het proces van
fibrinevorming, of de fibrinolyse die gepaard gaan met een bloedingsneiging voor.
Sommige daarvan zijn bijzonder zeldzaam, terwijl andere erfelijke afwijkingen veel
vaker voorkomen. De ziekten die van belang zijn in dit proefschrift zullen hieronder
kort worden besproken.
Een bekende bloederziekte is haemofilie. Patie¨nten met haemofilie missen stollingsfactor
VIII (haemofilie A) of IX (haemofilie B) welke betrokken zijn bij het proces van
trombinevorming. Deze patie¨nten hebben afhankelijk van de ernst van de ziekte
(hoeveel actief eiwit ze nog aanmaken) een milde tot ernstige bloedingsneiging, die zich
vooral uit als spier- en gewrichtsbloedingen, nabloeden na kleine ingrepen zoals kiezen
trekken, en ernstig bloedverlies bij trauma of operaties. Behandeling van haemofilie
bestaat uit het teruggeven van de missende stollingsfactor. Vroeger werd dit eiwit
gezuiverd uit plasma van bloeddonoren, tegenwoordig zijn ook producten op de markt
die verkregen zijn via recombinant DNA technieken. Het nadeel van producten
verkregen uit humaan materiaal is de kans op besmetting met virussen zoals het HIV
virus en hepatitis B en C. Behandeling van haemofilie met gezuiverde stollingsfactoren
wordt vaak bemoeilijkt doordat het lichaam antistoffen tegen de missende factor gaat
aanmaken. De getransfundeerde factor is immers een lichaamsvreemde stof voor de
haemofilie patie¨nt. Na het ontwikkelen van antistoffen is het geven van gezuiverd
factor VIII of IX zinloos, omdat deze meteen door de antistof geneutraliseerd wordt.
Een zeldzame afwijking aan de bloedplaatjes staat bekend als Glanzmann’s
Thrombasthenia (GT). Patie¨nten met deze afwijking missen een receptor (aIIbb3) op
het bloedplaatje. Deze receptor is betrokken bij zowel de hechting van het plaatje aan
de adhesieve eiwitten buiten het vat, als bij het hechten van de bloedplaatjes aan
elkaar. Patie¨nten met GT hebben een ernstige bloedingsneiging gekarakteriseerd door
neusbloedingen, blauwe plekken, tandvlees bloedingen, overvloedig menstrueren,
gastrointestinale bloedingen, en ernstig bloedverlies bij trauma of operaties.
Behandeling van GT bestaat uit het transfunderen van gezonde bloedplaatjes, of het
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geven van synthetische medicijnen zoals DDAVP of remmers van de fibrinolyse zoals
trasylol. Het nadeel van bloedplaatjestransfusie is dat antistoffen tegen zowel de
missende receptor als tegen HLA determinanten op het plaatje (de exacte
samenstelling van deze eiwitten is bij ieder mens anders) ontwikkeld kunnen worden.
Ook hier is weer het transfunderen van bloedplaatjes na het ontwikkelen van
antistoffen zinloos, en moet een alternatieve behandeling gezocht worden.
Een zeer complexe verworven bloedingsneiging wordt gevonden bij patie¨nten met
chronisch of acuut leverlijden. Deze patie¨nten hebben afwijkingen in bloedplaatjes
aantal en functie, trombine en fibrinevorming, en in het fibrinolysesysteem. Dit komt
onder meer omdat bijna alle eiwitten die betrokken zijn bij de haemostase gemaakt
worden in de lever. Deze patie¨nten kunnen bloeden na kleine ingrepen zoals een
leverbiopsie of een kiesextractie. Bij grotere chirurgische ingrepen (zoals een
levertransplantatie) treedt vaak ernstig bloedverlies op, dat gecorrigeerd moet worden
door transfusie van bloedproducten.
Patie¨nten met trombose krijgen vaak medicijnen die haemostatische processen remmen
(antitrombotica) of stolselafbraak stimuleren (fibrinolytica). Remmers van
bloedplaatjes, zoals aspirine (wat plaatjes activatie remt) of medicijnen die aIIbb3
remmen, remmers van trombinevorming, en stimulators van de fibrinolyse worden
toegepast bij preventie en/of behandeling van trombose. Het nadeel van deze
medicijnen is dat ze terwijl ze trombose voorkomen, ook een bloedingsneiging induceren.
Recombinant stollingsfactor VIIa (rFVIIa) – een doekje voor het bloeden
Geactiveerd bloedstollingsfactor VII gezuiverd uit humaan plasma werd in 1983 voor
het eerst toegepast bij een patie¨nt met haemofilie A die een operatie moest ondergaan.
Deze patie¨nt kon vanwege de aanwezigheid van antistoffen tegen factor VIII niet met
factor VIII concentraat behandeld worden. Het idee was, dat door infusie van
geactiveerd factor VII in hoge concentratie trombinevorming gestimuleerd zou kunnen
worden, en dat het stollingsdefect veroorzaakt door de factor VIII of IX deficie¨ntie
daardoor gecompenseerd zou worden. Deze en de daaropvolgende behandelingen met
plasma factor VIIa waren succesvol. Echter, het was niet realistisch om een groot
aantal patie¨nten met plasma gezuiverd factor VIIa te gaan behandelen omdat humaan
plasma maar erg weinig factor VII bevat, en de zuivering bovendien een lage opbrengst
gaf. Daarom werd besloten factor VIIa als recombinant eiwit te gaan produceren, wat
mogelijk werd toen het gen voor dit eiwit in 1986 gekloneerd werd. Klinische trials met
rFVIIa lieten zien dat haemofilie patie¨nten met antistoffen veilig en effectief behandeld
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konden worden tijdens bloedingen of chirurgische ingrepen. rFVIIa werd in 1996 in
Europa geregistreerd als behandelmethode voor patie¨nten met haemofilie en
antistoffen tegen de missende factor.
Het gegeven dat rFVIIa bij haemofilie patie¨nten veilig en effectief trombinegeneratie lijkt
te verhogen opende de weg naar nieuwe toepassingen. Patie¨nten met bloedplaatjes-
afwijkingen (zoals GT), leverziekte, en patie¨nten behandeld met antitrombotica lijken
veilig en effectief met rFVIIa behandeld te kunnen worden tijdens bloedingen.
Bovendien lijkt rFVIIa ook bloedverlies tijdens levertransplantaties, en tijdens
chirurgische ingrepen bij patie¨nten zonder stollingsafwijking te kunnen verminderen.
Als laatste lijkt rFVIIa een zeer effectief middel om oncontroleerbare bloedingen te
stelpen bij patie¨nten zonder stollingsafwijking (bijvoorbeeld bloedingen ten gevolge van
trauma). rFVIIa lijkt dus een soort universeel middel om bloedingen te stoppen of
voorkomen of om bloedverlies tegen te gaan.
Hoewel de haemostatische effecten van rFVIIa worden toegeschreven aan versterking
van trombinegeneratie op de plaats van de vaatwandbeschadiging, is over het exacte
mechanisme dat voor die versterkte trombinevorming zorgt, als over hoe die versterkte
trombinevorming nou precies bijdraagt tot het induceren van permanente haemostase
nog weinig bekend. Ook wordt niet goed begrepen waarom zeer hoge concentraties
rFVIIa nodig zijn voor het induceren van haemostase.
Een van de discussies in de literatuur is of het versterken van de trombinevorming door
rFVIIa via een TF afhankelijk of onafhankelijk mechanisme verloopt. Als rFVIIa zou
werken via een TF afhankelijk mechanisme, is niet geheel duidelijk waarom zulke hoge
concentraties nodig zijn voor het induceren van haemostase. De affiniteit van VIIa voor
TF is namelijk bijzonder groot, en TF zou al verzadigd met rFVIIa moeten zijn bij veel
lagere concentraties. Er is echter voorgesteld dat deze hoge rFVIIa concentraties nodig
zijn, omdat rFVIIa competitie aangaat met niet geactiveerd factor VII. Een TF
onafhankelijk mechanisme gaat uit van directe binding van rFVIIa aan geactiveerde
bloedplaatjes, waarop vervolgens trombinevorming plaatsvindt. De affiniteit van
rFVIIa voor geactiveerde plaatjes is vele malen lager dan de affiniteit voor TF, en dit
zou de reden zijn voor de hoge rFVIIa concentraties nodig voor het stelpen van
bloedingen.
Het doel van dit proefschrift was meer inzicht te krijgen over het werkings-mechanisme
van rFVIIa in de verschillende ziektebeelden.
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rFVIIa en haemofilie
In het eerste deel van dit proefschrift is gekeken naar de consequenties van versterkte
trombinevorming door rFVIIa in plasma van patie¨nten met haemofilie A. Het was al
bekend dat rFVIIa in haemofilieplasma de vorming van een fibrinestolsel kon
versnellen. In hoofdstuk 2 is gekeken naar de invloed van rFVIIa op de afbraak van
het fibrinestolsel door het fibrinolytisch systeem. Eerder is beschreven dat haemofilie
wellicht niet alleen een probleem van vorming van het fibrinestolsel veroorzaakt, maar
dat dit stolsel wellicht ook vatbaarder is voor afbraak door het fibrinolytisch systeem
omdat TAFI activatie verminderd of afwezig is. In hoofdstuk 2 laten we zien dat
rFVIIa niet alleen de stolselvorming versneld, maar dat ook de afbraak van het stolsel
geremd wordt door versterking van TAFI activatie. Er is echter veel meer rFVIIa
nodig voor maximale TAFI activatie dan voor versnelling van de stolselvorming. Dit
zou mede een verklaring kunnen zijn waarom hoge rFVIIa concentraties noodzakelijk
zijn om permanente haemostase te induceren in deze patie¨ntengroep.
rFVIIa en leverziekten
Nadat een antifibrinolytisch effect van rFVIIa in plasma van haemofilie patie¨nten
gevonden was, was de volgende hypothese dat ditzelfde mechanisme ook op zou
kunnen gaan in plasma van patie¨nten met leverziekten. In hoofdstuk 3 is een
literatuuroverzicht van de haemostatische afwijkingen in patie¨nten met leverziekten
gegeven. Een van de aspecten die beschreven is in de literatuur is het optreden van
hyperfibrinolyse (versnelde stolselafbraak) in een deel van die patie¨nten. Omdat TAFI
een vrij recent ontdekt eiwit is, is nog weinig bekend over de rol van TAFI in patie¨nten
met leverziekten. In hoofdstuk 4 is een studie beschreven over dit onderwerp. Zoals
verwacht vonden we verlaagde TAFI concentraties in patie¨nten met stabiele
levercirrhose (TAFI wordt net als vele andere haemostatische eiwitten gemaakt in de
lever). Echter, wanneer gekeken werd naar stolselafbraak in plasma van deze patie¨nten
werd geen hyperfibrinolyse gevonden. Wij vonden dat verlaagde concentraties van
eiwitten die de fibrinolyse remmen (zoals TAFI) gecompenseerd werden door lage
concentraties van eiwitten die de fibrinolyse stimuleren. De discrepantie tussen onze
bevindingen en de in eerdere literatuur beschreven resultaten zijn waarschijnlijk te
wijten aan verschillen in de experimentele opzet.
Vervolgens is in hoofdstuk 5 het effect van rFVIIa op stolselvorming en stolselafbraak in
plasma van patie¨nten met stabiele levercirrhose en in plasma van patie¨nten die een
Samenvatting
186
levertransplantatie ondergaan bekeken. In tegenstelling tot de situatie in
haemofilieplasma, heeft toevoeging van rFVIIa aan plasma van patie¨nten met
leverlijden geen effect op de fibrinolyse, waarschijnlijk omdat al maximale bescherming
tegen stolselafbraak aanwezig is. De effectiviteit van rFVIIa in leverziekten is dus
waarschijnlijk toe te schrijven aan versnelling van stolselvorming.
rFVIIa en anticoagulantia
In hoofdstuk 6 is gekeken naar de effecten van medicijnen die fibrinegeneratie remmen
(door stolfactoren te remmen) op de fibrinolyse. Van al deze medicijnen zijn de
remmende effecten op stolselvorming algemeen geaccepteerd, maar er is nooit eerder
onderzoek gedaan naar het effect op TAFI activatie (en dus bescherming tegen
stolselafbraak). Er werd gevonden dat de medicijnen die mede gericht zijn tegen
geactiveerd stollingsfactor X (zoals de zeer veel gebruikte heparine-achtigen) maar niet
degenen die TF of trombine remmen de fibrinolyse stimuleren. De stimulatie van
fibrinolyse door factor Xa remmers wordt waarschijnlijk veroorzaakt doordat deze
medicijnen niet alleen de kleine hoeveelheid trombine nodig voor de vorming van een
fibrinestolsel vertragen, maar ook de aanmaak van grote hoeveelheden trombine die
nodig is voor TAFI activatie tegengaan.
In hoofdstuk 7 is gekeken naar de effecten van een nieuw antitromboticum,
fondaparinux, een heparine derivaat dat specifiek factor Xa remt. Dit nieuwe medicijn
lijkt superieur ten opzichte van traditionele heparine-achtigen wat betreft effectiviteit
bij het voorkomen van diep veneuze trombose na operaties. Echter, er is nog geen
goede behandelmethode voor patie¨nten die bloedingen krijgen ten gevolge van
behandeling met fondaparinux. Een mogelijk effectieve therapie voor patie¨nten
behandeld met fondaparinux die een bloeding krijgen is de toediening van rFVIIa.
Daarom werden de effecten van rFVIIa op stolselvorming en stolselafbraak in plasma
waaraan fondaparinux was toegevoegd onderzocht. Fondaparinux remt dus de
stolselvorming en stimuleert stolselafbraak door TAFI activatie te remmen. rFVIIa
gaat de remming van stolselvorming door fondaparinux volledig tegen. De stimulatie
van stolselafbraak door fondaparinux wordt door rFVIIa gedeeltelijk gecompenseerd.
rFVIIa zou dus mogelijk een goede therapie zijn voor patie¨nten die bloedingen
ontwikkelen nadat ze met fondaparinux behandeld zijn.
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rFVIIa en aIIbb3 deficie¨ntie
Nadat in het grootste deel van dit proefschrift de effecten van rFVIIa op stolselvorming
en stolselbescherming door middel van TAFI activatie zijn bekeken, wordt in hoofdstuk
8 ingegaan op de effecten van trombine gevormd via rFVIIa op bloedplaatjesadhesie
onder stromingscondities. Bloedplaatjes van patie¨nten met GT hechten niet aan elkaar
en slecht aan adhesieve eiwitten die zich vlak onder de bloedvatwand bevinden. Als
geı¨soleerde bloedplaatjes van GT patie¨nten gemengd met rode bloedcellen over de
extracellulaire matrix van gekweekte endotheelcellen geı¨soleerd uit humane navel-
strengen werden geleid, was de adhesie van deze plaatjes aan het oppervlak erg laag.
Als nu aan de bloedplaatjes rFVIIa en de stolfactoren X en II werden toegevoegd, nam
de adhesie aanzienlijk toe. Hetzelfde werd gezien als remmers van aIIbb3 (o.a. remmers
die ook als antithromboticum worden toegepast) werden gebruikt. Ook de adhesie van
aIIbb3-deficie¨nte plaatjes aan collageen nam aanzienlijk toe wanneer de stolfactoren
werden toegevoegd. We hebben laten zien dat TF onafhankelijke trombine vorming
verantwoordelijk is voor deze toename in adhesie. Deze trombine wordt gevormd
doordat rFVIIa bindt aan al geadhereerde plaatjes, factor X activeert, en vervolgens
protrombine geactiveerd wordt. Het gevormde trombine activeert plaatjes die in
oplossing zijn, of die over het oppervlak rollen, waardoor ze zich permanent aan het
oppervlak hechten.
De toename in adhesie alleen kan nog niet de therapeutische efficie¨ntie van rFVIIa bij
GT patie¨nten verklaren. De bloedplaatjes verkleven immers nog steeds niet aan elkaar,
en er kan nog steeds geen stabiele plaatjesprop worden gevormd. Echter, de geactiveerde
bloedplaatjes vormen een oppervlak voor verdere trombinevorming, wat resulteert in
een versterking van fibrinegeneratie. De versterkte fibrinevorming door rFVIIa zou
dus het plaatjesdefect in GT kunnen compenseren.
Conclusies van dit proefschrift
De in dit proefschrift beschreven studies geven meer inzicht in het werkingsmechanisme
van rFVIIa in verschillende ziektenbeelden. Allereerst lijkt het erop dat in sommige
situaties rFVIIa niet alleen maar bijdraagt tot een snellere stolselvorming, maar dat
rFVIIa via versterkte TAFI activatie het stolsel beschermt tegen afbraak door het
fibrinolytisch systeem. Dit mechanisme is tot nu toe alleen nog maar onderzocht in
laboratoriummodellen. Of dit mechanisme in het menselijk lichaam ook van toepassing
is, is vooralsnog onduidelijk. Bovendien is het belang van TAFI in de fysiologie en
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pathofysiologie van de bloedstolling nog onduidelijk. Wellicht dat dierexperimentele
modellen meer duidelijkheid over deze vragen zouden kunnen geven.
Ook suggereren studies beschreven in dit proefschrift dat versterking van
trombinegeneratie via rFVIIa tot een versterking van adhesie van bloedplaatjes aan de
beschadigde vaatwand kan leiden, en dat de verhoogde depositie van bloedplaatjes
meehelpt verdere trombine- en fibrinegeneratie te stimuleren. Het is voorstelbaar dat
versterking van trombinegeneratie door rFVIIa in elk ziektebeeld leidt tot versterking
van plaatjesdepositie, versterking van fibrinevorming, en versterking van TAFI
activatie. Onderzoek in de toekomst zal deze hypothese en het belang van deze
verschillende mechanismen moeten onderzoeken. Experimenten met proefdieren lijken
onvermijdelijk om een beter inzicht te krijgen in structuur en samenstelling van een
haemostatische prop, gemaakt in af- of aanwezigheid van rFVIIa, in vivo.
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Het is af! Vier jaar vol leren, pipetteren, schrijven, reizen, brainstormen, eten, drinken, en
meer van het soort onzin dat je als AIO doet, zitten er op. Het proefschrift wat uit deze 4
jaar voortgekomen is, is het resultaat van veel samenwerkingsverbanden en ik ben erg
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Flip, de grootste bijdrage was van jou. Erg bedankt voor alle vrijheid, wijsheid, en
eigenwijsheid (fles wijn verwedden om de uitkomst van een experiment.....). De open
deur mentaliteit en het feit dat je niet ‘baas’ maar ‘begeleider’ was, heeft mij erg
gemotiveerd gehouden. Ik hoop dat ik je nog vaker lastig mag vallen!
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Pim Tijburg. Beste Pim, erg bedankt voor je onmetelijke vertrouwen, je in mijn ogen
soms wat premature enthousiasme na een enkel experiment, onze vele discussies over
wetenschap, leven en toekomst, de inhoud van je adressenboek (veel essentiele
samenwerkingen zijn toch bij jou begonnen), nakijken van manuscripten, en natuurlijk
de afdeling secundaire arbeidsvoorwaarden.
Jelle, behalve dat je erg veel gepipetteerd, geperfundeerd, en gefluoriseerd hebt (en veel
resultaten zijn in dit boekje terug te vinden!), ben je ook een perfecte collega en
borrelkoning!
Sultana, topstudent! Jij hebt in je eentje de fundering voor hoofdstuk 8 gelegd. Ik vond
het erg leuk om je te begeleiden.
Joost Meijers, jouw belangrijkste bijdrage aan dit boekje is toch wel je suggestie om eens
wat lysis assays met VIIa te gaan doen geweest. Ook bedankt voor je interesse,
vertrouwen (‘hoe kan dit nou briljant zijn als ik er niet bij sta ?!’) en voor je
‘belangeloze’ bijdrage aan allerhande ‘klusjes’ (vragen/eiwitten/plasma’s).
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Laurent Mosnier, erg bedankt voor 3 artikelen samen, en voor je hulp met alles wat met
TAFI te maken heeft.
Frank Leebeek, wat begon als een obscuur transport van wat plasma samples van het
Dijkzigt naar het UMC, heeft uiteindelijk geleid tot 3 publicaties. Bedankt voor je
enthousiasme, en je kennis over stolling en leverziekten. Er zijn nog te veel ideeen,
gemaakt in verloren uurtjes op vliegvelden, blijven liggen. Wellicht nog iets voor de
toekomst.
Harry Janssen, bedankt voor het leveren (no pun intended) van de plasmasamples voor
hoofdstuk 4, en voor je positieve houding ten opzichte van het manuscript.
Karina Meijer en Jan van der Meer, bedankt voor het uitwisselen van plasma en labdata
van de levertransplantatiestudie.
Mies Kappers-Klunne en Marjolein Peters wil ik bedanken voor de hulp in mijn
zoektocht naar Glanzmann plaatjes.
Evelien Mauser-Bunschoten ben ik erkentelijk voor het uitwisselen van plasma en
klinische data wat betreft rFVIIa en haemofilie.
Rob Fijnheer, voor grappen & grollen, en voor je hulp met het verzamelen van haemofilie
plasma’s in het begin.
Thierry Lambert, I’m very happy that you were willing to share your plasma samples,
with chapter 2 of this thesis as a result.
Danie¨lle Horbach, hier is ie dan! Jij bent degene geweest die mij enthousiast heeft
gemaakt voor het werken aan stolling (toen ik nog jong en onschuldig was.....).
It was a privilege to work on this project, which was both financially and scientifically
sponsored by Novo Nordisk. I am really happy with the support and enthousiasm I
got from a lot of people from Novo Nordisk.
First of all I have to thank Yves Laurian. Dear Yves, your enthousiasm for our work,
your knowledge on NovoSeven in platelet related bleeding disorders, and all your
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efforts to provide us with materials to perform the best possible research have been a
great help.
Roger Houben, bedankt voor je interesse, en voor in meer of mindere mate zinvolle
gesprekken aan bar en telefoon.
Marianne Baak, erg bedankt voor al die kleine dingen die het allemaal weer iets
makkelijker voor me maakten.
Charles Pyke, Egon Persson, Rasmus Røjkjær, Marianne Kjalke, and Ulla Hedner,
thanks for giving me the opportunity to work in your lab, and for the exchange of
knowledge and materials the past 4 years. Your hospitality during my stay has been
great – however, I could have done without the ‘schnapps’......
Dear Ulla, thanks for your enthousiasm – it’s an honour that you’re part of my thesis
review committee.
Britt Sørensen, you’ve been a great ‘roommate’. Annette Danielsen, thanks for getting
me started in the lab, and for cleaning up after me. Also a big thank you to the rest of the
partygirls!
Ditte Tornehave, many thanks for introducing me to the world of histology. Steen
Kryger, thanks for your help – unfortunately the ‘bloody’ tails turned out to be a more
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Marie Johannessen and Vinnie Nielsen, how a couple of days work can make it into a
thesis! Thanks!
Tsja, en dan de afdeling koffie leuten, borrelen, congresvermaak, weekendvermaak.
Behalve van radio 3, moet het vermaak toch van collega’s en aanverwante figuren
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Allereerst alle borrel/karaoke/cocktail figuren. Geheel in willekeurige volgorde: Klitje
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me Tonnie again!), Beef (voor dia’s & vroeger), Rob (rechtop, ontzettend bedankt voor
‘lysis analyzer’ en de rest van de ongein), Larry (waar blijft die bierkoelkast nou?), Edje
(vreemde eend, breezah, wah blijf me thrui?), Achmed & labinhoud (jong geleerd, oud
gedronken, Agnes ff pauze), Crucell (Glendah......Maarten.....enzo), Ingrid (hoofdstuk
apart).
Andere labbewoners, ex-labbewoners, studenten, het was een feest. Tinus, bedankt voor
prikken, ouwehoeren & koffie. Marion voor compromitterende foto’s op het www.
Lab routine Bep, bedankt voor hulp & vermaak. Yke, afreageer babbelbox, grijze wijze!
Mijn paranimfen. Janine, a.k.a. Moniek!, voorkant n=3, slap ouwehoeren, rock’n’roll
life, always forbidden, onbegrijpelijke electronische onderwerpen wie met onbekende
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avondturen.
Theo Lisman, ontzettend bedankt voor lay-out en drukken van dit boekje.
Mijn opa (laudatio non olet) en oma (koffie zwart, 2 koekjes).
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